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ABSTRACT 
 
COGNITIVE ENHANCEMENT WITH STIMULANTS: 
EFFECTS AND CORRELATES 
Irena P. Ilieva 
Martha J. Farah 
 
Does non-medical use of prescription stimulants improve healthy cognition? 
What distinguishes healthy users of ADHD medication from their peers? The present 
project examined stimulants’ cognitive enhancement effects and the psychological 
profile of non-medical stimulant users. Study 1, a double-blind, placebo-controlled 
experiment, found no enhancing effect of mixed amphetamine salts (Adderall) on healthy 
participants’ inhibitory control, working memory, episodic memory, convergent creativity, 
perceptual intelligence, and a standardized achievement test. No moderating effects of 
baseline performance or COMT genotype were detected. Despite the lack of 
enhancement observed for most measures and most participants, participants 
nevertheless believed their performance was more enhanced by the active capsule than 
by placebo. In Study 2, we conducted a meta-analysis to determine whether stimulants’ 
cognitive enhancement potential is truly non-existent or simply small. Based on 47 
double-blind, placebo-controlled experiments, we found evidence for small effects of 
amphetamine and methylphenidate on inhibitory control, working memory and episodic 
memory. Given the absence of conclusive evidence for practically significant stimulant 
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effects in healthy people, we conducted Study 3 to infer about the motives for use from 
users’ psychological profile. Non-medical stimulant use appeared more strongly related 
to individuals’ perceived attention functioning than to their objectively measured 
attentional performance. Users reported lower motivation during the laboratory attention 
test and described their everyday study habits as poorer than a control group with no 
history of stimulant use. Taken together, these data imply that enhancement users 
struggle with below-average functioning in one or several cognitive, affective and 
behavioral domains, possibly seeking stimulants to compensate for these problems. 
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PREFACE 
 
Cognitive enhancement refers to the use of psychiatric medication to optimize 
healthy cognition. Pharmacological approaches to the enhancement of cognition have 
sparked interest for decades (Rassmussen, 2008). Currently, a popular enhancement 
approach involves the use of ADHD medications, most commonly Adderall and Ritalin, 
by healthy young people without ADHD who seek to compete successfully in school or 
at work. The present work discusses the effects, correlates and implications of this 
practice. 
Relative to other risky behaviors, unprescribed stimulant use is highly prevalent. 
Among college students, the prevalence of lifetime use, though as low as 2 % on some 
campuses (Nowak et al., 2007), can exceed 35% (Low & Gendazcek, 2002) on others. 
Most popular among college students, stimulants are also used non-medically by 
surgeons, lawyers, financial traders and professional academinics (Franke et al., 2014, 
Talbot, 2009, Sahakian & Morein-Zamir, 2011), especially during times of high pressure 
for productivity (DeSantis et al., 2008). Aside from the United States, use has been 
documented in Canada, Western Europe and Australia (Sahakian and Morein-Zamir, 
2007; Franke, 2011; Castaldi et al., 2012; Partridge et al., 2013). 
Not only is interest in the non-medical use of drugs like Adderall and Ritalin high, 
but access to these medications is relatively easy. When diagnosing clinicians rely only 
on self-report, symptoms of ADHD can be easily faked to obtain a prescription. 
Stimulants may be prescribed even without a diagnosis if the physician views medication 
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as a tool for alleviating distress independent of the presence of a diagnosable condition 
(Greely et al., 2008). Between 14.7 % and 26% of people with ADHD have indicated 
diverting their medication to undiagnosed peers (e.g., Poulin et al., 2007; Poulin et al., 
2001). ADHD medications are affordable, especially if used only occasionally (DeSantis 
et al., 2008). The availability and wide interest in unprescribed stimulants underscore the 
importance of examining their enhancement potential.  
Knowledge about stimulants’ enhancement effects can benefit both individual 
users and society at large. In theory, cognitive enhancement holds substantial promise 
for progress in virtually all areas of life. To name a few examples, enhancement tools 
can improve medical professionals’ decision-making, aircraft pilots’ vigilance, students’ 
grasp of the material. Incrementally, cognitive enhancement may even facilitate scientific 
and medical progress, for instance, by leading to the discovery of cures for previously 
intractable diseases (Roache, 2008). An assessment of stimulant-related benefits is a 
crucial first step towards determining if these hypothetical perspectives are realistic.  
Additionally, data on the advantageous effects of cognitive enhancers can help 
scientists, ethicists and policy-makers weigh the benefits against the costs. Several risks 
of non-medical stimulant use require consideration, including the potential for abuse, 
dependence and cardiovascular problems (Chatterjee, 2009), the possibility of 
detrimental stimulant effects on some facets of cognition (e.g., de Wit et al., 2014), the 
uncertainty about stimulants’ underresearched long-term side effects (Farah et al., 
2004), the potential for coercion into use and the danger of uneven access for different 
social classes (Farah et al., 2004). Assessing the actual potential of currently available 
enhancement agents is an important step towards a cost-benefit analysis. 
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One source of knowledge about stimulants’ enhancement effects is non-medical 
users’ own reports. According to past research, these reports depict ADHD medications 
as beneficial for healthy attention, memory, intelligence, alertness and energy (Rabiner 
et al., 2009, DeSantis et al., 2008). These intuitions may be riddled with optimistic 
misconceptions. Evidence is accumulating that the general public may harbor an overly 
rosy view of cognitive enhancers’ promises. For instance, some users inappropriately 
discount the risks of self-medication, based on the false assumption that FDA approval 
alone guarantees a drug’s safety even without medical supervision (DeSantis et al., 
2010). College students overestimate the actual prevalence of use on campuses 
(McCabe et al., 2008), potentially leading to a perception of use as more normative, and 
possibly, as more beneficial. Media portrayals of enhancement use may be facilitating an 
uncritical belief in ADHD medications’ positive effects: an analysis of media coverage on 
the topic showed that 85% of retrieved texts included no reference to the scientific 
literature on enhancement effectiveness. These texts, while almost invariably 
emphasizing advantages of enhancement, mentioned the dangers only occasionally 
(Partridge et al., 2011). Taken together, these factors raise the possibility that users’ 
perceptions of enhancement stimulants’ effects may be positively biased.  
Laboratory experiments on stimulants’ effects on objective cognitive tests can 
provide more conclusive estimates of these medications’ promise. Yet, despite decades 
of relevant research, this goal has remained elusive. As will be discussed in Studies 1 
and 2, double-blind, placebo-controlled research on these medications’ effects on 
various facets of cognition (e.g., episodic and working memory, inhibitory control, other 
executive functions)  has yielded a mixture of positive and null results. The explanation 
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for these inconsistencies is unclear: research limitations might be masking practically 
significant effects; stimulant effects might be overall small; or the literature might be 
reflecting a combination of true null effects and selectively published false positive 
findings. Moreover, as elaborated in Study 1, assessment of the individual differences 
moderators of stimulant enhancement effects have been inconclusive because 
conducted in small samples with designs allowing alternative interpretations. Thus, the 
effects of prescription stimulants on healthy cognition have remained an open question.  
An examination of stimulants’ costs and benefits also has to take into account the 
psychological profile of users. Cognitive and affective problems experienced by users at 
baseline may impact stimulants’ effects. For instance, it has previously been suspected 
that users suffer from untreated ADHD: such a pattern would increase the probability of 
stimulant benefits, but also increase the risks. Self-medication could demotivate 
appropriate help seeking for a potentially impairing condition. True pathology might lead 
to more frequent unpresecribed medication use, in turn leading to more exposure to 
medication risks without access to medical supervision. Thus, an assessment of the 
psychological characteristics of users is important component of evaluating the costs 
and benefits of cognitive enhancement. As will be discussed in Study 3, conclusive data 
on important aspects of users’ profile is still unavailable.  
Study 1 of the present dissertation assesses the objectively measured and 
subjectively perceived effects of mixed amphetamine salts (Adderall) on healthy 
memory, inhibitory control, intelligence, creativity and standardized test performance in a 
double-blind, placebo-controlled trial. The experiment also evaluates the role of two of 
these effects’ candidate moderators: baseline cognitive performance and COMT 
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genotype. Study 2 is a meta-analysis of amphetamine and methylphenidate’s effects on 
inhibitory control, working memory and episodic memory, which incorporates an 
assessment of publication bias. Study 3 examines real-world enhancement users’ 
psychological profile, comparing their attention functioning (self-reported and objectively 
measured), study habits and motivation to a control group who has never used ADHD 
medication.  
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CHAPTER 1 
OBJECTIVE AND SUBJECTIVE COGNITIVE ENHANCING EFFECTS OF MIXED 
AMPHETAMINE SALTS IN HEALTHY PEOPLE 
 
Cognitive enhancement refers to the use of neuropsychological drugs, most 
commonly psychostimulants such as amphetamine and methyphenidate, by cognitively 
normal, healthy people to improve cognitive function. Evidence suggests that 
enhancement is a common practice and may be gaining in popularity. A study on a 
large 2001 sample of undergraduate programs including institutions of different size, 
location, religious affiliation and private/public status, showed an almost 7% lifetime 
prevalence of nonmedical stimulant use (McCabe, Knight, Teter & Wechsler, 2005). 
Although this study did not distinguish between cognitive enhancement and other 
nonmedical uses, more recent surveys of college students have done so and indicate 
that cognitive enhancement is the primary motivation for most students using stimulants 
(e.g., DeSantis, Webb, & Noar, 2008; see Smith & Farah, 2011, for a review).  These 
more recent studies also indicate substantially larger proportions of students using 
prescription stimulants compared to the McCabe and colleagues’ estimates, although 
the samples have been smaller and less representative.  Aside from college students, 
enhancement use of stimulants has also been reported among professionals from 
various fields (e.g., lawyers, journalists, Madrigal, 2008; Maher, 2008; Talbot, 2009).  
Stimulants’ Actual Cognitive Enhancement Effects 
One possible reason for the growing enhancement use of stimulants is that the 
drugs truly improve cognitive abilities such as learning and executive function, 
presumably through their effects on catecholamine neurotransmission (Meyer & 
Quenzer, 2005). Yet, in the aggregate, the evidence supporting stimulants’ beneficial 
effects on healthy cognition is mixed. For example, Chamberlain, Robbins, Winder-
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Rhodes, Muller, Sahakian, Blackwell and Barnett (2010) reviewed studies in which 
CANTAB tasks had been used to assess stimulant effects in patients and healthy 
control participants.  They concluded that “acute doses of medication improved aspects 
of cognition, though findings were more consistent in subjects with ADHD than in 
healthy volunteers.”  Reviewing the literature on the cognitive effects of 
methylphenidate, Repantis, Schlattmann, Laisney & Heuser (2010) state that they were 
“not able to provide sufficient evidence of positive effects in healthy individuals from 
objective tests.”  Similarly, Hall and Lucke (2010) state that “There is very weak 
evidence that putatively neuroenhancing pharmaceuticals in fact enhance cognitive 
function.” An even stronger view was presented by Advokat (2010), whose reading of 
the literature led her to suggest that “studies in non-ADHD adults suggest that 
stimulants may actually impair performance on tasks that require adaptation, flexibility 
and planning.”  
Most recently, Smith and Farah (2011) surveyed more than fifty experiments on 
the effects of amphetamine and methylphenidate on a wide array of cognitive functions, 
including memory (episodic memory, procedural memory and probabilistic learning) and 
executive functions (working memory, cognitive control) in healthy young adults. They 
discovered a roughly even mixture of significant enhancement effects and null findings 
overall.  Studies on episodic memory tended to show an enhancing effect of stimulants 
when retention intervals were longer than an hour, whereas evidence for enhancement 
of other functions was less clear.  For executive functions (including inhibitory control, 
working memory and other executive functions) many studies reported significant 
enhancing effects but some did not.  In addition, when found, these effects were 
sometimes qualified by complex interactions between the order of drug and placebo 
administration, participants’ cognitive performance on placebo, and participants’ 
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genotypes. The possibility that other null results have been found but not published 
(publication bias, also known as the “file drawer effect”) must be considered. In sum, a 
number of recent reviews have concluded that the cognitive enhancement potential of 
stimulants has not received firm empirical support. 
Several factors may explain the inconsistency between users’ beliefs that 
stimulants enhance cognition and the equivocal evidence for these effects.  One 
possibility is that the assessment of enhancement effects in the laboratory has been 
impeded by problems such as unmeasured moderators, poor measurement of 
moderators or low statistical power.  These would be especially serious challenges to 
research in this area if the effects of stimulants are small and dependent on individual 
differences. Another possibility is that stimulants create a subjective perception of 
enhancement, possibly more salient and wide-spread than the actual effects.  The rest 
of this section will elaborate on these potential explanations. 
Challenges in Assessing the Enhancing Effects of Stimulants 
Among the challenges standing in the way of settling the question of stimulants’ 
enhancement potential are the following four.  The majority of published studies fail to 
meet any of these challenges, and no study has so far been designed to address all 
four. These challenges motivate the design of the present double-blind, placebo 
controlled, cross-over trial on the cognitive enhancement effects of mixed ampheramine 
salts (MAS, brand name Adderall). 
Moderation of enhancement effects by individual differences. One reason 
why previous research may have failed to detect significant evidence for enhancement 
is that stimulants may be effective for some individuals but not for others.  Thus, studies 
that have not measured or analyzed the effect of moderating individual differences may 
have erroneously concluded that the effects are small or nonexistent.   One candidate 
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moderator is individuals’ endogenous dopamine activity. The relationship between 
dopamine activity and cognitive performance is believed to follow an inverted U-shaped 
curve, in which intermediate dopamine levels are optimal for cognitive performance, 
whereas low and high levels are detrimental (Robbins & Arnsten, 2009). Therefore, 
individuals at different starting points on this curve would benefit differentially from the 
increase of dopamine activity caused by a dose of stimulant. Individuals with sub-
optimal baseline dopamine levels would be moved upward on the curve to higher 
cognitive performance.  By contrast, individuals with high baseline dopamine, standing 
at the peak or on the downward-sloping portion of the curve, would move downward in 
cognitive performance. 
Several studies have provided evidence for the moderation of stimulant effects 
by endogenous dopamine activity, as indexed by participants’ Catechol O-
methyltransferase (COMT) genotype.  A common polymorphism of the COMT gene 
determines the activity of the COMT enzyme, which breaks down dopamine and 
norepinephrine. Hence, the COMT genotype influences the level of synaptic dopamine. 
Mattay and colleagues (2003) have shown that individuals whose COMT genotype is 
associated with higher endogenous dopamine show less enhancement by 
amphetamine and in certain tasks may actually perform worse on the drug. 
Another possible moderator of amphetamine’s cognitive enhancing effects is 
cognitive ability. Several studies have found that participants who perform worse than 
average when on placebo are more likely to be enhanced by stimulants (Farah, Haimm, 
Sankoorikal & Chatterjee, 2008; De Wit, Crean & Richards, 2000; de Wit, Enggasser  & 
Richards, 2002, Mattay et al., 2000; Metha, Owen, Sahakian, Mavaddat, Pickard & 
Robbins, 2000). Findings of both COMT-moderated and performance-moderated 
enhancement suggest that some of the null results in literature may result from a 
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mixture of true enhancing effects for some individuals and absent or even reversed 
effects for others.  Measurement of these two potential moderating factors is therefore 
crucial for determining the true enhancement potential of stimulant drugs.  In the 
present study we measure both.  
Regression to mean and measurement of baseline performance. Baseline 
performance, as a moderator of enhancement, has typically been indexed by 
performance on placebo.  This measure is problematic because of the phenomenon of 
regression to the mean. To the extent that there is measurement error in the data, 
participants who score well in the placebo condition would be expected to score less 
well on average in a different session, and participants who score poorly in the placebo 
condition would be expected to score somewhat better on average in a different 
session.  Consequently, even in the absence of moderation by baseline, placebo scores 
may appear to moderate the difference between drug and placebo purely due to 
regression to the mean. For this reason, we obtain a measure of baseline ability that is 
independent from participants’ performance on drug and placebo. 
Moderation by order of drug administration. Some previous within-subjects 
trials on the effects of stimulants on cognition have unexpectedly revealed a third 
moderator of enhancement effects. In particular, significant enhancement effects on 
three different tasks have been observed when the drug was administered before 
placebo, but not after (Elliott, Sahakian, Matthews, Bannerjea, Rimmer & Robbins, 
1997). Such moderation is difficult to interpret; it might reflect a specificity of stimulant 
effects to novel tasks, or a specificity to more difficult tasks, or it may be a type II error.  
If order is not controlled and analyzed in within-subjects studies, the effects of 
stimulants could be inflated or diluted.   Between-subjects studies are not free of this 
problem, as all participants effectively receive the drug or placebo first.  If stimulant 
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effects are fleeting, then single-session between-subjects studies would overestimate 
the effectiveness of the drug.  Accordingly, in the present study we control for the order 
of drug administration both experimentally (i.e., by counterbalancing the variable 
between participants) and statistically. 
Statistical power. Insufficient statistical power to detect practically significant 
effects has been a major obstacle to discovering stimulants’ cognitive enhancing 
properties. Most of the experiments reviewed by Smith & Farah (2011) used samples of 
fewer than 40 participants, many with between-subjects designs.  The present within-
subject study’s sample size of 46 was chosen to give us 95% power to detect a 
medium-size effect (Cohen’s d = 0.5) on any single measure. 
Perceptions of Enhancement 
Another way to explain the discrepancy between the rising enhancement use 
and the inconclusive empirical evidence for its effectiveness would be to hypothesize an 
inconsistency between stimulants’ perceived and actual effects on healthy cognition. 
Specifically, people may use stimulants for cognitive enhancement because they feel 
that the drugs improve their performance, even in the absence of actual effects. For this 
to be the case, two conditions need to be satisfied: first, participants must perceive their 
own performance as higher; second, they must attribute this higher performance to the 
drug. 
Addressing the former condition, a number of studies have asked whether self-
estimation of performance increases as a function of stimulants. This idea was first 
considered by researchers in the middle of the 20th century, motivated in part by 
concerns about amphetamine’s effect on the judgment of military personnel.  For 
example, Davis (1947) summarized his experience with British soldiers in World War II 
by writing that “the subject who has taken amphetamine usually judges the effects more 
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favorably than the experimenter.”  Experimental evidence has provided converging 
support for this finding (Smith & Beecher, 1964; Hurst, Weidner & Radlow, 1967, 
despite a null finding in Baranski et al., 1997). In Smith & Beecher’s double-blind, 
placebo-controlled trial on amphetamine, participants took a calculus test.  Although 
they overestimated their performance in both conditions, the magnitude of 
overestimation was significantly greater in the amphetamine group.  In a recent study 
with modafinil, a nontraditional stimulant, Baranski, Pigeau, Dinich & Jacobs (2004) 
reported a trend toward more positive evaluation of performance with modafinil 
compared to placebo in a battery of cognitive tests.  The idea that drug effects on 
subjective assessment of performance may interfere with our ability to judge drug 
effectiveness for cognitive enhancement was raised more recently by Hall and Lucke 
(2010) who pointed out that, when taken by healthy people, stimulants may inflate self-
confidence, while failing to improve actual performance.  Although previous research 
has reported some evidence for amphetamine’s effects on self-evaluation, no research 
study, to our knowledge, has assessed whether participants specifically attribute this 
improved performance to the drug. Only if this is the case can the subjective drug 
effects explain the growing stimulant enhancement use in the absence of firm evidence 
for actual effects.  For this reason, in addition to measuring the objective effects of the 
MAS on cognitive performance, we also obtained rating of subjective perceptions of the 
effects of the ingested pills. 
The Present Study 
The purpose of the present double-blind, placebo-controlled, crossover study 
was to examine the actual and perceived cognitive enhancing effects of MAS on 
healthy young adults who were not sleep-deprived.  MAS is equivalent to the brand 
name drug Adderall, which has been characterized as the “drug of choice” for cognitive 
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enhancement among college students (DeSantis, Noar & Webb, 2009).  We predicted 
that, relative to placebo, Adderall would improve performance on a wide range of 
cognitive functions, including episodic and working memory, inhibitory control and 
creativity, as well as performance on tasks based on standardized tests. We further 
expected that low cognitive performers, as well as carriers of the val-val variant of the 
COMT gene would benefit from the drug more that high performers and met-met 
carriers, respectively. An alternative hypothesis was that MAS might evoke a subjective 
perception of enhancement, more salient than the drug’s actual enhancing effects. If 
substantiated, either of these predictions would provide a possible explanation of the 
growing psychostimulant use among healthy people. 
Method 
Participants 
Participants were 46 Caucasian native English speakers (22 male and 24 
female), aged 21-30 (M age = 24, SD = 2.88), who responded to advertisements posted 
in the area of Drexel University and the University of Pennsylvania, as well as to email 
announcements at the University of Pennsylvania), inviting participation in tests of 
memory, creativity, intelligence and personality. Participants were excluded if they 
reported a history of medical conditions contraindicated for stimulant use, including any 
neurological or psychiatric disease, seizure disorder, high blood pressure, glaucoma, 
gastrointestinal blockage, heart disease, or thyroid problems.  Also excluded were 
participants using any other stimulants or substances that could interact with 
amphetamine, including addictive, psychoactive, neurological and blood-pressure 
drugs; anti-histamines; non-prescription dietary supplements; weight-loss pills, and 
caffeine consumption estimated to exceed 700mg/day.  Off-drug blood pressure 
measured to exceed 140/90 at the beginning of the study was another exclusion 
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criterion because of the likelihood that the drug would increase blood pressure further.  
Women who were pregnant or likely to become pregnant were not allowed to 
participate.  We also excluded potential participants who had previously used 
psychostimulant drugs to rule out sensitization (Paulson & Robinson, 1995) as an 
explanation for enhancement effects and tolerance (Schenk & Partridge, 1997) as an 
explanation for a lack of such effects.  
Drug 
20 mg of mixed amphetamine salts (sulfate salts of dextroamphetamine and 
amphetamine, with the dextro isomer of amphetamine saccharate and d, l-
amphetamine aspartate monohydrate, with d-amphetamine and l-amphetamine in 3:1 
ratio) and placebo were administered in visually indistinguishable capsules. The 
selected dose is within the range of doses used in the enhancement literature, with 
some studies using lower doses, some higher, and some equivalent (Smith & Farah, 
2011). The test drug was supplied by the University of Pennsylvania Investigational 
Drug Service.  
Tasks 
There were three versions of each task, to avoid repetition of items or trial 
orders across baseline, placebo and MAS conditions.  The three versions were of 
moderate and comparable difficulty as determined by pilot testing.  One version was 
consistently used for the baseline condition while the other two versions were used 
equally often in the MAS and placebo conditions.  The 13 measures are listed in Table 
1.1 and are described here. 
Memory. The consolidation of information into memory is central to learning and 
hence to academic and life success. Two tasks assessed memory with measures of 
verbal and visual recognition and verbal recall. 
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Face Memory. In this test of episodic memory participants saw a sequence of 
20 briefly flashed face images. Each stimulus was presented for 2250 ms, with an inter-
trial interval of 750 ms. Encoding was followed by approximately two hours of cognitive 
testing, after which participants completed a recognition test. This test consisted of the 
20 previously presented targets intermixed with 20 new faces. Presentation duration 
and inter-trial interval at test were the same as those at the encoding phase. Our main 
dependent measure was number correct (total number correct out of total number of 
trials presented). 
Word Memory (two measures). Another test of episodic memory, this task 
presented participants with 25 words presented for 3s each with no intertrial interval.  
After approximately two hours performing other cognitive tasks, two measures of word 
memory were then obtained.  In word recall, participants freely recalled as many words 
as possible.   Performance was measured as number recalled.  A word recognition test 
followed, in which participants viewed the 25 earlier words intermixed with 25 new 
words, presented in the same way as during encoding. The dependent measure in this 
case was number correct. 
Working memory. Working memory is an aspect of executive function that 
involves active short-term maintenance of information and is essential for many forms 
of thinking and problem-solving.  Two tasks assessed verbal and visual working 
memory. 
Digit Span Forward and Backward (two measures). In this test of working 
memory, derived from a subtest of the Weschler Adult Intelligence Scale, the 
experimenter read digit sequences at a rate of approximately 1 digit per second and 
participants typed each sequence immediately after hearing it. In the Digit Span 
Forward task, 14 sequences were presented, with two each of lengths from 2 to 8. 
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Participants reported the digits in the order they heard them. In the Digit Span 
Backward condition, 14 different sequences of length 2-8 were presented and 
participants reported the digits in reverse order. The digit sequences gradually 
increased in length (from two to eight digits). A response was counted as correct only if 
all the digits within a sequence were reported correctly and in the correct order (i.e., no 
partial credit). Number correct for Digit Span Forward is generally viewed as a simple 
measure of maintenance capacity and Digit Span Backward as a measure of ability to 
simultaneously maintain and process information (The Psychological Corporation, 
2002). 
Object-2-Back. Object-2-Back tests the ability to maintain and update 
information in working memory despite interference (Postle, D’Esposito, & Corkin, 
2003).  Participants saw a sequence of 155 random polygons, each flashed briefly, for 
duration of 1000ms. Interstimulus interval was 500 ms. Participants had to press a 
button every time the currently presented object matched the object two shapes back. 
The dependent variable was the number of omission errors, which is associated 
specifically with working memory ability in n-back tasks (Oberauer, 2005). 
Inhibitory control. The ability to withhold a habitual response or resist 
distraction by a salient stimulus is important for enabling us to act appropriately in many 
contexts.  Two tasks assessed inhibitory control over responses and stimuli. 
Go/No-go.  Go/No-Go is a test of inhibitory control (see Braver, Barch, Gray, 
Molfese & Snyder, 2001), in which participants viewed a sequence of briefly flashed 
digits 1-9 (stimulus duration: 300ms; interstimulus interval: 400ms). Participants were 
asked to press a key as quickly as possible in response to all digits except for the digit 
4. The digit 4 appeared on 15% of the 200 trials. For this task, the only opportunities for 
inhibitory control failure occur on the “4” trials and therefore the dependent measure 
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was the number of commission errors (i.e., the number of trials on which participants 
failed to withold a response to the “4”; Helmers et al., 1995).  
Flanker. This test of inhibitory control (Eriksen & Eriksen, 1974) presented 
participants with 200 images of five horizontally aligned arrows. Participants were 
instructed to indicate as quickly and accurately as possible the direction (left or right) of 
the central arrow. In congruent trials, all arrows pointed in the same direction. In 
incongruent trials, the middle arrow pointed in a direction opposite to that of the 
peripheral arrows. The sequence consisted of an equal number of congruent and 
incongruent stimuli. Each stimulus remained on the screen until the participant 
responded; the response initiated a 1s blank screen before the next stimulus appeared. 
The measure of inhibitory control, termed here inhibition cost, was the ratio of the 
median reaction time of incongruent trials to the median reaction time in response to 
congruent trials. 
Creativity. Creativity is often defined as the ability to recombine familiar 
concepts in new and useful ways.  It has been operationalized with tasks that require 
participants to find associations among disparate concepts and to view complex visual 
patterns in alternative ways.  The two tasks used here were previously used by us in a 
study of the effects of MAS on creativity (Farah, Haimm, Sankoorikal, Smith & 
Chatterjee, 2008).  
Remote Associations Test. In this test of convergent creativity (Mednick, 
1962) participants must generate the word which associates a group of three other 
words. For example, presented with the stimulus triad “round – manners – tennis,” they 
had to answer “table.” The test included 15 triads, for each of which participants had 30 
s to respond. The dependent measure was number correct. 
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Group Embedded Figures Task. Another measure of convergent creativity 
(Noppe & Gallagher, 1996) this test presented participants with complex geometric 
designs and a smaller element from the design. Within each larger design participants 
had to find and trace the specificed target element, which is “embedded,” that is, not 
immediately apparent, given the overall visual gestalt of the design.  An example is 
shown in Figure 1.1. Participants completed 6 items within a 2-minute time-limit for the 
whole test. The dependent measure was number correct. 
Standardized tests. Among the many standardized tests of intelligence and 
achievement are Raven’s Advanced Progressive Matrices, a nonverbal test of fluid 
intelligence, and the Scholastic Achievement Test (SAT), taken by college applicants in 
the US.  The two tasks here were composed of individual items taken from these 
standardized tests. 
Raven’s Advanced Progressive Matrices.  In this test of nonverbal 
intelligence (Raven, 1976) participants saw a series of abstract patterns, each of which 
had a missing piece. Participants had to choose the best fitting piece from 6 options.  
Each version of the test consisted of 12 items. Completion time for the whole test was 
limited to 10 min. The measure of interest was number correct. 
Scholastic Achievement Test (SAT; two measures).  This standardized test 
includes sections assessing “critical reading,” “writing” and “mathematics.”  We selected 
questions from a book of practice tests and grouped them into two sections, “Verbal” 
and “Math.”  The former consisted of 48 multiple-choice questions completed under a 
40-minute time limit.  Question types (and corresponding number of questions) were as 
follows: Sentence Completion (7), Reading Comprehension (26), Improving Sentences 
(9), Identifying Sentence Errors (6). The Math section consisted of 27 questions (19 in 
multiple-choice and 8 in free-response format) testing algebra, geometry and other 
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miscellaneous high-school-level problems, to be completed under a 28-minute time limit 
without the use of a calculator.  The measures of interest for SAT-Verbal and SAT-Math 
were number correct. 
Perceived drug effect. Perceived effect was examined through the following 
self-report prompt: “The following question refers to all tests completed TODAY. How 
and how much did the drug influence (either positively or negatively) your performance 
on the tests? Please use the scale below. You answer can be any number between 1 
and 100." The scale referred to was a line, ranging from 1 to 100, and labeled as 
follows: 1 = “the drug impaired my performance extremely”; 25 = “the drug somewhat 
impaired my performance”; 50 = “the drug had no effect”; 75 = “the drug somewhat 
improved my performance”; 100 = “the drug improved my performance extremely. 
Procedure 
The study took place over seven sessions, which included consent and practice 
(Session 1), followed by the full battery of cognitive tasks, for the baseline (i.e., no pill), 
placebo and MAS conditions (Sessions 2-7).  Baseline testing (Sessions 2-3) always 
preceded drug/placebo testing (Sessions 4-7) to minimize the influence of practice 
effects on data from the placebo and MAS conditions. During on-pill Sessions 4-7, the 
order of drug administration was counterbalanced, in a way that 24 participants 
received MAS in Sessions 3 and 4, and 22 participants received the drug in Sessions 6 
and 7 The timeline of the study, including session sequence and timing, is presented in 
Figure 1.2.  
Session 1: Intake interview, instructions and practice. The first session 
consisted of consent procedure, followed by practice versions of the actual tests. The 
practice tests were identical to the experimental versions, except for comprising of 
fewer trials and different items. At the end of the session, participants were instructed to 
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abstain, for the rest of the study, from drugs containing stimulants or interacting with 
stimulants (or to notify the study personnel if they had to take such drugs). Participants 
were also asked to avoid heavy meals on test days. 
Session 2 and 3: Baseline testing. Sessions 2 and 3 provided a measure of 
unmedicated (off-drug, off-placebo) performance.  The placebo condition was not used 
as a measure of baseline, so that regression to the mean would not be mistaken for 
moderation by cognitive ability.  
After the initial blood pressure measurement, participants completed an SAT 
test (one Verbal and one Math section) and a battery of cognitive tests (described 
above), respectively in Session 2 and 3. These baseline tests were a version of the to-
be-administered on-pill battery.  
Sessions 4-7: Testing on drug and placebo. The goal of these four sessions 
was to measure participants’ cognitive performance on MAS and on placebo. At the 
onset of these sessions, participants reported the amount of sleep and caffeine 
consumption during the previous 24 hours. They answered questions on their diet and 
medication intake to determine compliance with earlier instructions and had their blood 
pressure measured at the beginning and end of these sessions. Participants  also 
underwent a urine drug test to corroborate self report and deter use of excluded drugs 
(amphetamine, cocaine, barbiturates, benzodiazepine, phencyclidine and 
tetrahydrocannabinol). Female participants were administered a urine pregnancy test.  
Participants with positive results on any of these tests were excluded. After an initial 
blood pressure measurement (participants were excluded if the measurement 
exceeded 140/90), participants were randomly assigned to take either MAS (20mg) or a 
visually indistinguishable placebo capsule in a double-blind manner. A 75-minute 
waiting period followed. We chose this interval to ensure that the peak drug plasma 
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level, which is reached 2-3 hours after administration (Angrist et al., 1987) would occur 
during the testing. During the waiting time participants remained in the testing area and 
either read student periodicals or watched documentary DVDs (no homework or 
exciting movies were allowed).  Five minutes before testing (70 minutes after drug 
intake), blood pressure was taken again and participants were excluded if the 
measurement exceeded 150/100. In sessions 4 and 6 the battery of tests included 
personality, mood and attributional style questionnaires (not relevant to cognitive 
enhancement and therefore not discussed further here) and test materials assessing 
verbal and mathematical abilities from the SAT.  In sessions 5 and 7 the remaining 
cognitive tests were administered, in the same order for all participants. The two 
nonbaseline versions of the tasks were counterbalanced with both drug condition (MAS, 
placebo) and session order. After the cognitive battery (sessions 5 and 7) participants 
reported their perception of the pill’s influence on their performance using the scale 
described earlier. At the end of the session, participants were reminded of the 
restriction on caffeine use and heavy-meal consumption for the rest of the study. If 
finishing the study, participants were thanked and paid. 
Data Analysis Approach 
Outlier removal. We removed outliers by excluding individual scores 3 SD 
above or below the mean of either the drug, placebo or baseline on each cognitive and 
subjective measure. If, on a particular measure, an individual participant’s baseline, 
drug, or placebo score met the criterion for an outlier, we excluded all the data (i.e., 
MAS, Placebo and baseline) of this participant from analyses of that same task. This 
led to the exclusion of a total of 22 data points, or .85% of all data.  
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Missing Data. 143 task performance measures (or 5.55% of all data) were 
missing due to technical problems (50 data points), evidence of participants’ failure to 
understand the task instructions (9 data points), or experimenter error (84 data points). 
Statistical Tests. In overview, our approach to statistical testing was based 
primarily on mixed model analysis of variance (ANOVA) with drug (MAS or placebo) as 
a within-subjects factor and drug order and test version order as between-subject 
factors.  Multivariate analysis of variance (MANOVA) was used to assess the effects of 
drug across all 13 measures of cognitive ability and ANOVA to assess drug effects on 
each individual measure of cognitive ability and on ratings of perceived enhancement.  
Moderation of cognitive enhancement by baseline ability and COMT genotype was 
tested within the same framework.  We also use multivariate regression and simple 
bivariate correlation in order to test two specific relations involving non-categorical 
factors (the moderating effect of COMT val load and the relation between perceived and 
actual enhancement).  All analyses were conducted in SPSS 20. The significance 
threshold was set to the standard cutoff of .05.  Results are reported without correction 
for multiple comparisons, a lenient approach that maximizes our ability to identify 
positive results at the risk of increasing possible false positive results. 
Results 
 
Effects of Mixed Amphetamine Salts 
Table 1.2 shows the means and standard deviations of performance in each 
task for the baseline, placebo and MAS conditions. To examine whether cognitive 
performance differed between MAS and Placebo sessions, we conducted a 2(Drug: 
MAS; Placebo) x 2 (Drug Order: MAS first; Placebo first) x 2 (Test Version Order: 
Version 1 first; Version 2 first) mixed-model MANOVA with repeated measures on the 
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first factor. The dependent variables were scores for 13 measures (listed in Table 
1.1).On this test, the difference between MAS and placebo performance did not reach 
significance (F (13, 13) = 1.71, p = .17), indicating that there was no overall enhancing 
effect of MAS on cognitive performance in the tasks.  We also failed to observe any 
significant two-way interaction between the drug conditions and either the drug order or 
the version order: (F (13, 13) = .59, p = .83; F (13, 13) = 1.28, p = .33, respectively).  
The absence of a Drug x Drug Order interaction indicates that MAS is no more or less 
enhancing when taken before or after the placebo session.  However, given the 
inclusion of a Baseline condition before all MAS and placebo conditions, these results 
do not rule out the possibility that MAS could enhance performance with novel tasks.  A 
marginally significant three-way (Drug x Drug Order x Version Order) interaction was 
observed (F (13, 13) = 2.14, p = .09). This interaction, which indicates differential drug 
effects on different versions of the tasks depending upon the order in which they were 
performed, does not lend itself to any obvious interpretation.  The possibility that the 
versions differed in difficulty, and the order in which they were encountered 
synergistically compounded these difficulty differences, is not supported by a 
comparison of performance across versions from placebo conditions. 
Although we began by testing the multivariate hypothesis that MAS would 
enhance overall performance across tasks, we also had a priori hypotheses about MAS 
effects on each of the 13 measures obtained in the project.  We therefore followed up 
the MANOVA with a series of univariate 2 (Drug: MAS; Placebo) x 2 (Drug Order) x 2 
(Test Version Order) mixed-model ANOVAs with repeated measures on the first factor. 
These analyses tested the effect of MAS on each of the 13 cognitive measures listed in 
Table 1.1. Again, these analyses revealed no effects of MAS and no two-way 
interactions between drug and order or drug and version for any of the 13 measures. 
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The three-way interaction trend noted above emerged as significant (without correction 
for multiple comparisons) for five of the thirteen measures: Face Recognition, Flanker, 
Remote Associations, Embedded Figures, SAT Math. All main effects and interactions 
are shown in Table 1.1. 
Faced with null results for the effect of MAS on cognitive performance in these 
tasks, we asked whether differences in participants’ sleep prior to the MAS and placebo 
test days could have obscured the drug’s enhancing effect.  Self-reported sleep 
duration did not differ significantly between the sessions (t (41) = .91, p = .37 for 
neurocognitive testing sessions; t (45) = .74, p = .47 for SAT sessions), and showed a 
trend in the opposite direction to that hypothesized here, toward more sleep before 
MAS test sessions (M = 7.12, SD = 1.26 for neurocognitive testing sessions; M = 7.15, 
SD = 1.30 for SAT sessions) than placebo (M = 6.89 h, SD = 1.53 for neurocognitive 
testing sessions; M =6.98, SD = 1.45 for SAT testing sessions). 
Moderation of MAS Effect by Baseline Performance 
To determine whether MAS enhances cognition for some people, with an effect 
that is moderated by baseline cognitive performance, we first separated participants 
into two groups according to whether their baseline performance was above or below 
the median and then conducted a series of 2 (Drug: MAS; Placebo) x 2 (Baseline 
Performance: Below-Median; Above-Median) x 2 (Drug Order) x 2 (Test Version Order) 
mixed-model ANOVAs with repeated measures on the first factor for each of the 13 
cognitive performance measures. (MANOVA was not carried out because different 
participants fall in the upper and lower groups for different measures).  Significant 
interactions between drug and baseline performance emerged on two measures: Word 
Recall (F (1,36) = 4.78, p = .04) and, replicating our earlier study of MAS effects on this 
task (Farah et al., 2008), Embedded Figures (F (1, 28) = 8.48, p < .01). There was also 
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a marginal trend toward significance for Raven’s Progressive Matrices ( F (1,29) = 2.83, 
p = .10).  In all three cases, the pattern of means was consistent with the prediction, 
based on the literature discussed earlier, of relatively more enhancement for the lower 
performing participants.  As shown in Figure 1.3, MAS tended to improve performance 
for the below-median baseline performers, while acting in the opposite direction for the 
above-median performers.   
In addition to comparing the effects of MAS between higher and lower 
performing participants, we can also ask whether low performers, the subgroup 
exclusively expected to benefit from the drug, shows enhancement. This question was 
addressed by a series of 2 (Drug: MAS; Placebo) x 2 (Drug Order: MAS first; Placebo 
first) x 2 (Test Version Order: Version 1 first; Version 2 first) mixed-model ANOVAs with 
repeated measures on the first factor for each of the 13 measures only among the 
subsample performing below the median on baseline.  The effect of the drug was 
significant on Word Recall (F (1, 16) = 6.71, p = .02, Embedded Figures (F (1, 12) = 
8.41, p = .01; and Raven’s Progressive Matrices (F (1, 16) = 5.36, p = .03). None of the 
remaining measures showed evidence of enhancement for the lower performing 
participants. See Table 1.3. for other results which, because extraneous to our 
prediction, are not discussed further. 
Moderation of MAS Effect by COMT Genotype.   
Given the findings reviewed earlier of moderation of amphetamine enhancement 
effects by COMT genotype, we divided participants into three groups depending on 
whether they had val-val, val-met, or met-met alleles of COMT.  Because a MANOVA 
using genotype as a 3-level factor would not capture the ordering among the three 
groups we instead employed three alternative sets of analyses. 
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First, we conducted a regression analysis, which included val load, drug order 
and version order to predict a composite of the differences between MAS and placebo.  
The overall model was not significant, p = 0.28.  Second, we carried out thirteen 
additional regressions to examine the effects of val load, drug order and version order 
on MAS effect (i.e., drug minus placebo score) on each separate measure. Overall 
regression models for SAT Math and Verbal were marginally significant (F (3,43) = 
2.52, p = .07; F (3,43) = 2.25, p = .10, respectively). On SAT Math, the effect of COMT 
was significant (b = .35, t = 2.38, p = .02); this effect was near significant on SAT Verbal 
(b = .24, t = 1.64, p = .11). The patterns of means complied with the prediction that 
people with val-val genotype are more susceptible to enhancement than those with 
met-met genotype (see Figure 1.4).  
Third, we used MANOVA to contrast the effects of MAS on the two groups of 
homozygous participants with a 2 (Drug: MAS; Placebo) x 2 (COMT genotype: val-val; 
met-met) x 2 (Drug Order) x 2 (Test Version Order) mixed-model MANOVA, as well as 
with corresponding ANOVAs for each of the 13 measures.  Neither the multivariate test 
for COMT moderation was significant, ( F (5, 1) = .64, p = .73), nor any of the univariate 
tests, p > 0.26 in all cases, with the exception of a significant Drug x COMT interaction 
on SAT Math (F (1, 11) = 13.06,  p < .00) which again complied with the predicted 
pattern of relatively greater enhancement for homozygous val than homozygous met 
participants (see Figure 1.4).  Additionally, a significant drug effect emerged on SAT 
Math: F (1, 11) = 5.63,  p = .04, although as shown Figure 1.4, this main effect of drug 
was an overall impairing effect. Main effects of COMT genotype were found for Word 
Recognition (F (1, 10) = 5.42, p = .04), along with borderline significant effects for Word 
Recall (F (1, 10) = 4.65,  p = .06), SAT Verbal (F (1, 11) = 4.24,  p = .06) and Object-2-
  
 
 
 
22
Back Omissions (F (1, 10) = 4.22,  p = .07). The met-met genotype was associated with 
better performance than the val-val in all three cases.  
As with the analyses of baseline performance moderation, we followed up these 
analyses of genotype moderation with direct comparisons of drug and placebo 
performance in just the subjects for whom the drug would be expected, a priori, to be 
more helpful.  We first carried out a 2(Drug: MAS; Placebo) x 2 (Drug Order: MAS first; 
Placebo first) x 2 (Test Version Order: Version 1 first; Version 2 first) mixed-model 
MANOVA with repeated measures on the first factor and the 13 performance measures 
as the dependent variables.  The effect of MAS did not reach significance (F (2, 1) = 
.27, p = .81), nor did other effects or interactions, p > .49 in all cases. We then ran a 
series of 2 (Drug: MAS; Placebo) x 2 (Drug Order: MAS first; Placebo first) x 2 (Test 
Version Order: Version 1 first; Version 2 first) mixed-model ANOVAs with repeated 
measures on the first factor for each of the 13 measures only among the subsample 
homozygous for the val allele. The effect of the drug did not reach significance on any 
of the measures (all p’s > .24). See Table 1.3. for other results which, because 
extraneous to our prediction, are not discussed further. 
In sum, as with the analysis of moderation by baseline performance, we found 
mixed evidence for the moderation by COMT: little evidence supported the predicted 
moderation but when such moderation was observed, it was generally consistent with 
the hypothesis of relatively greater enhancement in carriers of the val allele. 
Perceived enhancement 
We examined MAS’s effect on perceived enhancement through a 2 (Drug: MAS; 
Placebo) x2 (Drug Order) x2 (Test Version Order) ANOVA, with repeated measures on 
the first factor. A main effect of drug (F (1, 40) = 4.09, p = .05) indicated that 
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participants perceived MAS (M = 55.18, SD = 14.87) as slightly more beneficial for 
cognitive performance than placebo (M = 50.25, SD = 3.95). 
Although the earlier analyses demonstrate that MAS did not enhance cognition 
by any of the measures examined, it is nevertheless possible that subjective 
perceptions of enhancement are related to degree of true enhancement.  To test this, 
we correlated the difference in perceived enhancement between MAS and placebo, on 
the one hand, and the corresponding difference scores on each of our 11 cognitive 
performance measures (no measure of perceived enhancement was administered 
during SAT Math and Verbal sessions). Ten of the 11 correlations did not reach 
statistical significance.  A significant correlation emerged between perceived and actual 
enhancement on Go/No-go (r = .33, p = .04).  To assess the relation between 
subjective perceptions and performance on all of the tasks together, we also created a 
composite of the differences between MAS and placebo sessions from each measure. 
This composite score did not correlate significantly with perceived enhancement: r = -
.06, p = .76.  In sum, on average participants believed that the MAS had enhanced their 
cognitive performance more than placebo.  This perception stands in contrast to the 
reality: There was no actual enhancement on average nor were participants who felt 
more enhanced by the MAS more likely to show a true enhancement effect. 
Discussion 
 
Conclusions and relation to wider enhancement literature 
Does MAS enhance cognition in healthy young adults? Our study was designed 
to overcome several challenges that have hampered previous attempts to answer this 
question.  It had sufficient power to detect a medium-size effect for any one measure of 
cognitive performance.  We nevertheless failed to find enhancement with any of the 13 
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measures we used.  Of course, a different drug or a different does of MAS have led to a 
different finding. Nevertheless, we can state that a standard clinical dose of a drug that 
is commonly used for cognitive enhancement did not enhance cognition in an 
adequately powered study. The most straightforward interpretation of these results is 
that MAS is not a powerful cognitive enhancer.  If it does enhance cognition in healthy 
and adequately-rested young adults, the effects are likely to be small. 
These findings raise the question of why many published studies find large 
effects of amphetamine on cognitive performance with tests of memory, executive 
function and other cognitive processes.  We believe that the answer is related to a set 
of problems, specifically low study power, flexibility in specific outcomes to be tested 
and publication bias against null results, which bedevil all branches of science, as 
explained in Ioannidis’s (2005) provocatively titled article, “Why most published 
research findings are false.”  The impact of these problems on psychology and 
neuroscience research, in the absence of any intentional malfeasance has been 
discussed by Ioannidis (2011), Lehrer (2010) and Simmons, Nelson & Simonsohn 
(2011) among others.  Research on cognitive enhancement is not particularly 
susceptible to these problems, compared to other research topics, but neither is it 
immune to them.  As a result, it is difficult to estimate the true robustness and effect 
size of cognitive enhancement with MAS and other stimulant medications by surveying 
the published literature.  
On the assumption that the enhancing effects are real but are too small to be 
reliably captured in studies with sample sizes in the range typically used, one would 
expect a mix of positive and null results to be obtained.  Of course, those effects that 
are found would show relatively large effect sizes, because only those results that by 
chance err on the large side would achieve significance.  This is the pattern that we 
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have seen in the literature, particularly regarding the effects of amphetamine on 
executive functions (Smith & Farah, 2011).  
In the present study we also tested the hypotheses that MAS is enhancing for 
subsets of healthy young adults, specifically those who are less cognitively capable or 
who are homozygous for the Val allele of the COMT gene.  Here too we generally failed 
to support these hypotheses, although a minority of specific statistical tests showed the 
predicted patterns. 
Finally, we found a small but reliable effect of MAS on judgments of 
enhancement, reminiscent of Davis’s (1947) observations of soldiers in World War II 
quoted earlier.  Participants believed themselves to be more enhanced by the pill when 
given MAS compared to placebo.  Although not apparent for every individual 
participant, the overall tendency was for participants to feel that their cognitive 
performance has been enhanced by MAS.  This may in part explain MAS’s popularity 
as a cognitive enhancer. 
Limitations of the present study  
The present study was carefully designed to sample a wide array of cognitive 
abilities, to have adequate power and to measure potential moderators.  In other 
respects, however, its design leaves some important questions unanswered.  Most 
importantly, like most published studies in the enhancement literature (Smith & Farah, 
2011), we did not vary drug dose and cannot know whether a higher or lower dose of 
the drug might have produced different results.  Similarly, we did not test the cognitive 
enhancing potential of other enhancers, such as methylphenidate and modafinil, leaving 
open the possibility that these drugs may significantly improve healthy people’s 
cognitive performance. We did not measure bioavailability of the drug (e.g., plasma 
amphetamine) and so cannot quantify how this varied across participants and sessions, 
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for example as a function of individual differences in drug metabolism or food 
consumed before a session.  Different or more frequent assessments of the perceived 
effects of MAS might have revealed more nuanced results or measured perceived 
enhancement more reliably. Our participants were not representative of the general 
population; in addition to the restricted age range, they met a number of health and 
lifestyle criteria for inclusion, including never having used prescription stimulants and 
being low or moderate consumers of caffeine.  Perhaps different results would have 
been obtained with people who have already self-selected to use stimulants or who 
enjoy large daily doses of caffeine. 
Implications for neuroethics 
The present results have several implications for the neuroethics of cognitive 
enhancement.  We believe that the issues of fairness, freedom and agency, discussed 
so extensively in the neuroethics literature (e.g., Farah, Illes, Cook-Deegan, Gardner, 
Kandel, King, Parens, Sahakian, & Wolpe, 2004) are not moot despite the present 
results.  It is of course true that the most thoughtful and incisive ethical analysis is 
pointless if applied to an inaccurate representation of the empirical facts of the matter.  
But we believe that Hall and Lucke (2010) are too dismissive of the realities of cognitive 
enhancement when they write “Guidelines for enhancement prescription are … 
premature.  More skepticism needs to be expressed about neuroenhancement claims 
for pharmaceuticals and bioethicists should be much more cautious in … making 
proposals that will facilitate such use.” (p. 2042).  The present results suggest only that 
the effects of one currently available enhancement drug are small when measured in 
laboratory tests of memory, executive function and tests of intellectual aptitude.  These 
results leave many questions unanswered. 
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Among the important open questions are: How helpful might a small 
enhancement effect be over time? Might the effects be larger when measured under 
real-world conditions (e.g., with distractions in the environment or for longer and hence 
more tedious tasks than the typical memory or executive function experiment) or in a 
different state (e.g., after sleep deprivation)?  Does MAS exert a larger effect on other 
processes, such as motivation to work, which are not captured by laboratory studies of 
memory and executive function but which nevertheless impact academic and other 
cognitive work?  Or are users primarily attracted to this drug because of the illusory 
perception of enhancement our participants reported?  These are important questions 
for future research, which will furnish the needed empirical basis for discussions of 
enhancement ethics and policy. 
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CHAPTER 2 
PRESCRIPTION STIMULANTS’ EFFECTS ON HEALTHY INHIBITORY CONTROL, 
WORKING AND EPISODIC MEMORY: A META-ANALYSIS 
 
The scientific and popular literatures both document the use of prescription 
medications by healthy young people to enhance cognitive performance in school and on 
the job (e.g., Smith & Farah, 2011; Talbot, 2009).  This practice, called ‘cognitive 
enhancement’, has provoked wide discussion of its potential social, ethical and public 
health consequences (Farah et al., 2004; Greely et al., 2008; Sahakian & Morein-Zamir, 
2011). Recently another question concerning cognitive enhancement has arisen:  To what 
degree do the medications used for cognitive enhancement in fact improve the abilities of 
cognitively normal individuals?  
In view of the prevalence of cognitive enhancement and the intensity of academic 
and policy interest in this practice, it is surprising that the answer to this question has not 
been clearly established.  The empirical literature on the effects of these stimulants on 
cognition in normal subjects has yielded variable results, with some reviewers doubting 
their efficacy altogether.  For example, in reviewing the literature on the cognitive effects of 
methylphenidate, Repantis, Schlattmann, Laisney & Heuser (2010) concluded that they 
were “not able to provide sufficient evidence of positive effects in healthy individuals from 
objective tests.” Hall and Lucke (2010) stated “There is very weak evidence that putatively 
neuroenhancing pharmaceuticals in fact enhance cognitive function.” Advokat (2010) 
concluded her review of the literature by stating that “studies in non-ADHD adults suggest 
that stimulants may actually impair performance on tasks that require adaptation, flexibility 
and planning.” 
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Smith and Farah (2011) attempted to test the hypothesis that stimulants enhance 
cognitive performance in normal healthy subjects with a systematic literature review.  We 
included studies of amphetamine and methylphenidate’s effects on episodic and procedural 
memory and three categories of executive function: working memory, inhibitory control, and 
third category of other executive function tasks that did not fit into either of the first two.  
Results were mixed, large effects, small effects and null effects all reported. For example, 
over a third of the executive function studies reported null results. One interpretation of this 
pattern is that the drugs confer a small benefit, which may fail to be detected in some 
studies because of inadequate power.  The other possibility that chance positive findings, 
combined with publication bias, may be responsible for the positive evidence that exists in 
the literature.  Thus, despite the large literature included in our review, we were forced to 
conclude that “there remains great uncertainty regarding the size and robustness of these 
effects.” Meta-analysis is a method that can distinguish between the competing 
interpretations of the findings in the cognitive enhancement literature. 
The primary goal of the present meta-analysis is to obtain a quantitative estimate of 
the cognitive effects of the stimulants amphetamine and methylphenidate.  They are 
commonly prescribed for the treatment of Attention Deficit Hyperactivity Disorder, but are 
frequently diverted for enhancement use by students and others (e.g., McCabe et al., 2006; 
Puolin et al., 2007; Wilens et al., 2008).  Guided by the findings of Smith and Farah’s 
(2011) review, we focus on the cognitive processes that seemed most likely to be 
enhanced by stimulants, specifically inhibitory control, working memory and episodic 
memory.  In addition, because this earlier review found the strongest evidence of episodic 
memory enhancement after long delays between learning and test, we distinguish between 
episodic memory tested soon after learning (within 30 minutes following learning trials) and 
episodic memory tested after longer intervals (1 hour to 1 week).  
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The meta-analysis has two additional goals:  One is to test hypotheses about 
moderators of the effects, that is, differences between studies that might account for the 
variability in effectiveness noted across different studies.  For example, perhaps one of the 
stimulants is effective and the other less so, or perhaps low doses are more effective than 
higher doses.  The final goal is to assess the role of publication bias in shaping the 
literature and potentially inflating effect size estimates.  This would happen if, as 
hypothesized previously (e.g., Smith & Farah, 2011), underpowered studies obtained large 
statistically significant effects by chance and thereby entered the literature while the 
balancing effects of smaller or null results from similar studies remained unpublished. 
Method 
Search strategies 
Online databases PubMed and PsychInfo were searched with key words 
“amphetamine” and “methylphenidate,” each combined with each of the following: 
"executive function," "executive control," "cognitive control," “inhibitory control," “inhibition,” 
“working memory,” “flanker,” "stop signal task," "stop task," “no-go,” “card-sort,” “ID/ED,” 
"set shifting,” “Sternberg memory,” “Stroop,” “Digit Span,” “memory,” “learning,” “recall,” 
“recognition,” “retention.” These searches were narrowed to exclude research on non-
human subjects, qualitative studies, and non-empirical publications (e.g., review papers, 
meta-analyses, lectures, news articles, etc.).  In addition, the reference sections of the 
following review papers were searched for relevant articles: Advokat (2010), Chamberlain 
et al. (2010), Repantis, et al. (2010) and Smith & Farah (2011). Finally, we searched the list 
of articles being reviewed by an American Academy of Neurology committee studying 
cognitive enhancement on which the last author serves.  All research published through the 
end of December 2012 was eligible.  
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We also sought relevant unpublished data to include in the meta-analyses. Twenty 
researchers active in the area were contacted for unpublished data on amphetamine or 
methylphenidate effects on episodic memory, working memory or inhibitory control in 
healthy non-elderly adults.  In addition, fourteen requests were made for additional data 
from studies published in the past 10 years but originally reporting insufficient data to 
calculate effect sizes. This led to obtaining 2 data sets of studies in progress or in 
submission, as well as additional effect size data from 4 published reports.   
Criteria for study eligibility 
Publication type and language. Empirical investigations in any report format were 
eligible for inclusion in the meta-analysis. These included journal articles, as well as 
dissertations, conference presentations and unpublished data sets. The latter three were 
considered in an attempt to minimize the influence of publication bias on the obtained effect 
size estimates. Only reports in English were included. 
Participants. Eligible participants were young and middle-aged adults. Research 
on children, elderly, criminal or mentally ill participants was excluded. Studies were also 
excluded if the experimental procedure entailed sleep deprivation. 
Research design: methodological quality. A double-blind, placebo-controlled 
design was required for inclusion. This criterion aimed to maximize the methodological 
quality of the meta-analyzed material.  
Research design: intervention. Eligible interventions were orally administered 
amphetamine and methylphenidate, with drugs administered before the start of the 
cognitive protocol (e.g. not after learning in a memory experiment). We only included 
research on single dose administration (the only study on the effect of repeated 
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administration was excluded due to lack of consistency of intervention strength with the rest 
of the available research). In the included studies, the interval between drug administration 
and the cognitive task ranged between 30 min - 4.5 hours for amphetamine studies, and 40 
min – 4.5 hours for research on methylphenidate. These intervals are within the 
medications’ window of effectiveness (Vree & van Rossum, 1970; Angrist et al., 1987; 
Volkow et al., 1998). In addition, it is not unreasonable to suspect that these waiting times 
have ecological validity, with users working or studying similar intervals after drug intake.  
Studies including multiple intervention arms, such as different drugs or transcranial 
magnetic stimulation (TMS), were included only if the effects of amphetamine and 
methylphenidate could be assessed in isolation (e.g. without concurrent TMS) and 
compared to placebo. 
Cognitive systems under investigation. Four abilities central to academic and 
professional work were included, based on the findings of Smith and Farah’s (2011) 
literature review.  They were: inhibitory control, the ability to override dominant, habitual or 
automatic responses for the sake of implementing more adaptive, goal-directed behaviors; 
working memory, the capacity to temporarily store and manipulate information in the 
service of other ongoing cognitive functions; episodic memory, the ability to encode, store 
and retrieve task-relevant information, assessed shortly after learning (i.e. within 30 mins) 
and at longer delays (1 hour – 1 week). Whenever task descriptions were not sufficient to 
identify the cognitive function tested, the data were excluded. 
Outcome measures. Performance can be measured by response time, overall 
accuracy, or specific types of error such as misses or false alarms. Overall in the literature, 
research reports varied in the types and number of outcome measures reported for each 
task. To maintain the validity and consistency of outcome measures in our analyses, we 
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designed an a-priori outcome selection procedure, shown in Table 2.1. Our outcome 
selection strategy favored the most widely used and construct valid measures, but also 
included second-best options, whenever our first choices were not reported. In general, we 
favored error measures over reaction time measures unless accuracy was near ceiling, in 
which case reaction time data, if available, were coded. On tests of inhibitory control, 
instead of overall accuracy, more specific accuracy measures (or the relationships thereof) 
were used, such as a measure of false alarms on Go/No-go tasks or the contrast in 
performance on incongruent and congruent trials of Flanker and Stroop. Whenever 
relevant, our main outcome measure was tailored to the specific design of the task. 
Particularly, two variants of the Stop Signal Task of inhibitory control have been used in the 
examined literature: a version where the probability of stopping is allowed to vary and is the 
main measure of inhibition (e.g., Fillmore et al., 2005), and a version where the probability 
of stopping is held constant (e.g., de Wit et al., 2002, Logan et al. 1997), in which case stop 
signal reaction time is the main outcome. Eligible outcome measures for each task are 
shown in Table 2.1.  
Process of determining study eligibility  
The search process, summarized in Figure 2.1, led to the identification of a total of 
1799 titles, which were narrowed down to 1505 after 294 duplicate papers were removed. 
After screening the titles of these papers, additional 1304 reports were excluded for not 
meeting the inclusion criteria. The remaining 201 studies were assessed for eligibility by 
applying the exclusion criteria to the abstract, and, in case of insufficient data, to the full 
text.  
Of the remaining 201 studies, 73 were excluded because the measured cognitive 
constructs (e.g., simple reaction time, sustained attention, creativity, intelligence, fear 
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conditioning, motor performance, reward processing, probabilistic learning,  etc.) were 
outside the scope of the present review. Twelve studies failed to meet the criteria for 
eligible participants (mice: n = 1; elderly participants: n = 6; children: n = 2; mentally ill 
participants: n = 2, including 1 study on ADHD and 1 study on cocaine abuse; criminal 
participants: n = 1). Eighteen reports lacked a double-blind placebo-controlled design 
(when these design features were not explicitly mentioned, the study was excluded). 16 
reports were excluded due to ineligible intervention. These included 4 studies which tested 
drugs other than amphetamine or methylphenidate; 4 studies in which drugs were 
administered intravenously; 4 studies conducted in the context of sleep deprivation; 2 
studies in which outcomes were measured under TMS; 1 study in which drug 
administration followed (as opposed to preceding) learning; 1 study which tested the effect 
of multiple drug doses. Seven studies in language other than English were excluded. Four 
studies could not be retrieved from available online and paper sources. Four studies were 
excluded because duplicating the data of already included research. In 19 of the remaining 
otherwise eligible studies, reported data were insufficient to calculate effect size and 
authors did not respond to our requests for the needed additional information. The final 
analyses were based on 48 papers reporting at least one relevant effect size (44 published 
reports, 3 unpublished data sets and 1 dissertation with a total of 1409 participants). The 
first and the second author independently conducted the eligibility determination 
procedures; disagreements were resolved by consensus after reviewing the experimental 
reports. 
Coding procedures 
All studies were coded by the first author, according to a standardized coding 
manual. Coded variables included: means and standard deviations for performance under 
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drug and placebo; sample size; outcome measure; effect direction; significance level; and 
six moderators.  The moderators, and rationale for examining their effects, were as follows. 
1) Drug (methylphenidate vs. amphetamine). This moderator analysis was 
conducted to examine if amphetamine and methylphenidate differ in their cognitive 
enhancement potential. To our knowledge of the enhancement literature, no previous study 
has compared the enhancement effects of these two medications. 
2) Dose (low vs. high).  The cognitive effects of stimulants are dose-dependent 
(e.g., Robbins, 2000). In examining the role of dose in enhancement effects, we defined a 
“high” dose as amphetamine > = 20 mg and methylphenidate > = 40 mg. Doses below 
these benchmarks were coded as “low.” 
3) Caffeine restriction (present vs. absent). We explored the possibility that 
stimulants may be especially helpful in countering caffeine withdrawal, while possibly 
having limited effects on non-caffeine withdrawn individuals. The presence or absence of 
instructions to abstain from caffeinated beverages on the day of the experiment was coded 
as a possible moderator.   
4) Gender distribution in the sample (percent male participants). In the past, higher 
rates of enhancement use have been reported among male students (e.g., Teter et al., 
2005) and differences in stimulants’ subjective effects have been shown to vary as a 
function of gender and menstrual phase (White, Justice & DeWit, 2002).  The percentage of 
males in the study sample was therefore tested as a moderator. 
5) Risk of ceiling or floor effects (suspected vs. not). Ceiling and floor effects could 
attenuate the estimated effect size. In these analyses, we examined whether the effect size 
in studies with no restriction of range differed from the effect size estimate in studies with 
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suspected floor or ceiling effects. A study was coded as being at risk of range restriction if 
the larger among the means in the drug and placebo conditions was less than 1 SD away 
from the scale’s floor, or if the smaller mean was less than 1 SD away from the scale’s 
ceiling. In case of moderation, our goal was to focus on the effect size estimate in the group 
of studies without suspected floor or ceiling effects. 
6) Reason to publish if drug effects are null (present vs. absent). For the purpose of 
assessing publication bias for reports of behavioral effects of stimulants, we distinguished 
between effect sizes from studies that focused only on the effects of amphetamine or 
methylphenidate on healthy individuals and studies that also included clinical groups, other 
drugs or nonbehavioral measures such as PET, fMRI, EEG or ERP. We expected that 
smaller stimulant enhancement effects would be published in the context of studies 
addressing multiple questions (due to the higher likelihood of a positive finding given 
multiple measures and the greater resources invested in measuring neural activity and 
administering multiple interventions).  
Effect sizes were calculated using means and standard deviations. Where these 
descriptives were not presented, we estimated them from published graphs. We favored 
descriptive over inferential statistics based on previous research showing that, in repeated-
measures designs (the majority of the included studies), effect size estimates from 
descriptive statistics are less biased than those from repeated-measures inferential 
statistics (Dunlap, Cortina, Vaslow & Burke, 1996). In the absence of descriptive data, we 
estimated effect sizes from F (provided df = 1), t and/or p-values. If effect sizes were 
directly reported, we estimated their confidence intervals for requivalent  (Rosenthal & Rubin, 
2003) and converted the values to d. When data were unavailable from either reports or 
from graphs, they were requested from authors.  
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The second author independently coded 44% of the means and standard 
deviations (including data, estimated from graphs) in the placebo and drug conditions. 
Analyses of reliability showed excellent agreement (two-way mixed-model ICC for absolute 
agreement > .99 in all cases).  
Handling of missing data. Effect size data could not be retrieved or calculated 
from 19 reports. We performed all meta-analyses excluding all missing data. We did not 
impute data in missing cells because we had no reason to infer either zero or average sizes 
of these unreported effects (Cooper, 2010). In other words, we had no sufficient data to 
ensure that these analyses would improve our effect size estimates, instead of introducing 
error.  
Statistical Methods 
Effect size metrics.  Hedge’s g was used as the primary effect size measure, 
whereby a value of .2 is conventionally considered small, .5 is considered medium and .8 is 
considered large.  Hedge’s g is obtained by multiplying the effect size Cohen’s d by a 
coefficient J which corrects for the tendency for studies with small sample sizes to bias the 
mean effect size positively due to publication bias: J = . In combining effect 
sizes, each was weighted by an estimate of its precision, i.e., the inverse of the squared 
standard error of the effect size.   
For within-subjects designs, employed in the vast majority of the meta-analyzed 
papers, we have the option of calculating the effect size in two ways.  Typically for such 
designs, a measure of performance change is scaled by units of variability of change.  This 
addresses the question, “How much drug-related benefit can one expect, relative to the 
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variability of change scores in the sample?”  Alternatively, the effect size can be expressed, 
as in with between-subjects designs, as the size of the drug treatment effect on 
performance, measured in units of performance variability.  Specifically, using this 
approach, the difference in performance attributable to the drug is measured against the 
standard deviation of the sample’s placebo performance.  In effect, this addresses the 
question “how far along the distribution of normal performance does the drug push 
subjects?”  This question is very appropriate to the study of cognitive enhancement when 
used to gain a competitive edge relative to an unmedicated population. Additionally, some 
authors have argued that “subject differences are always of theoretical interest” because 
“they are present in the population to which we want to generalize,” justifying the calculation 
of effect sizes from either within- or between-subject designs in units of variability (Cortina & 
Nouri, 2000, p. 49). We report both types of effect size analysis here, placing primary 
emphasis on effect sizes measured relative to normal variability.   
To conduct our primary analyses, we included research with both within- and 
between-subjects designs, and relied on effect sizes calculated as shown below.  These 
formulas, typically used for between-subjects designs, were modified so that the observed 
standard deviations in the placebo condition are entered in the analyses as values for both 
medication and placebo conditions. In particular: 
, 
where: SD = 	(- (-)-   and SE = SD ×
	  +

  
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In these analyses, t, F and p values were used to derive effect sizes from between-
subjects designs, using the following formulas:  Hedges’  and
 .  Inferential statistics from within-subjects designs were not 
included in these analyses because they inherently reflect drug effects relative to variability 
of change, rather than relative to performance variability. 
Our secondary analyses focused on the change score (drug minus placebo), 
specifically, the average benefit due to drug, relative to variability of change within the 
sample. Only within-subjects designs contained information relevant to this question. To 
calculate Hedge’s g for change in within-subjects designs, the following formulas were 
used.  
g = , 
where: SDDIFF = 	SD ! + SD" -2CorrSD !SD" , and . 
Alternatively, Hedges’ g =  ,  and . These formulas 
require the value of the correlation between repeated measures, which were not reported in 
the published studies.  These values, necessary to adjust for the dependency between 
repeated measures in effect size calculations, were estimated based on similar data sets1,2.  
                                                           
1 Correlations were obtained from Ilieva et al., 2013 (Flanker, Go/No-go, NBack, Digit Span Backward and Forward, delayed 
memory for words and faces; 46 partipants), Mintzer et al., 2007 (NBack, Sternberg memory task, delayed memory for 
g = J ×
t 2
2N1N2
N1 +N2
SE =
1
N1
+
1
N2
+
d 2
2(N1 + N2 )
J ×
(MDRUG −MPBO )× 2(1−Corr)
SDDIFF






SE =
SDDIFF
N
J
t
N
SE =
1
N
× 1+
d 2
2
  
 
 
 
40
Handling of studies with more than one effect size. One of the assumptions of 
meta-analysis is that each effect size comes from an independent sample. If this 
assumption is violated by the inclusion of more than one effect size per study, between-
study variance will be underestimated and the significance of the summary effect size will 
be overestimated. The following steps were taken to reduce the available data to a single 
effect size per study.  
1) When effect sizes for more than one construct per study were available, data on 
each construct (i.e., inhibition, working memory, short-term and long-term episodic 
memory) were separated in an individual meta-analysis. 
2) When multiple doses of a drug were compared to placebo within the same 
study, effect size data from all doses were coded and averaged. 
3) When, in a given study, effect sizes were reported for more than one eligible 
task and/or measure per construct, a single average effect size estimate per construct was 
obtained.  
4) When outcome data were available from various time intervals after the 
administration of the drug (e.g., when inhibitory control was tested 1 hour, 2 hours and 3 
hours after drug administration, or when long-term episodic memory was measured at 
various different retention intervals), the average effect size was entered in the main 
analyses.  
                                                                                                                                                                           
words, 18 participants) and Hamidovic et al. (2009), combined with a set of unpublished data from Dr. Harriet de Wit’s 
laboratory (Stop Signal task, 299 participants). When correlations for a given task (e.g., NBack) were available from more 
than one data set, we estimated a composite through meta-analyzing the available correlations based on a random effects 
model. For tasks for which data on observed correlations were lacking, we imputed an estimate of the correlation for the 
corresponding cognitive construct, obtained through meta-analyzing the available observed correlations for tasks within that 
construct based a random effects model.  
2 To estimate the potential for error in case of inaccurate imputed correlations, we repeated our main analyses after varying the 
correlations between .2, .5 and .8. This led to minimal changes in the reported patterns of findings (largest change in effect size was g 
= 0.02).  
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Fixed vs. random effects model. A fixed effects model assumes that the only 
source of effect size variability is sampling error. It therefore produces an effect size 
estimate that describes the analyzed studies but cannot be generalized to other trials. By 
contrast, in a random effects model variability is assumed to arise from both sampling error 
and between-study variability. Effect sizes derived from this model can be generalized to 
research outside of the analyzed studies. For the present meta-analysis, we selected a 
random-effects model because of the variability between individual studies in each meta-
analysis (different drugs, doses, waiting times between drug administration and testing, 
measures of each specific cognitive function, individual differences between samples), and 
also because we wanted to generalize the findings beyond the examined research.  
Estimation of heterogeneity. Tests for heterogeneity determine whether the 
dispersion of the individual effect sizes around their mean value is greater than predicted 
solely on the basis of subject-level sampling error. One of the tests employed uses the Q 
statistic, which, if significant, rejects a null hypothesis of homogeneity. The second test, 
based on the I2 statistic, generates an estimate of the between-study variance as a 
percentage of the total variance (between subjects plus subject-level). Conventions for low, 
moderate and high heterogeneity correspond to I2 values of 25, 50 and 75 (Lipsey & 
Wilson, 2001).  
Moderator analyses. Most commonly in the literature, moderator analyses are 
conducted only following a finding of significant heterogeneity. In contrast to this approach, 
we decided to conduct moderator analyses regardless of the results of the heterogeneity 
tests because a homogeneous set of findings may emerge either in the absence of 
moderators, or in the presence of moderators whose effects cancel each other out. 
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We examined the effect of the dichotomous moderators described earlier, using 
mixed effects analyses. This analytical model assumes that the effect size variation is due 
to a combination of systematic associations between moderators and effect sizes, random 
differences between studies and subject level sampling error. Finally, the moderating role of 
gender composition (measured as % male), was examined through meta-regression, given 
the continuous nature of this moderator. 
A feature of the data on some moderator variables demanded the following 
modification in some of the analyses. When analyzing the moderating role of dose and 
ceiling/floor effects, there were a few cases of more than one level of the moderating 
variable for per study (this occurred more than one drug dose was administered per 
sample, or when floor/ceiling effects were suspected for one outcome within a study, but 
not for another). In these cases, we relied on two approaches to analysis. First, to satisfy 
the assumption of independence between effect sizes, we excluded studies which included 
data on more than one level of each moderator variable. In a second version of the 
analyses, we used the shifting-unit method of analysis (Cooper et al., 2010). The shifting-
unit method allows violation of the assumption of meta-analysis in which a study can 
contribute an effect size to each level of the moderator (e.g., high and low dose). The 
advantage of the first approach is that the analysis assumptions remain unviolated; the 
advantage of the second approach is that it makes use of maximum possible data points. 
The findings based on the two approaches were in agreement, so we only report data 
based on the second one.  
Publication bias. Publication bias refers to the greater tendency of studies with 
significant results to be published than non-significant findings. Publication bias can 
therefore bias the results of meta-analyses because the more significant findings typically 
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have larger effect sizes than those remaining in file drawers (Lipsey & Wilson, 2001). To 
minimize bias in the current meta-analysis, we made efforts to locate and retrieve 
unpublished data (see Search Strategies above). Additionally, we used three methods to 
assess the evidence for publication bias and the stability of the effect size estimates and to 
determine unbiased effect sizes: funnel plots, fail-safe N and trim and fill (Lipsey & Wilson, 
2001). These analyses were conducted without correcting effect sizes by the factor J, 
described earlier. Only data from published reports were included in these analyses.  
A funnel plot permits a qualitative test of publication bias, by showing the effect 
sizes of the analyzed studies plotted against an estimate of those studies’ precision (the 
inverse of standard error of the effect size in our graphs).  Effect size estimates from more 
accurate studies (towards the top of the graph) should cluster closely around the true effect 
size, while effect sizes from less accurate studies should appear more broadly dispersed 
below.  In the absence of publication bias, the more broadly dispersed effect size estimates 
should extend in a roughly symmetrical arrangement to either side of the more accurate 
estimates.  A negative skew, where points in the lower left quadrant appear to be missing, 
is consistent with the operation of publication bias.  
In cases of publication bias, the trim and fill procedure calculates an unbiased 
estimate of the effect size. In this procedure, the most extreme positive effects are removed 
(“trimmed”) from analysis and a mirror image of the trimmed effect sizes with the opposite 
direction is then imputed.  Unbiased estimates of the overall effect size and its variance are 
calculated, respectively, from the trimmed and filled data.     
The fail-safe N indicates the number of studies with a zero effect size that, if added 
to the analysis, would render the obtained mean effect size non-significant. The value of 
fail-safe N is considered large (and publication bias an unlikely influence on the effect size 
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estimate) if it exceeds 5k+ 10, where k is the number of meta-analyzed studies (Rothstein 
et al., 2006).   
Tests for outliers. The presence of outlier effect sizes was assessed through the 
Sample-Adjusted Meta-Analytic Deviancy (SAMD) statistic. For each study, the value of 
this statistic represents the difference between this study’s effect size and the point 
estimate of the effect size uninfluenced by this study, a difference weighed by the relevant 
variance terms (Huffcutt & Arthur, 1995). An effect size was considered an outlier if it met 
both of the following two criteria (Sockol, Epperson & Barber, 2011): First, in a scree plot of 
the distribution of absolute SAMD values, it deviates markedly from the slope (Huffcutt & 
Arthur, 1995). Second, it falls in the top or bottom 2.5% of the t distribution (which the 
SAMD distribution approximates). This conservative, two-pronged method for outlier 
detection was chosen because outliers could result from either error or true between-study 
variation (Sockol et al., 2011).  
Software. The data were analyzed primarily using Comprehensive Meta-Analysis 
2.0, with the exception of meta-regression analyses, completed in R 3.0.0. 
 
Results 
 
Overview of results.  We report meta-analyses for the effects of stimulants on the 
four constructs of interest: inhibitory control, working memory, short-term episodic memory 
and delayed episodic memory.  Two sets of results are presented, corresponding to the two 
different ways of measuring effect sizes from within-subjects designs described earlier.  For 
each cognitive construct we first present meta-analyses of within- and between-subjects 
studies combined, measuring the size of the drug effect relative to variability in the normal 
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population.  We then present the effect sizes estimated in separate meta-analyses for 
within-subjects and matched-groups studies using the formula for within-subject effect sizes 
described earlier. For the main analyses we also report the results of moderator analyses 
and three measures related to publication bias. In reporting our secondary analyses we do 
not detail the results of moderator and publication bias analyses, which in all cases were 
qualitatively similar to the results in our main analyses. Most effect sizes were small. 
Evidence of publication bias emerged in two cognitive domains. Characteristics of all effect 
sizes (outcomes, magnitude of effect, sample sizes, values of moderator variables) are 
presented in Tables 2.2-2.5. 
Stimulants’ effects on healthy inhibitory control 
25 studies (including 2 unpublished) reported sufficient data to calculate the size of 
stimulants’ effect on inhibitory control. After examining the values of the SAMD statistic, no 
value fell within the top 2.5% of the distribution or notably deviated from the relatively flat 
line of the scree plot. Not all of these studies were suitable for each analysis: i.e., a study 
whose effect size was derived from a repeated-measures t-value was excluded from 
analyses relative to normal variability; and a between-subjects study was excluded from 
analyses relative to variability of change. Data for calculating effect sizes relative to normal 
variability were available from 24 studies (see Table 2.2); effect size relative to variability of 
gain scores was also estimated from 24 studies.  
Stimulants’ mean effect on inhibitory control, when measured relative to normative 
variability of performance, was small but significantly different from zero: Hedges’ g = 0.20, 
95% CI [.11; .30]. Effect size measured relative to the variability of gain scores was similarly 
small and significantly different from zero: Hedges’ g = 0.19, 95% CI [.11; .26]. No evidence 
for between-study heterogeneity emerged: Q (23) = 7.82, p > 0.99; I2 = 0.00. Moderator 
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analyses indicated that none of the candidate moderators impacted significantly the 
stimulant effects on cognition (all p’s > 0.20).  
A funnel plot based only on the published studies (N = 22) showed no evidence for 
publication bias: the distribution of studies was roughly symmetrical (Fig. 2.2). The trim and 
fill procedure led to the exclusion of no study, and the adjusted effect size estimates 
remained the same as reported above. However, the fail-safe N method indicated that 39 
studies (less than two studies per each published report) with an effect size of zero would 
nullify the obtained results. Taken together, the lack of negative skew in the funnel plot and 
the robustness of the effect-size estimate to trim-and-fill adjustment, converge to suggest 
that the effect estimate obtained for inhibitory control is most likely not affected by 
publication bias. In other words, there is no evidence to suspect that the relatively modest 
number of studies needed to nullify the result have remained in file drawers.  
Stimulants’ effects on healthy working memory 
Effect size data on stimulants’ effects on working memory were available from 23 
studies, 3 of which were unpublished. None of the effect sizes were outliers by our criteria. 
Relevant statistics for calculating ES relative to normal variability were available from 20 
studies (Table 2.3). Effect size relative to variability of gain scores was calculated based on 
23 studies with within-subjects or matched-groups designs.  
Our main analyses indicated a near-significant small stimulant effect on working 
memory: Hedges’ g = 0.13, 95% CI [-0.02; 0.27]. When measured relative to variability of 
the gain scores, the effect size was again estimated to be small, but this time reached 
significance: g = 0.13, 95% CI [0.06; 0.20]. There was no significant evidence for 
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heterogeneity: Q (19) = 7.74, p = 0.99, I2 = 0.00. Moderator analyses were performed, but 
no evidence emerged for moderation by any of the examined variables (all p’s > 0.57).   
The funnel plots, based on published studies only (Fig. 2.3) showed slight negative 
skew. The trim and fill procedure trimmed 5 data points, reducing the above-reported effect 
size to a non-significant trend of d = 0.06, 95% CI [-.08; .20]. Because the gain score effect 
size was significant, whereas the primary effect size was not, here we also report the trim-
and-fill results from our secondary analyses, where the effect size was again reduced to 
non-significant: d = 0.06, 95% CI [-0.03, 0.15], given a negatively skewed funnel plot. Taken 
together, the trim-and-fill correction and the skew of the funnel plot, suggest the presence of 
publication bias. Fail-safe N analyses were obviated by the lack of significance in the 
obtained effect size estimate. 
Stimulants’ effects on healthy people’s short-term episodic memory 
14 effect sizes (1 unpublished) were considered for inclusion in the meta-analysis. 
Two SAMD values, equaling -8.53 (Burns, 1967) and 2.18 (Zeeuws et al., 2010a), 
exceeded the cutoff for exclusion and deviated markedly from the relatively flat line on the 
scree plot of absolute SAMD values. Therefore, these studies were excluded from further 
analyses after confirming correct data entry.  
Based on 12 studies (see Table 2.4), the mean effect of stimulants on short-term 
episodic memory, relative to normal variation of performance, was small but significant: 
Hedges’ g =0.20, 95% CI [.01; .38]. This was similar to the result observed when the effect 
size was measured relative to variability of gain scores (12 studies): Hedges’ g =0 .22, 95% 
CI [.09; .35]. No evidence for heterogeneity emerged in our main analyses: Q (11) = 4.44, p 
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= 0.96, I2 =0 .00. Moderator analyses indicated no significant influence of any of the 
examined moderators (all p’s > 0.64).  
A funnel plot, based on the 11 published studies, showed slight negative 
asymmetry (Fig. 2.4), despite the largest study having the largest effect. The trim and fill 
procedure trimmed 3 studies, reducing the effect size estimate to a non-significant d = 0.12, 
95% CI [-0.06, 0.29]. According to the fail-safe N procedure, a mere 2 studies with an effect 
size of zero would be needed to nullify the obtained effect, casting doubt on the robustness 
of the effect.    
Stimulant effects on healthy people’s delayed episodic memory 
12 effect sizes describing stimulants’ effects on delayed episodic memory were 
reported. One outlier was excluded, given a SAMD value of 3.35 (Zeeuws et al., 2010a), 
which fell in the top 2.5% of the distribution of SAMD scores.   
Based on the remaining 11 effect sizes, estimated relative to normal variability (see 
Table 2.5), stimulants’ mean effect on delayed episodic memory was significantly different 
from zero and medium in size: g = .45, 95% CI = [.27, .63]. Similarly, analyses focusing on 
the mean gain, relative to the sample’s variability of change, showed a medium-sized 
effect: Hedges’ g =0.44, 95% CI [.26; .62]. There was no evidence for significant between-
study heterogeneity: I2 = 0.00, Q (10) = 9.67, p = 0.47. We found a small but significant 
moderating effect of gender: Q(1) = 7.44, p < 0.01, beta = 0.01, with larger drug effects for 
larger proportions of men in samples. In addition, there was a significant moderating effect 
of dose: Q (1) = 5.49, p = 0.02, indicating a larger effect for the smaller dose: g = 0.64, 95% 
CI [0.40; 0.88] than the larger dose: g = 0.20, 95% CI [-.08; .48]. Note that these 
moderation effects are confounded with each other and with research group:  all studies 
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that used low doses of stimulants came from the same research group, tested only male 
subjects, and tended to test memory over longer retention intervals (1 hour – 1 week), while 
among tests of the high drug dose, the percent of men in the sample ranged between 48-
70% and retention intervals, with one exception, were 2 hours.  No other factors were found 
to significantly moderate stimulants’ effects (all p’s > 0.52).  
The funnel plot of these studies was negatively skewed, suggesting publication bias 
(Fig. 2.5). The trim and fill method trimmed 5 studies, reducing the estimated effect size to d 
= 0.26, 95% CI [0.04; 0.47]. According to the fail-safe N procedure, 59 studies were needed 
to nullify the significance level of the result. The negative skew of the funnel plot, combined 
with the trim and fill correction, suggest the presence of publication bias and indicate that 
the true effect size may be small. It is important to note, though, that inferences from the 
funnel plot must be qualified by the presence of significant moderation (see Lau et al., 
2006). In particular, the studies with the six largest effect sizes came from the same lab and 
tested the effect of a low stimulant dose on male-only samples, in part, over relatively 
longer retention intervals. Four of the five remaining studies with smaller effect sizes came 
from other research groups, and examined the effects of a high stimulant dose on a mixed-
gender sample over relatively shorter delays. Thus, the funnel plot might reflect true 
publication bias, or might be driven by between-study differences. If the latter is the case, 
the trim-and-fill-adjusted effect size may be be underestimating the true effect size (e.g., 
Peters et al., 2007). Unfortunately, the proposed methods of unconfounding publication 
bias and moderating factors (e.g., conducting funnel plot analyses within a subgroup of 
studies) are applicable only to large meta-analyses (see Peters et al., 2010). 
  
 
 
 
50
 
 
Discussion 
 
Summary and interpretation of results 
Earlier research has failed to distinguish whether stimulants’ effects are small or 
non-existent (Smith & Farah, 2011; Ilieva, Boland & Farah, 2013). The present findings 
supported generally small effects of amphetamine and methylphenidate on executive 
function and memory.  Specifically, in a set of experiments limited to high-quality designs, 
we found a small but significant degree of enhancement of inhibitory control and short-term 
episodic memory. Effects on working memory were small and significant in one of our two 
analyses.  Delayed episodic memory was unique in showing a medium-sized effect.  
However, both working memory and delayed episodic memory findings were qualified by 
possible publication bias. 
Several potentially important moderators were tested because of their scientific 
relevance for understanding the effects of stimulants on cognition and their practical 
relevance in determining whether stimulants might be more effective cognitive enhancers 
under some circumstances than others.  Moderator analyses yielded only a few significant 
findings.  Stimulant effects on delayed episodic memory were moderated by gender, with 
larger effects for samples with more males, and by dosage, with larger effects for smaller 
doses.  Unfortunately, these two moderators were confounded in the studies analyzed, and 
also confounded with research laboratory and retention interval, so we cannot draw firm 
conclusions about the effects of gender or dose. 
Where no effects of moderators were found, this may be due to uncertainty or 
imprecision in moderator coding, for instance the dichotomization of drug dose, or the 
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possibility of non-linear relationships between drug effect and the continuous moderators of 
sample gender and dose.  Finally, partly for the sake of limiting the number of comparisons 
and partly due to limited availability of the relevant information, we examined only a subset 
of all relevant moderators. For instance, we did not explore the moderating role of 
participant age, level of education, waiting time between drug administration and testing, 
length of testing session or time of day.  Moderators of great interest, which might be 
expected to affect results based on previous studies but which could not be assessed due 
to insufficient available data, include individuals’ baseline cognitive ability and individuals’ 
variants of dopamine-related genes such as COMT and DRD2 (see Mattay et al., 2003 and 
Hamidovic et al., 2009, but see also Wardle et al., 2013 and Ilieva et al., 2013 for null 
results of COMT’s moderating effects). Consistent with the nonmonotonic relation between 
dopamine levels and performance, there is evidence that stimulants can impair 
performance in normal individuals who are especially high-performing (Farah, et al., 2008; 
De Wit, Crean & Richards, 2000; de Wit, Enggasser & Richards, 2002, Mattay et al., 2000). 
It remains possible that some individuals who would not qualify for a diagnosis of ADHD 
could nevertheless benefit from stimulants to a greater degree than indicated by the 
present results, and that some individuals could be impaired. 
Neuroethical Implications 
What do the results reported here imply for neuroethical issues surrounding the use 
of stimulants for enhancement?  Should we be concerned about the fairness of students 
and workers competing with the help of stimulant drugs?  Is there a genuine benefit to be 
weighed against the risks of using these prescription drugs for enhancement?  The overall 
small effects of stimulants on healthy people’s inhibitory control, working and episodic 
memory might be taken to mean that these drugs would not deliver a practically significant 
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performance advantage, and neuroethical discussions are therefore moot at best (and 
encouraging a false belief in the drugs’ efficacy at worst, e.g., Hall & Lucke, 2010).  
Nevertheless, the present findings provide reason to temper these and other more 
extreme skeptical assessments of stimulant medications for cognitive enhancement of 
healthy, cognitively normal individuals. Furthermore, small effects can make a difference in 
academic and professional outcomes. Even on a single occasion, a small effect might 
make the difference between good and very good performance, or between passing a 
school entrance or licensing exam or failing.  It is also possible that these drugs may give a 
larger boost to cognitive functions not examined here (e.g., sustained attention, processing 
speed), to people not specifically studied in this meta-analysis (e.g., healthy participants 
with low cognitive performance or specific combination of genotypes), or to performance 
under conditions not tested here, for example fatigue, sleep deprivation, extreme distraction 
or repeated stimulant intake (e.g., Breitenstein et al., 2006).  A final possibility is that 
prescription stimulants enhance work performance by altering users’ emotions about, and 
interest in, tasks they would otherwise find boring and unrewarding (Vrecko, 2013; Ilieva & 
Farah, 2013).  
The results of this meta-analysis cannot address these possibilities. Thus, there 
may well be solid reason for continued discourse on the effects, misuses, and ethical 
implications of cognitive enhancement with stimulants, a discourse, which the present data 
can importantly inform. 
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CHAPTER 3 
ATTENTION, MOTIVATION AND STUDY HABITS IN USERS OF UNPRESCRIBED 
ADHD MEDICATION 
 
Recent research has cast doubt on the cognitive enhancement potential of 
prescription stimulants in people without ADHD (Smith & Farah, 2011; Chamberlain et 
al., 2010). Yet, the use of stimulant medication among healthy people is on the rise 
(Smith & Farah, 2011). Thus, it remains an open question what drives the enhancement 
uses of medications like Adderall and Ritalin. This paper will focus on three non-
mutually exclusive candidate explanations of the surprisingly wide-spread enhancement 
stimulant use given the limited empirical evidence for the efficacy of cognitive 
enhancement: the possibility that use is related to users’ attention problems, low 
motivation, or suboptimal study habits. Our goal was to examine if users and non-users 
differ on these dimensions – a first step towards investigating, down the road, important 
directional causal questions: Do users self-medicate undiagnosed attention difficulties? 
Do they intervene in perceived attention problems despite objectively normal attention? 
Do they compensate for low motivation or inefficient approaches to learning by resorting 
to unprescribed stimulants?  
Attention Problems and Unprescribed Stimulant Use 
Several researchers have suspected attention problems among non-medical 
stimulant users. This hypothesis has received support from a number of studies of 
college students, finding higher self-reported inattention and/or impulsivity in users, 
compared to their non-using peers (Arria et al., 2011; Rabiner et al., 2009; Peterkin et 
al., 2011; Rabiner et al., 2010). Moreover, longitudinal data have shown that self-
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reported attention difficulties in the beginning of college predict prospectively the onset 
of enhancement use (Rabiner et al., 2010). 
Nevertheless, the proposed role of attention problems in non-medical stimulant 
use is strongly qualified by a research limitation shared by past investigations. Previous 
studies have solely relied on self-report assessments of attention – measures 
susceptible to bias (e.g., see Hunt et al., 2011). For instance, users might consciously 
or unconsciously exaggerate their symptoms to justify self-medication. Alternatively, 
students surrounded by high achieving peers might perceive their normal attention 
abilities as deficient. Thus, without converging evidence from self-report and objective 
neuropsychological testing, it is difficult to infer and explain users’ attentional 
impairment. 
The most widely used objective test of attention is the Test of Variables of 
Attention (TOVA). The TOVA is a continuous performance test, which presents subjects 
with a sequence of simple geometric figures signaling either a “go” or a “no-go” 
response. Several strengths of this instrument make it suitable for the objective 
assessment of attention. Age- and gender-normed standard scores are automatically 
generated, allowing an inference about the clinical significance of participants’ 
performance. Malingering is detectable through an index of symptom exaggeration, 
considered positive if relevant conditions are met (e.g., if post-commission responses 
are quicker than the mean reaction time). The TOVA has better sensitivity and 
specificity than standard continuous performance tests: Its 22-minute duration prevents 
above-threshold performance purely due to a compensatory strategy when actual 
attention difficulties are present. Additionally, the test’s non-verbal stimuli help 
differentiate attention problems from reading disorder (Forbes, 1998; Hunt et al., 2011). 
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Thus, this test is a suitable instrument to evaluate whether enhancement stimulant 
users have objectively lower attention performance, given their subjectively perceived 
or reported attentional difficulties. 
Motivation and Unprescribed Stimulant Use 
Aside from optimal attention, non-medical stimulant users might be seeking 
increased motivation to study. Several lines of research have converged to suggest that 
stimulants are beneficial for improving motivation. Motivation encompasses a variety of 
facets, including, but not limited to liking (e.g., enjoying a task) and wanting (e.g., 
ascribing value to the task outcome; expending effort in a task). Animal research shows 
that stimulants increase activity in the mesolimbic dopamine system, which is central to 
motivation (Butcher et al., 1988, Drevets et al., 2001; Volkow et al., 2004). Double-blind, 
placebo controlled laboratory experiments of stimulant effects in humans have 
documented elevated self-reported interest in a mathematical task, correlated with 
change in striatal dopamine (Volkow et al., 2004); increased enjoyment of viewing IAPS 
images (Wardle et al., 2012); increased expenditure of effort for reward in a laboratory 
task (Wardle et al., 2011); and a stimulant-related increase in self-reported energy (e.g., 
de Wit et al., 2000, Costa et al., 2012). A survey from our lab indicated that 
enhancement users rate stimulants’ motivational effects as at least as pronounced as 
the cognitive ones (Ilieva & Farah, 2013). Thus, a number of experiments, using self-
report, behavioral and neural measures, have supported the effects of ADHD 
medications on motivation in non-clinical samples. 
Research on enhancement users’ experiences has found that that stimulants’ 
motivational properties are highly sought for. A recent study, based on semi-structured 
interviews and qualitative analyses, showed that users particularly value the stimulant-
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related increases in drive and task enjoyment (Vrecko, 2013).  As representative 
participants noted, “[on Adderall] I didn’t want to stop what I was doing until it was 
completed up to a certain level of my satisfaction,” and “You’re interested in what you’re 
doing even if it’s boring.” Structured surveys asking participants to choose among 
candidate motives for unprescribed stimulant use have found that a majority of users 
seeks a stimulant-driven increase of energy and task enjoyment (e.g., DeSantis et al., 
2008, Bavarian et al., 2013, Teter et al., 2005). 
Given their interest in stimulants’ motivational properties, might users have 
overall lower motivation for cognitive tasks than controls? To address this question, we 
examined users’ and controls’ subjective experience of the TOVA, focusing on how 
boring they found the task and how driven they were to do well. Our self-report measure 
is useful in distinguishing the subjective experience of motivation from attentional 
performance during cognitive testing. It is also appropriate for a preliminary 
investigation, which, if yielding significant findings, can substantiate a more 
comprehensive assessment of more facets of motivation in future. 
Study Habits and Unprescribed Stimulant Use 
Whether or not they have an attentional disorder or low motivation for their 
schoolwork, stimulant enhancement users may also seek medication to compensate for 
poor study habits. We use the term study habits to describe study practices that either 
facilitate or impede successful and efficient learning. Here, we are interested in study 
habits at a behavioral level, without attempting to parse out the relative causal 
contributions of psychopathology, lack of proper instruction and training, low 
achievement motivation, low self-control or unfavorable situational factors. 
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Several lines of research converge to suggest the possibility of suboptimal study 
habits among non-medical stimulant users. Previous work has indicated that users 
spend less time studying and skip more classes than their non-using peers (Arria et al., 
2011, 2013). Cramming for exams and improving study skills have been identified as 
common motives for unprescribed ADHD medication use  (de Santis et al., 2008, Hildt 
et al., 2014, Peterkin et al., 2011). An inverse relationship has been documented 
between trait Conscientiousness and unprescribed stimulant use (Benotsch et al., 
2013). Taken together, these data raise the possibility that use is associated with the 
quality of students’ study habits – a construct more specific to academic behavior than 
trait conscientiousness, but, as shown below, more comprehensive than the isolated 
student behaviors examined previously. 
Previous research has identified a number of study practices beneficial for 
learning. Spaced practice of to-be-learned material leads to longer-term retention than 
massed practice. Retrieval practice improves memory relative to no practice or to 
repeated exposure to the same material. Critical analysis of the studied material (e.g., 
interpreting and interconnecting information) is another strategy shown to benefit 
retrieval (see Roediger & Pyc, 2012; Dunlosky et al., 2013; Bjork, Dunlosky & Kornell, 
2013, for reviews of the solid body of research that supports the effectiveness of these 
approaches). Other activities found to correlate with successful learning outcomes in 
school and at work include: persistence despite failure or boredom, time management, 
the tendency to work in distraction-free environments, as well as planning and 
monitoring one’s goal-directed behavior (Sitzman & Ely, 2011; Crede & Phillips, 2011). 
The small to moderate size of the correlations with learning outcomes does not 
necessarily discount the importance of these study practices: they may be an important 
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determinant of success, though acting only in conjunction with intelligence and other 
factors and effective only if applied properly (Bjork et al., 2013). 
We asked whether users and controls differ on this broader, more 
comprehensive array of study habits. To address this question, we compiled our own 
set of self-report items borrowed from several existing scales (see Appendix), with the 
aim of assessing: 1) study habits previously shown to effectively promote learning and 
achievement; and 2) study habits (e.g., note-taking and class participation) that 
appeared important for academic success to three independent research staff members 
who reviewed the published scales. Despite the availability of a multitude of published 
measures of study habits in the literature (e.g., Pintrich et al., 1991; Schmeck et al., 
1991; Nonis & Hudson, 2011; Kornell & Bjork, 2007; Grendler & Garavalia, 2000; 
Christopolous et al., 1987; Biggs, 1987, etc.), we decided against directly using one of 
these measures, because none met fully our first and main aim, as described above. 
The Present Study 
The goals of the present study were to examine attention, motivation and study 
habits in stimulant enhancement users, relative to controls with no history of ADHD 
medication use. We conducted a multimodal assessment of attention, combining a 
subjective measure with an objective neuropsychological test. We predicted lower self-
reported attention among users, while making two alternative hypotheses about user-
control differences on objectively measured attention. If use relates to true attention 
problems, we expected to see lower TOVA performance in users than controls. 
Alternatively, if use is more strongly driven by perceived functioning than by objective 
problems, we expected an interaction pattern, indicating relatively lower functioning on 
self-report in users than controls, despite comparable objective performance in the two 
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groups. We further predicted lower level of self-reported motivation among users for the 
duration of the TOVA, as well as less optimal self-reported study habits, relative to 
controls. We were interested both whether these outcomes distinguish users from 
controls, as well as whether they remain significant even after holding constant 
previously documented group differences on depression, anxiety and substance use 
(Dussault & Weyandt, 2011; Weyandt et al., 2009; Rabiner et al., 2010; Teter et al., 
2010; Arria et al., 2013; McCabe et al., 2004; McCabe & West, 2013). Examining the 
functioning of enhancement users is a necessary first step towards asking, down the 
road, what factors contribute causally to non-medical ADHD medication use. 
Method 
Participants 
The analyzed data is from 128 participants, a sample size selected to attain 
80% power of detecting medium-sized effect (Cohen’s d >= 0.5) in our main analyses. 
The sample consisted of 61 enhancement users of prescription stimulants (27 female, 
34 male) and 67 controls (37 female, 30 male), who reported no lifetime prescription 
stimulant use. All participants were young adults (age range 18-28, M = 20.95, SD = 
2.05) who denied a history of ADHD diagnosis. Participants were recruited through 
university-affiliated recruitment web-sites and flyers on university campuses in 
Philadelphia. The project was advertised as “a research study comparing users of 
unprescribed ADHD medication to people who have never used such drugs.” 
In addition to this final sample of 128 participants, 48 more participants began 
the study without completing it or without being included in the analyses. Of these 38, 
24 participants (14 users and 10 controls) dropped out after completing part of the 
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study3. Additional 24 participants were excluded for the following reasons: possible 
symptom exaggeration on the TOVA (n = 4); inconsistent information about history of 
ADHD at different assessment points (n = 1); inconsistent information about 
enhancement use (admitted vs. denied) at different assessments (n = 5); five or more 
alcoholic drinks the evening before the TOVA (n = 7); four or fewer hours of sleep the 
night before the TOVA (n = 3); the equivalent of a cup of coffee or more before the 
TOVA, given no typical caffeine intake4 (n = 3); runs of sequential omission errors (a 
rare pattern of performance typical of narcolepsy and seizure disorders, n = 1). The 
latter criterion was applied because we were interested in generalizing our finding to a 
relatively typical population of young people. Participants who took medications with 
stimulant properties (e.g., stimulant medications, modafinil, atomoxetine, bupropion) 
before the TOVA were ineligible, but none presented to the lab meeting this criterion. 
Procedure 
The study began with a screening survey, excluding people with an ADHD 
diagnosis, as well as people outside of the 18-30 age range. Potential participants were 
also asked about lifetime use of prescription stimulants (yes vs. no). Depending on user 
status, they were directed to two separate sign-up lists. This early distinction between 
users and non-users allowed us to keep the number of enrolled participants roughly 
equal between groups. 
                                                           
3 In the sample of 24 people who dropped out, users reported higher levels of depression (p = 0.04), anxiety (0.03 > ps 
> 0.04), substance use (p < 0.01), and attention problems (0.11 > p > 0.08) than controls. Users also reported less 
optimal study habits (p = 0.18) than controls. As will be shown below, these trends suggest that user-control 
relationships in noncompleters, at least based on these available data, are consistent with our findings among 
completers.  
4 TOVA performance has been documented to be sensitive to caffeine intake only among those who do not habitually 
take caffeine (Hunt et al., 2011) 
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The initial phase of the actual study consisted of an online battery of self-report 
assessments on study habits, attention, anxiety, depression, and substance use, 
administered in that order. A separate second session began with the Test of Variables 
of Attention (TOVA), continued with participants’ self-report on their motivation during 
the computerized test and a self-report on the incidence of their enhancement stimulant 
use. The session concluded with a report on medication use, caffeine intake, alcohol 
and illicit substance intake, as well amount of sleep before testing and history of ADHD 
diagnosis. A day prior to the study, subjects had been contacted with instructions to 
take their usual amount of sleep before testing and to refrain from taking more caffeine 
than usual on the test day. 74 participants (36 users) were tested in lab by blind 
experimenters; for the remaining 54 participants (25 users) testers were not blind to 
user status5.  
Materials 
Main measures 
Enhancement Stimulant Use. Participants indicated the number of occasions 
of unprescribed ADHD medication use in the past month, past year and in their lifetime. 
The measure, adapted from Teter et al. (2010), read as follows: “On how many 
occasions have you used ADHD medication (e.g., Adderall, Ritalin, or other), without 
a prescription, to help you do well at school and/or work?” Our main analyses were 
based on the incidence of lifetime use (given its greatest range among the three 
                                                           
5 To assess possible experimenter effects on each of the TOVA indexes, we examined the interactions between user 
status and tester blindness, based on a series of two-way independent-samples ANOVAs. No significant interactions 
emerged. There were no effects of tester blindness on any of the TOVA variables within the separate subsamples of 
users and controls, according to the results of t-tests and Mann-Whitney tests (all ps > 0.38).  
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measures). Sensitivity analyses using data on past-year and past-month use were also 
conducted.  
Barkley & Murphy ADHD Current Symptom Scale. This self-report ADHD 
assessment instrument incorporates scales of inattention (9 items) and impulsivity (9 
items), as well as an evaluation of symptom-related impairment. The scale items 
correspond to DSM-IV-defined ADHD symptoms, with wording adapted for adult 
populations. Participants indicate the frequency of each symptom on a 0 (“Never or 
rarely”) – 4 (“Very often”) scale. An indication of frequent or very frequent manifestation 
of at least 6 inattention or 6 hyperactivity symptoms meets the scale’s cutoff for 
clinically significant impairment. The scale has demonstrated excellent positive 
predictive value (0.8-1) but limited negative predictive value (0.3) in previous research 
(O’Donnell et al. 2001). Thus, diagnosis cannot be established purely based on the 
results of the scale, in the absence of report from other informants on the nature, 
severity, pervasiveness and childhood onset of the diffculties (Murphy & Adler, 2004). 
Test of Variables of Attention (TOVA). The TOVA is a 21.6-minute continuous 
performance test. Participants are presented with a sequence of briefly flashed simple 
geometric figures, requiring participants either to press a button as quickly as possible 
or to withhold responding. The first half of the test taxes inattention, given infrequent 
target presentation, based on a target:non-target ratio of 1:3.5. The second half taxes 
impulsivity, given frequent target presentation, based on the reverse target:non-target 
ratio of 3.5:1. Throughout the test, stimulus presentation is 100 ms and interstimulus 
interval is 2s. The TOVA provides a symptom exaggeration index, which is considered 
positive if at least two of the following four criteria are met: quick post-commission 
responses, slow commission errors, extreme omission, commission or reaction time 
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variability scores. The TOVA’s specificity and sensitivity in identifying ADHD have been 
estimated to range between 67%-86% (Greenberg & Waldman, 1993; Forbes, 1998; 
Schatz et al., 2001). 
Our dependent variables included three measures of inattention: omission 
errors, reaction time variability, and reaction time; one measure of impulsivity: 
commission errors; and the overall attention performance index (API) score. The API 
reflects a linear combination of reaction time in the first half of the test, sensitivity (d’) in 
the second half of the test, and reaction time variability over the duration of the total 
test. This is a combination of variables, previously indicated to best predict ADHD 
(Greenberg & Waldman, 1993). The API falls on a -10 to +10 range, where negative 
numbers are suggestive of clinically significant attention problems. The remaining 
dependent measures are automatically reported as standard scores, with higher 
standard scores indicating better performance.  
Motivation and subjective experience during the TOVA. Participants rated 
their experience of completing the TOVA test on six scales. Four of these items 
assessed two aspects of motivation: boredom (“unpleasant” – “enjoyable,” “very fun” – 
“very boring,”) and drive (“not motivated to do well” – “very motivated,” effort invested in 
the task: “as much as possible” – “none at all”). Two items assessed how difficult and 
how tiring participants found the test (“easy” – “difficult,” “very-exhausting” – “not tiring 
at all”).  All items were scored on 5-point scales. These measures were completed 
twice: once at the end of the short TOVA practice test, and once at the end of the full 
actual TOVA test. 
Study Habits. A 34-item self-report measure assessed a variety of study habits, 
including self-testing and rehearsal, spaced practice, effort and persistence, critical 
  
 
 
 
64
analysis of the material, time management, preference for work-appropriate spaces, 
self-monitoring of goal-directed activities, class attendance, assignment completion, 
time spent studying, among others. Participants were presented with statements, each 
describing a study habit, and asked to indicate how frequently they rely on that study 
habit, using a 0 (Never) – 4 (Always) scale. Items were compiled from previously 
published scales on study habits. In our sample, the scale had good-to-excellent 
internal consistency: Cronbach’s alpha = 0.88. Furthermore, in this sample, the 
measure of study habits was significantly associated with GPA (r = 0.38, ps < 0.01), 
depression (BDI: r = -0.31, Spearman’s rho = -0.23, ps =< 0.01), trait anxiety (STAI-
general: r = -0.30, Spearman’s rho = 0.30, p < 0.01), and self-reported attention 
(Current Symptom Scale Total Score: r = -0.35, Spearman’s rho = - 0.29, ps < 0.01; 
Current Symptom Scale - Inattention Subscale: r = -0.47, Spearman’s rho = 0.40, ps < 
0.01; B Current Symptom Scale - Impulsivity Subscale: r = -0.18, Spearman’s rho = 
0.04; rho = - 0.17, p = 0.06). We found no correlations between Study Habits and any of 
the TOVA indexes. 
Secondary Measures 
Secondary measures reflected demographics, as well as several control 
variables (e.g., depression, anxiety, substance use).  
Beck Depression Inventory – II (BDI). The BDI is a measure of depression 
severity, tailored to reflect the DSM-IV diagnostic criteria. Each of the 21 irems on the 
BDI is rated on a 0-3 severity scale for a maximum score of 63. Conventionally, scores 
in the ranges 0-9; 10-19; 20-29 and 30-63 reflect, respectively, minimal, mild, moderate 
and severe depression. The BDI has excellent reliability and validity (e.g., Steer et al., 
1999; Storch at al., 2004). 
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State Trait Anxiety Inventory (STAI). The STAI is a widely used self-report 
assessment of anxiety, from which we selectively focused on the 20-item subscale 
reflecting trait anxiety. Participants were asked to rate the extent to which they 
experience various anxiety symptoms (e.g., nervousness, insecurity) on a 0 (not at all) 
– 3 (very much so) scale. The test has high test-retest reliability and correlates highly 
with other anxiety questionnaires (Spielberger, 1983), although it does not consistently 
differentiate anxiety from depression (Bados et al., 2010, Balsamo et al., 2013). 
Substance Use. To assess substance use, participants were given a list of 
addictive, commonly abused substances, some of which were also identified with a 
street name. These included: tobacco, marijuana, MDMA (“molly” or “ecstasy”), 
cocaine, hallucinogenic mushrooms, LSD, heroin, methamphetamine, opioids, 
unprescribed opioid painkillers, PCP (“angel dust”), hashish, unprescribed barbiturates 
or benzodiazepines, and inhalants. For each substance, participants indicated the 
number of occasions of use in their lifetime. 
Other demographic and control variables. Data were also collected on 
participants’ gender, undergraduate institution, GPA, and current occupation. To 
examine some situational factors, potentially affecting TOVA performance, we 
administered a list of open-ended questions about medication intake (type and dose) 
within 24 hours before the TOVA; caffeine intake (type and amount of caffeinated drink) 
on the day of the TOVA, as well as on a typical day; and alcohol and substance use 
(type and amount of substance) within 24 hours before the TOVA. We also inquired 
about the number of hours participants slept the night before the TOVA. Before the 
objective attention test, all participants confirmed that their vision was normal or 
corrected-to-normal. 
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Results 
 
Data Distributions and Choice of Parametric vs. Non-parametric Tests 
Several of our main variables of interest had non-normal distributions, as 
indicated by a series of significant Shapiro-Wilks tests. Non-normally distributed 
variables included all indexes of objective attention (TOVA: omissions, commissions, 
reaction time variability, reaction time and API) and subjective attention (Current 
Symptom Scale: inattention subscale, impulsivity subscale and total score), as well as 
the BDI, STAI-general, our measures of substance use incidence and amount of sleep 
pre-TOVA. These distributions were skewed, in some cases pronouncedly so: a 
majority of data indicated uniformly high functioning, while increasingly fewer subjects 
showed (or reported) increasingly greater problem severity. We attempted several 
transformations (square root, square, ln and log10) of the raw or the reversed scores, 
but without attaining normality. Hence, our main analyses relied on non-parametric 
tests. Secondarily, we conducted parametric procedures with untransformed data. 
Measures of study habits and motivation were normally distributed, allowing analyses 
using parametric procedures only.  
Handling of Outliers 
We winsorized all data by substituting the three highest and three lowest data 
points (4.7% of the data) with the next most extreme data point.  
Handling of External Variables 
Based on consistent past findings (Dussault & Weyandt, 2011; Weyandt et al., 
2009; Rabiner et al., 2010; Teter et al., 2010; Arria et al., 2013; McCabe et al., 2004; 
McCabe & West, 2013), we assumed that elevated levels of depression, anxiety, and 
  
 
 
 
67
substance use are characteristic of users. Thus in our main analyses, we do not 
statistically control for these variables, in order not to partial meaningful group variance 
out of the analyses. If we held constant the values of depression, anxiety and 
substance use between groups, we run the risk of obtaining findings unrepresentative 
of a substantial proportion of users (Miller & Chapman, 2001). However, in a secondary 
set of analyses, we do enter the third variables as predictors in the model, to assess if 
users and controls differ on attention, motivation and study habits above and beyond 
their previously documented differences on depression, anxiety, and substance use.  
Subsets of Data Analyzed 
Our main analyses, which are reported below, were conducted based on the full 
sample of eligible participants. In addition, we replicated these analyses in two subsets 
of participants. First, we excluded participants (n = 5) who disclosed having used 
enhancement medication only once in their lifetime. Our reasoning was that one-time 
users might be unrepresentative of people who use continually, for instance, by finding 
stimulants unhelpful, by experiencing side effects as intolerable, or by functioning 
relatively more highly than other users in the areas of interest in the present study. 
Secondly, we replicated our analyses in users with API scores within normal limits (n = 
109). User-control differences on motivation and study habits were most likely to be 
detected in this subsample, as was the evidence for disparities between perceived 
attention problems and high functioning on objectively measured attention. The results 
of these two sets of secondary analyses are only reported when different in direction or 
significance level from the findings of the main analyses.  
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Characteristics of Enhancement Users 
A chi square test for independence indicated a non-significant relationship 
between gender and user status (χ²= 1.53, p = 0.22). Contrary to intuitive expectations, 
there was a borderline significant trend for users to report more time having slept the 
night before testing (M = 7.40, SD = 1.19) than non-users (M = 7.02, SD = 0.97): t (122) 
= 1.93, p = 0.06. Positive correlations between hours of sleep and lifetime incidence of 
use were significant (r = 0.18, p = 0.05; Spearman’s rho = 0.21, p = 0.02). Users were 
more likely than controls to have taken a cup of coffee or more (or a roughly equivalent 
amount of another caffeinated drink) on the test day: χ² (1) = 5.29, p = 0.02. Consistent 
with past findings (Dussault & Weyandt, 2011; Weyandt et al., 2009; Rabiner et al., 
2010; Teter et al., 2010; Arria et al., 2013; McCabe et al., 2004; McCabe & West, 
2013), users reported higher levels of depression (t (126) = 3.28, p < 0.01; Mann-
Whitney U = 2,633.50, z = 2.82, p < 0.01), trait anxiety (t (127) = 3.35, p < 0.01; Mann-
Whitney U = 2,677.50, z = 3.03, p < 0.01), and substance use (t (127) = 5.75, p < 0.01, 
Mann-Whitney U = 3,141.50, z = 5.28, p < 0.01) than controls. Finally, self-reported 
GPA was lower among enhancement users (M = 3.29, SD = 0.38) than controls (M = 
3.55, SD = 0.41), t (124) = 3.67, p < 0.01. Depression, anxiety, substance use and GPA 
were also significantly correlated with lifetime use, based on both parametric and non-
parametric tests.  
Stimulant Enhancement Use and Attention  
Non-parametric and parametric procedures consistently showed higher level of 
self-reported inattention (U = 2,619.50, z = 2.76, p < 0.01, one-tailed, d = 0.50; t (126) = 
2.95, p < 0.01, one-tailed, d = 0.52) and impulsivity (U = 2,637, z = 2.99, p < 0.01, one-
tailed, d = 0.54; t (126) = 3.26, p < 0.01, one-tailed, d = 0.57) on the Current Symptom 
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Scale among users than controls. Accordingly, users had higher total scores on this 
self-report scale: U = 2,669.50, z = 2.99, p < 0.01, one-tailed, d = 0.54; t (126) = 3.36, p 
< 0.01, one-tailed, d = 0.59. Lifetime enhancement use correlated with subjectively 
perceived attention problems: r = 0.31, Spearman’s rho = 0.28, ps < 0.01, one-tailed, 
for the Inattention subscale of the Current Symptom Scale; r = 0.35, Spearman’s rho = 
0.29, ps < 0.01, one-tailed, for the Impulsivity subscale of the Current Symptom Scale; r 
= 0.35, Spearman’s rho = 0.31, ps < 0.01, one-tailed, for the total score of this scale. 
Qualitatively similar patterns emerged when correlating the measures of attention with 
past-year and past-month enhancement use.  
On the objective test of attention, independent-samples Mann-Whitney tests 
showed a higher number of omission errors (the measure with the most pronouncedly 
skewed distribution) among users than controls (U = 1,610, z = 2.09, p = 0.02, one-
tailed, d = 0.38), as well as lower overall attention performance index on the TOVA 
among users (U = 1,693, z = 1.67, p = 0.05, one-tailed, d = 0.30). These differences 
emerged, even though, as shown above, users had slept slightly longer the night before 
testing and were more likely to have taken the equivalent of a cup of coffee before 
testing. In contrast, when a series of between-subjects one-way ANOVAs were applied 
to the skewed data distributions, no significant differences emerged between the groups 
on any index of objective attention (irrespective of whether we controlled for sleep and 
caffeine before testing).  
We also examined the correlations between incidence of enhancement use, on 
the one hand, and each index of objective attention. According to the results of non-
parametric tests, omission errors were weakly correlated with lifetime enhancement use 
(Spearman’s rho = 0.15, p = 0.05, one-tailed), and past-year use (Spearman’s rho = 
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0.19, p = 0.02, one-tailed). The relationship with past-month use did not reach 
significance, possibly due to the restricted range of this measure. No other correlations 
between enhancement use and the remaining indexes of objective attention emerged 
significant, based on either non-parametric or parametric tests (all ps > 0.08, one-tailed) 
and irrespective of controlling for sleep and caffeine before the TOVA in corresponding 
parametric regression analyses. Thus, unprescribed stimulant use was associated with 
objectively measured inattention, but less strongly and consistently than with perceived 
attention difficulties. 
Are the discrepancies between users’ and controls’ attention significantly more 
pronounced on subjective than on objective tests? We conducted a series of three 
mixed-model ANOVAs with test type (subjective vs. objective) as a repeated-measures 
factor and user status (users vs. controls) as a between-subjects factor. Dependent 
measures in each of these three analyses were the following pairs of indexes: 1) API 
(TOVA) and total score of the Current Symptom Scale; 2) a linear composite of 
Omissions plus RT Variability (TOVA) and Inattention subscale (Current Symptom 
Scale); 3) Commissions (TOVA) and Impulsivity (Current Symptom Scale). To convert 
the objective and subjective data to a common scale, we converted all outcomes to z-
scores with consistent directionality. We found a significant interaction on the tests of 
impulsivity, such that objective scores were very similar between users and controls, 
while users described themselves as more impaired than controls on self-report: F (1, 
126) = 4.48, p = 0.04. The same trends emerged on tests of inattention and of overall 
attention performance, but the interactions did not reach significance ( 0.15 < all ps < 
0.101). However, when participants who had used unprescribed stimulants only once 
were excluded, the interactions between user status and attention test type emerged 
significant on both impulsivity and inattention, showing comparable performance on the 
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objective test between the two groups, but lower perceived attention among users than 
controls (for inattention subtests: Finteraction (1, 121) = 4.78, p = 0.03; for impulsivity 
subtests: Finteraction (1,121) = 7.91, p < 0.01; for overall attention performance: Finteraction 
(1, 121) = 3.83, p = 0.053, see Fig. 3.1.). 
We further asked whether stimulant enhancement use is disproportionately 
more common among people whose scores fall in the attention tests’ range of clinically 
significant impairment. 9 users and 2 controls scored in the clinical range of the Current 
Symptom Scale. A significant chi square test for independence showed that users are 
significantly more likely to have above-threshold self-reported attention difficulties: chi 
χ² = 5.63, p = 0.02. In contrast, we found that 9 users and 10 controls performed below 
the API’s clinical cutoff on the TOVA (χ²< 0.01, p = 0.98). In sum, enhancement use 
appeared disproportionately common among people with self-reported attentional 
problems. Those with objectively measured attention problems were equally likely to 
report and deny stimulant enhancement use. 
Self-reports on participants’ experience of the TOVA showed positive 
correlations between the tendency to describe the test as difficult, on the one hand, and 
past-year (r = 0.19, p = 0.02, one-tailed; Spearman’s rho = 0.19, p = 0.02, one-tailed) 
and past-month use (r = 0.17 , p = 0.03, one-tailed; Spearman’s rho = 0.18, p = 0.03, 
one-tailed). No significant correlations with lifetime use emerged.  In addition, no 
correlation emerged between incidence of use (lifetime, past-year and past-month) and 
participants’ tendency to describe the attention test as tiring.  
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Stimulant Enhancement Use and Motivation 
An independent-samples t-test indicated that users reported lower overall 
motivation during the TOVA test than controls: t (126) = 3.09, p < 0.01, one-tailed, d = 
0.54, based on a composite of the four motivation-related items. A closer look at 
specific sub-groups of items indicated that users described the test as more boring (t 
(126) = 2.83, p < 0.01, one-tailed, d = 0.50, based on a composite of the items “very 
fun” – “very boring” and “unpleasant” – “enjoyable”) and, reportedly, were less driven to 
do well (t (126) = 2.11, p = 0.02, one-tailed, d = 0.37, based on a composite of the items 
“not motivated to do well” – “very motivated” and effort expended on the task: “as much 
as possible” -- “none at all”). Accordingly, the incidence of lifetime stimulant 
enhancement use was inversely correlated with the test motivation composite (r = -
0.26, Spearman’s rho = 0.28, ps < 0.01, one-tailed), task enjoyment (r = -0.24, rho = 
0.28, ps < 0.01, one-tailed) and drive (r = -0.17, p = 0.03, one-tailed; Spearman’s rho = 
-0.18, p = 0.03, one-tailed).  Correlations between these motivation indexes and past-
year use replicated the reported findings, whereas correlations with past-month use 
failed to reach significance, possibly due to the more restricted range of this measure.  
Another way of examining users’ motivation during the TOVA entails asking if 
their motivation ratings’ linear composite decreased more dramatically over the duration 
of the TOVA test, relative to the control group. We conducted a mixed-model ANOVA 
with user status as a between-subjects factor and motivation assessment time point 
(after TOVA practice; after the full test) as a within-subjects factor. No significant 
interaction emerged either based on the full sample, or after one-time users were 
excluded (ps interaction > 0.19). However, when only analyzing data from people with API 
scores within normal limits, the interaction between user status and pre-post 
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assessment emerged significant (F (1,105) = 4.21, p = 0.04). This interaction revealed 
that the drop in motivation from the beginning to the end of the TOVA was greater 
among users than controls with normal attention functioning.  
Stimulant Enhancement Use and Study Habits  
An independent-samples t-test indicated that users reported less optimal study 
habits than controls: t (126) = 2.65, p < 0.01, one-tailed, d = 0.48. Accordingly, ratings 
on study habits quality correlated inversely with the incidence of lifetime stimulant 
enhancement use: r = -0.20, p = 0.01, one-tailed, and past-year enhancement use: r = -
0.23, p < 0.01, one-tailed. No significant correlation with past-month use emerged (r = -
0.13, p = 0.07, one-tailed), possibly due to the relatively more restricted range of this 
scale.  
Analyses Controlling for External Variables 
In addition to describing the relationships between unprescribed stimulant use, 
on the one hand, and attention, motivation and study habits, on the other hand, we 
asked if these associations are significant after holding constant factors which have 
been previously documented to differ between users and controls: depression, anxiety 
and substance use. In other words, we were interested if use is associated with 
attention, motivation and study habits over and above what could be accounted for by 
depression, anxiety and substance use. We conducted a series of between-subjects 
ANOVAs for each outcome, with the control variables (trichotomized to circumvent 
distribution skewness) and user status as between-subjects factors. For analyses with 
TOVA indexes as outcomes, we additionally entered caffeine use (dichotomous) and 
sleep before the TOVA (trichotomized) as independent variables. In these analyses, we 
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found trend-level relationships between user status, on the one hand, and subjective 
and objective attention and study habits, on the other (0.16 < p < 0.07, one-tailed). The 
motivation composite remained related to user status after depression, anxiety and 
substance use were held constant: F (1, 127) = 4.96, p = 0.01, one-tailed (for the main 
effect of user status).  
Discussion 
 
Our study examined the psychological profile of people without diagnosed 
ADHD who use unprescribed stimulants to enhance their academic or professional 
performance. Aside from replicating previous findings of lower self-reported attention 
among users relative to their non-stimulant using peers, we extended these data in 
important ways. Specifically, we obtained evidence for somewhat lower functioning in 
users than controls on an objective, neuropsychological measure of attention, a 
measure not susceptible to the biases inherent in self-report. Furthermore, we found 
that, relative to controls, users describe their study habits as poorer and report lower 
motivation during laboratory attention testing. The motivational differences between the 
two groups remained significant even when statistically controlling for depression, 
anxiety and substance use.  
There are several ways to interpret the finding that the relationship of 
enhancement use with attention and study habits emerged only at trend level when 
holding constant depression, anxiety and/or substance use. This finding may indicate 
an absence of user-control differences on attention and study habits beyond what is 
already captured by depression, anxiety and substance use. Alternatively, attention and 
study habits may be related to use above and beyond the controlled variables, but 
these relationships might be weak and detectible only in larger samples. (In the 
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abstract, there is also the possibility that attentional difficulties and poor study habits 
merely co-occur with what actually predicts use, without being causally related to use. 
This possibility is unlikely, given previous findings showing that users identify the 
optimization of attention as the primarily motive for self-medication with stimulants, 
Boyd et al., 2006; Hall et al., 2005; Teter et al., 2005, 2006, and study habits as 
another, though less frequently endorsed, motive, Rabiner et al., 2009). Regardless of 
their relationship to the variables we controlled for, attention and study habits do appear 
more compromised on average in users than controls.  
Although both perceived and objectively measured attention difficulties were 
associated with unprescribed ADHD medication use, use appeared more strongly and 
robustly related to subjectively perceived attention functioning. Differences between 
users’ and controls’ attention were larger in size on subjective than on objective 
measures. Whereas consistently associated with all self-report attention measures, use 
remained unrelated to some TOVA indexes (incl. commission errors, the primary 
measure of impulsivity, and RT variability, one of the indicators of inattention). While 
individuals with clinically significant attention difficulties on self-report were 
disproportionately likely to use enhancement stimulants, participants with clinically 
significant difficulties on objectively measured attention were equally likely to report and 
deny use. Taken together, these patterns indicate stronger relationship of unprescribed 
ADHD medication use with a perception of attentional problems than with actual 
difficulties. 
What might explain the relatively weak relationship of objective attention to non-
medical stimulant use? Although some users may seek to medicate clinically significant 
attention problems or optimize normal attention, a majority may be relying on stimulants 
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to medicate poor study habits, demotivation, anergia and fatigue, possibly in some 
cases secondary to clinical or subclinical mood, anxiety or substance-related problems. 
If primarily emerging in these contexts, users’ attention difficulties would be expected to 
be relatively mild (i.e., not as pronounced as one would expect in ADHD), and the 
differences in users’ and controls’ functioning would be relatively subtle.  
While likely motivating the use of enhancement stimulants, low levels of 
perceived attention, task motivation and study habits may also, in part, be a product of 
unprescribed stimulant use. For instance, some users might be justifying self-
medication by perceiving or reporting attention difficulties; some might be deducing 
attentional impairment from the fact that the medication feels effective. At the same 
time, the availability of Adderall as a study aid might be reducing the perceived need for 
maintaining self-regulated study habits. Given our study’s cross-sectional design, a third 
variable may be explaining some of the documented relationships: people who admit to 
illicit medication use may be less prone to socially desirable responding than the rest of 
the sample. This could accounting in part for users’ less favorable self-reports. The 
present study cannot distinguish between these explanations, but, as outlined below, 
paves the way for future longitudinal and intervention studies, which can establish the 
direction and causality of the examined relationships. 
Limitations 
Several limitations of the present study require consideration. First, we relied on 
self-report to establish the incidence of unprescribed stimulant use and the absence of 
previous ADHD diagnosis. One could imagine that, motivated to get into the study, 
participants might have concealed ADHD diagnosis or dishonestly indicated a history of 
unprescribed medication use. Conversely, to avoid academic or legal repercussions, or 
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driven by social desirability, some might have concealed illicit prescription stimulant 
use. In the low-likelihood case of non-negligible systematic bias for dishonest reporting, 
our findings might be describing inaccurately the correlates of use. In the absence of 
systematic bias in reporting, the signal-to-noise ratio in our data might be suboptimal.  
Second, 24 participants dropped out of our study (i.e., completed the online 
survey but did not return for the TOVA), raising a question whether users with the most 
impaired objective attention remained untested. Fortunately, the number of non-
completers was roughly comparable between the user and control group (14 users vs. 
10 controls), reducing (though not eliminating) the possibility of systematic between-
group differences in the functioning of missed cases.  
Finally, given that the majority of our sample consisted of students (124 out of 
128) completing or having completed their undergraduate degree at the University of 
Pennsylvania (114 out of 128 participants), the generalizeability of our finding to other 
occupations or other undergraduate institutions is an open question. 
Future Directions 
The present study opens up important avenues for future research. First, 
subsequent investigations can examine the relationship of unprescribed stimulant use 
to complementing measures of motivation and study habits. For a behavioral 
assessment of specific learning strategies, one could employ (or modify) Son & 
Kornell’s (2009) paradigm, which asks participants to study word pairs for a subsequent 
test and observes their learning strategies (e.g., spaced vs. massed practice) in the lab. 
Modifications of this procedure could evaluate the previously unexamined relationship 
of enhancement use to individual study habits, including time allocation for task-
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oriented activity and choice of self-testing (vs. passive review of the material). 
Analogously, subsequent research can assess the relationship of enhancement use 
with a comprehensive array of motivation-related functions.  Motivation encompasses a 
number of facets, measurable through self-report and/or behavioral tests. Examples 
include the tendency to expend effort for reward (as measured through the behavioral 
EEfRT task, Treadway et al., 2011); trait drivenness (assessed by the Drive subscale of 
the Behavioral Activation scale) and positive expectancy for one’s performance. Thus, 
the present study substantiates a more comprehensive assessment of the relationship 
of stimulant self-medication to motivation and study habits, using measures of various 
modalities.  
Additionally, future investigations may ask questions about the directionality and 
causality of the relationships examined here. Longitudinal research can examine 
whether objective attention, motivation and study habits assessed in late adolescence 
prospectively predict the onset of non-medical stimulant use in young adulthood. 
Intervention studies can provide insights into the causal roles of motivation and study 
habits in non-medical stimulant use, while at the same time illuminating the approaches 
to reducing this risky behavior. Our study raises the possibility of several potentially 
effective interventions. Past research suggests that students harbor misconceptions 
about what study habits are optimal (Kornell & Bjork, 2008). A psychoeducational 
intervention addressing these misconceptions may improve study ativities and, 
potentially, reduce non-medical stimulant use. Cognitive-behavioral interventions may 
also be helpful in enhancing users’ motivation and study habits, while reducing 
academic impairment due to depression and anxiety. Research on the effects and 
mechanisms of these interventions (e.g., in comparison to a control condition, such as 
psychoeducation on the risks and uncertain benefits of stimulant self-medication) can 
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be informative of the causal roles of motivation and study habits in enhancement 
stimulant use. 
Future studies can investigate other aspects of enhancement users’ 
psychological profile, including possible weaknesses (e.g., planning and problem-
solving) in need of intervention and potential strengths to draw from in compensating for 
these weaknesses. Finally, given our small subsample of people with possible clinically 
significant attention problems who reported no ADHD diagnosis, future research and 
policy should identify and intervene into the barriers to appropriate diagnosis and 
treatment seeking. 
Conclusion 
Despite its limitations, the present study extends the previous literature on the 
correlates of stimulant enhancement in important ways. It shows that non-medical 
stimulant use is more strongly related to a subjective perception of attention difficulties, 
inefficient study habits and low task motivation than with actual attentional impairment. 
The present research has important implications for future research into the causal 
mechanisms of unprescribed ADHD medication use and into the interventions for 
discouraging this practice.  
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CHAPTER 4 
GENERAL DISCUSSION 
 
The present project examined stimulants’ cognitive enhancement effects in 
healthy people and the psychological profile of non-medical stimulant users. Study 1, an 
adequately powered double-blind, placebo-controlled experiment, found no enhancing 
effect of amphetamine on inhibitory control, working memory, episodic memory, 
convergent creativity, perceptual intelligence, and a standardized achievement test, 
despite evidence for subjectively perceived enhancement. No moderating effects of 
baseline performance or COMT genotype were detected. These findings suggest that 
drug effects on examined functions are either small or null. In Study 2, we conducted a 
meta-analysis to distinguish between these two possibilities. Our results showed overall 
small effects of amphetamine and methylphenidate, based on 47 double-blind, placebo-
controlled experiments on inhibitory control, working memory and episodic memory. 
Given the absence of conclusive evidence for practically significant stimulant effects in 
healthy people, we conducted Study 3 to address three candidate explanations of the 
increasing popularity of prescription stimulants’ non-medical use. Users reported lower 
motivation during a laboratory cognitive task and described their everyday study habits 
as poorer than a control group with no history of stimulant use. In addition, non-medical 
stimulant use was more strongly related to a perception of compromised attention than 
to deficits in objectively measured attention. Taken together, these data imply that 
enhancement users struggle with below-average functioning in one or several cognitive, 
affective and behavioral domains, compensating for these problems with an illicit 
intervention of uncertain practical significance.  
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The present research extends the previous literature in important ways. Study 1, 
unlike the majority of preceding experiments, had sufficient statistical power to detect 
medium-sized effects. It was also designed to rule out artifactual explanations of 
previously documented moderation effects. Whereas previous investigations were 
restricted to laboratory measures, Study 1 also assessed the effects of an 
enhancement drug on an ecologically valid test (the SAT). Study 2 built on the only 
previously published meta-analysis of stimulant enhancement effects (Repantis et al., 
2010), by: 1) incorporating more studies (47 vs. 17 in the published meta-analysis); 2) 
examining the effects of the two most commonly used enhancement stimulants (while 
Repantis et al., 2010 did not study amphetamine effects); 3) conducting tests of 
moderation; and 4) assessing the evidence for  publication bias. Study 3 complemented 
previously used subjective assessments of enhancement users’ attention with a 
converging neuropsychological test – a tool not free from the biases inherent in self-
report. In addition, Study 3 examined previously unaddressed questions about the 
psychological profile of enhancement users, with a focus on their study habits and task 
motivation.  
These investigations have important practical and ethical implications. 
Enhancement stimulants do not appear to pronouncedly optimize high-functioning 
people’s capacity for intelligence, memory and executive functions. It remains an open 
question whether these medications’ effects in healthy people are practical significant 
under given conditions (e.g., after repeated use), in specific contexts (e.g., task novelty) 
or in a particular subgroup. Thus, users of unprescribed stimulants appear to pursue 
uncertain benefits, while exposed to well-established risks, including risks for abuse, 
dependence, and cardiovascular problems. Stimulants may exacerbate functioning in 
some people, elevating anxiety in prone individuals, or demotivating persistent, self-
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regulated study habits by promising a study aid for a last-minute all-nighter. Costs of 
non-medical use may be substantial for people self-medicating clinically significant 
problems with stimulants – a practice which may deter from seeking appropriate 
medical supervision for a potentially impairing problem.  
Thus, aside from above-mentioned outstanding questions about the individual 
differences moderators and context-specificity of stimulants’ effects, the present studies 
suggest a further avenue for future research. The growing public interest in cognitive 
enhancement raises the question whether there are interventions that optimize 
cognition more effectively than unprescribed stimulants. The previous literature has 
identified a number of candidates, including caffeine, aerobic exercise, meditation, 
cognitive-behavioral interventions, psychoeducational techniques.  Comparing the 
effects of these enhancement approaches on various facets of cognition and identifying 
which intervention suits best which group of individuals may be a promising future 
avenue for the study of cognitive enhancement. 
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APPENDIX 
Study Habits Questionnaire 
1. I participate in class discussions even when the instructor does not call on me. 
2. When I study for a class I practice saying the material to myself over and over. 
3. I ask myself questions to make sure I understand the material I have been 
studying. 
4. I work through practice exercises and sample problems. 
5. When working outside of class, I know how to plan my time to get everything 
done. 
6. I don’t take all of the notes I should take. 
7. When studying outside of class, I keep track of how much time I need to get the 
work done. 
8. I review course material periodically 
9. I cram for exams. 
10. I spend more time studying than most of my friends 
11. I wait till the last minute to complete homework and get ready for exams. 
12. I make sure I keep up with the weekly readings and assignments. 
13. I attend class regularly. 
14. I usually study in a place where I can concentrate on my course work. 
15. When reading about research, I like to try out several alternative ways of 
interpreting the findings 
16. I rarely find time to review my notes or readings before an exam. 
17. I find it difficult to make much sense of the notes that I take down in class. 
18. I often find myself questioning things I hear or read to decide if I find them 
convincing. 
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19. When a theory, interpretation or conclusion is presented in class or in the 
readings, I try to decide if there is good supporting evidence. 
20. When I study for a class, I pull together information from different sources, such 
as lectures, readings, and discussions. 
21. I try to understand the course material by making connections between readings 
and the concepts from the lectures. 
22. When I become confused about something I’m reading for a class, I go back 
and try to figure it out. 
23. Before I study new course material thoroughly, I often skim it to see how it is 
organized. 
24. I try to change the way I study in order to fit the course requirements and 
instructor’s teaching style. 
25. I try to think through a topic and decide what I am supposed to learn from it, 
rather than just reading it over when studying. 
26. When studying, I try to determine which concepts I don’t understand well. 
27. When something presented in class is hard to understand, I get everything 
about it in my notes, so that I could figure it out later. 
28. I feel so lazy or bored when I study for my classes that I quit before I finish what 
I planned to do. 
29. I work hard to do well in my classes even if I don’t like what we are doing. 
30. When course work is difficult, I give up or only study the easy parts. 
31. I carefully complete all course assignments. 
32. I ask the instructor to clarify concepts I don’t understand well. 
33. When I can’t understand the material, I ask another student in the class for help. 
34. I can easily locate particular passages in a textbook when necessary. 
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TABLES 
 
Table 1.1. 
 
Drug Effect and Interactions, resulting from a series of 2(Drug: MAS; Placebo) x 2 (Drug 
Order: MAS first; Placebo first) x 2 (Test Version Order: Version 1 first; Version 2 first) 
mixed-model univariate ANOVAs with repeated measures on the first factor. The 
dependent variables were scores for 13 measures listed below. 
 
Test (Measure) Main/Interaction Effects df* F 
p, 
uncorrected 
Face Recognition 
(number correct) 
Drug 1, 40 78 .38 
Drug x Drug Order 1, 40 00 .95 
Drug x Version Order 1, 40 25 .62 
Drug x Drug Order x Version 
Order 1, 40 6.01 <.01 
 
Drug Order 1, 40 01 .91 
 
Version Order 1, 40 .83 .06 
 
Drug Order x Version Order 1, 40 51 .48 
Word Recall (number 
correct) 
Drug 1, 40 10 .76 
Drug x Drug Order 1, 40 .03 .32 
Drug x Version Order 1, 40 10 .76 
Drug x Drug Order x Version 
Order 1, 40 04 .85 
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Drug Order 1, 40 .24 .08 
 
Version Order 1, 40 28 .60 
 
Drug Order x Version Order 1, 40 33 .57 
Word Recognition 
(number correct) 
Drug 1, 40 82 .37 
Drug x Drug Order 1, 40 .46 .23 
Drug x Version Order 1, 40 .67 .20 
Drug x Drug Order x Version 
Order 1, 40 .15 .29 
 
Drug Order 1, 40 .88 .18 
 
Version Order 1, 40 .15 .02 
 
Drug Order x Version Order 1, 40 27 .61 
Digit Span Backward 
(number correct) 
Drug 1, 38 25 .62 
Drug x Drug Order 1, 38 00 .99 
Drug x Version Order 1, 38 .00 .17 
Drug x Drug Order x Version 
Order 1, 38 01 .92 
 
Drug Order 1, 38 18 .67 
 
Version Order 1, 38 37 .55 
 
Drug Order x Version Order 1, 38 .92 .06 
Digit Span Forward 
Drug .75 
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(number correct) 1, 38 10 
Drug x Drug Order 1, 38 .43 .13 
Drug x Version Order 1, 38 .04 .31 
Drug x Drug Order x Version 
Order 1, 38 29 .59 
Drug Order 1, 38 16 .69 
 
Version Order 1, 38 50 .49 
 
Drug Order x Version Order 1, 38 56 .46 
Object-2-Back 
(omissions) 
Drug 1, 41 .13 .74 
Drug x Drug Order 1, 41 28 .60 
Drug x Version Order 1, 41 98 .33 
Drug x Drug Order x Version 
Order 1, 41 11 .74 
 
Drug Order 1, 41 03 .86 
 
Version Order 1, 41 00 
1.0
0 
 
Drug Order x Version Order 1, 41 89 .35 
Go/No-go 
(comissions) 
Drug 1, 38 54 .47 
Drug x Drug Order 1, 38 28 .60 
Drug x Version Order 1, 38 28 .60 
Drug x Drug Order x Version 
Order 1, 38 12 .74 
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Drug Order 1, 38 18 .67 
 
Version Order 1, 38 29 .59 
 
Drug Order x Version Order 1, 38 34 .56 
Flanker (inhibition 
cost) 
 
 
Drug 1, 39 20 .66 
Drug x Drug Order 1, 39 13 .72 
Drug x Version Order 1, 39 00 .98 
Drug x Drug Order x Version 
Order 1, 39 .76 .04 
Drug Order 1, 39 05 .83 
Version Order 1, 39 05 .83 
 
Drug Order x Version Order 1, 39 17 .68 
Remote Associations 
(number correct) 
Drug 1, 42 .56 .12 
Drug x Drug Order 1, 42 01 .94 
Drug x Version Order 1, 42 .10 .16 
Drug x Drug Order x Version 
Order 1, 42 .44 .01 
Drug Order 1, 42 13 .72 
 
Version Order 1, 42 14 .72 
 
Drug Order x Version Order 1, 42 00 .95 
Embedded Figures 
Drug .46 
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(number correct) 1, 32 57 
Drug x Drug Order 1, 32 01 .93 
Drug x Version Order 1, 32 34 .56 
Drug x Drug Order x Version 
Order 1, 32 0.68 
<.0
1 
Drug Order 1, 32 .83 .19 
 
Version Order 1, 32 21 .65 
 
Drug Order x Version Order 1, 32 88 .35 
Raven (number 
correct) 
Drug 1, 33 01 .91 
Drug x Drug Order 1, 33 05 .80 
Drug x Version Order 1, 33 .92 .18 
Drug x Drug Order x Version 
Order 1, 33 05 .83 
 
Drug Order 1, 33 01 .93 
 
Version Order 1, 33 .28 .27 
 
Drug Order x Version Order 1, 33 .26 .14 
SAT Math (number 
correct) 
Drug 1, 41 .16 .29 
Drug x Drug Order 1, 41 55 .46 
Drug x Version Order 1, 41 .79 .19 
Drug x Drug Order x Version 
Order 1, 41 .56 .04 
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Drug Order 1, 41 10 .75 
 
Version Order 1, 41 .24 .14 
 
Drug Order x Version Order 1, 41 .02 .32 
SAT Verbal (number 
correct) 
Drug 1, 41 47 .49 
Drug x Drug Order 1, 41 .23 .14 
Drug x Version Order 1, 41 37 .55 
Drug x Drug Order x Version 
Order 1, 41 00 .98 
 
Drug Order 1, 41 16 .69 
 
Version Order 1, 41 24 .63 
 
Drug Order x Version Order 1, 41 .02 .16 
*df differed between tests due to differences in the number of excluded or 
missing data points per test.  
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Table 1.2. 
 
Means and standard deviations of performance on each dependent measure for 
the baseline, placebo and mixed amphetamine salts condition. 
 
Task (Measure) Condition N M SD 
Face Recognition 
(number correct) 
Baseline 44 29.05 3.25 
 Placebo 44 27.61 4.25 
 MAS 44 28.05 4.78 
Word Recall (number 
correct) 
Baseline 44 4.25 2.69 
 Placebo 44 4.50 4.05 
 MAS 44 4.59 3.36 
Word Recognition 
(number correct) 
Baseline 44 35.16 4.21 
 Placebo 44 34.93 5.65 
 MAS 44 34.39 5.04 
Digit Span Backward 
(number correct) 
Baseline 42 9.57 2.51 
 Placebo 42 10.05 2.70 
 MAS 42 10.17 2.80 
Digit Span Forward 
(number correct) 
Baseline 42 11.83 1.77 
 Placebo 42 12.24 1.59 
 MAS 42 12.17 1.67 
Object-2-Back 
(omissions) 
Baseline 45 10.38 4.90 
 Placebo 45 8.98 4.59 
 MAS 45 8.84 5.06 
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Go/No-go 
(commissions) 
Baseline 42 13.95 5.24 
 Placebo 42 15.12 6.20 
 MAS 42 14.55 5.50 
Flanker (inhibition cost) Baseline 43 1.16 .05 
 Placebo 43 1.16 .06 
 MAS 43 1.16 .05 
Remote Associations 
(number correct) 
Baseline 46 8.35 2.10 
 Placebo 46 7.89 2.50 
 MAS 46 8.48 2.18 
Embedded Figures 
(number correct) 
Baseline 36 2.88 1.79 
 Placebo 36 3.25 1.87 
 MAS 36 3.39 1.78 
Raven (number correct) Baseline 37 7.27 1.87 
 Placebo 37 8.19 2.16 
 MAS 37 8.11 1.84 
SAT Math (number 
correct) 
Baseline 45 12.98 5.39 
 Placebo 45 13.76 6.48 
 MAS 45 13.07 6.18 
SAT Verbal (number 
correct) 
Baseline 45 29.42 6.68 
 Placebo 45 30.73 7.25 
 MAS 45 30.29 7.51 
 
 
 
  
  
 
 
 
93
Table 1.3. 
 
From a total of 702 main effects and interactions, based on 78 univariate statistical 
analyses conducted, the following were significant but not reported in the text. The 
effects in this table are extraneous to our predictions, and hence not discussed further.  
 
Task 
(Measure) 
Statistical Test Main Effects 
and 
Interactions 
df F p 
uncorrected 
Face 
Recognition 
(number 
correct) 
2 (Drug:) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Drug x Drug 
Order x 
Version Order 
1, 
36 
14.1
5 
0.001 
Face 
Recognition 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order x 
Version Order 
1, 
10 
6.44 0.029 
Face 
Recognition 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
low-performers 
Drug x Drug 
Order x 
Version Order 
1, 
19 
11.5
1 
0.003 
Word Recall 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
36 
8.21 0.007 
Word 
Recognition 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Version Order 1, 
36 
5.06 0.030 
Digit Span 
Backwad 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
34 
15.4
8 
<.001 
Digit Span 
Forward 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
34 
5.05 0.031 
Digit Span 
Backwad 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Drug x 
Baseline x 
Drug Order x 
Version Order 
1, 
34 
8.01 0.007 
Digit Span 
Backwad 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order x 
COMT 
1, 
10 
4.97 0.050 
Object-2-Back 
(omissions) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Baseline 
Performance 
1, 
37 
16.3
7 
<.001 
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Order) ANOVA 
Object-2-Back 
(omissions) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order x 
COMT 
1, 
10 
4.96 0.05 
Object-2-Back 
(omissions) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x 
Version Order 
x COMT 
1, 
10 
5.78 0.037 
Go/No-go 
(commissions
) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
34 
6.87 0.013 
Go/No-go 
(commissions
) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
val-val participants 
Drug Order x 
Version Order 
1, 4 8.38 .044 
Flanker 
(inhibition 
cost) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
35 
11.8
9 
0.001 
Remote 
Associations 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Drug x Drug 
Order x 
Version Order 
1, 
38 
7.68 0.009 
Remote 
Associations 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
low-performers 
Drug x Drug 
Order x 
Version Order 
1, 
20 
8.67 0.008 
Embedded 
Figures 
(number 
correct) 
2 (Drug:) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order x 
Version Order 
1,7 6.03 0.044 
Embedded 
Figures 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
low-performers 
Drug x Drug 
Order x 
Version Order 
1, 
12 
11.3
5 
0.006 
Raven 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
29 
12.5
4 
0.001 
Raven 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
low-performers 
Drug x Drug 
Order 
1, 
16 
5.36 0.034 
Raven 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Drug x Raven 
Baseline x 
Drug Order 
1, 
29 
6.8 0.014 
Raven 
(number 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Drug x 
Version Order 
1, 
16 
8.58 0.010 
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correct) Order) ANOVA among 
low-performers 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
37 
47.2
1 
<.000 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
COMT x Drug 
Order x 
Version Order 
1, 
11 
8.68 0.013 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Drug x 
Baseline x 
Drug Order 
1, 
37 
4.12 0.050 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order 
1, 
11 
5.29 0.042 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
ANOVA 
Drug x Drug 
Order X 
COMT 
1, 
11 
9.63 0.010 
SAT Math 
(number 
correct) 
2 (Drug) x 2 (COMT 
genotype: val-val; met-
met) x 2 (Drug Order) x 2 
(Test Version Order) 
Drug x 
Version Order 
x COMT 
1, 
11 
7.9 0.017 
SAT Math 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
val-val participants 
Drug x 
Version Order 
1, 6 6.34 .045 
SAT Math 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
val-val participants 
Drug Order x 
Version Order 
1, 6 6.23 .042 
SAT Math 
(number 
correct) 
2 (Drug) x  2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA among 
low-performers 
Drug x 
Version Order 
x COMT 
1, 
18 
6.15 0.023 
SAT Verbal 
(number 
correct) 
2 (Drug) x 2 (Baseline 
Performance) x 2 (Drug 
Order) x 2 (Test Version 
Order) ANOVA 
Baseline 
Performance 
1, 
37 
31.4
3 
<.000 
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Table 2.1.  
Eligible Measures for Examined Tasks 
 
 
 
Cognitive 
Construct 
 
Task 
 
Eligible Measure(s) 
 
 
Reference 
supporting choice 
of measure 
Inhibitory 
control 
Stop Signal 
Task 
Depending on task design: 
• Stop Signal RT (Mean Go RT 
minus Mean Stop Delay) 
• Probability of inhibiting a 
response 
 
• Logan et al. 
(1997) 
 
• Lappin & Eriksen 
(1966)  
Go/No-go • False alarms or no-go 
accuracy  
• Helmers et al. 
(1995), Aron et 
al. (2004) 
Wisconsin 
Card-sort 
• Perseverative errors  
• If unavailable: accuracy  
• Heaton et al. 
(1993) 
ID/ED • Perseverative extra-
dimensional shift errors 
• Robbins et al. 
(1998) 
Flanker • Difference or ratio between 
accuracy in the congruent 
and incongruent conditions 
• If unavailable: incongruent 
condition accuracy 
• If accuracy was at ceiling, 
corresponding reaction times 
(RTs) were coded 
• Eriksen & Eriksen 
(1974) 
Stroop • Difference or ratio between 
accuracy in the congruent 
and incongruent conditions 
• If unavailable: incongruent 
condition accuracy 
• If accuracy was at ceiling, 
corresponding RTs were 
coded 
• Stroop (1935) 
Antisaccade 
task 
• Error saccades toward the 
target  
• Everling & Fisher 
(1998)  
Working 
Memory 
NBack1 • d’, difference between hits 
and false alarms, or overall 
accuracy 
• If unavailable:omissions or 
hit rate 
• When the available 
measures from the list above 
were at ceiling, RTs were 
coded instead2 
• Jaeggi et al. 
(2010), Kane et 
al. (2007) 
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Rapid 
Information 
Processing 
• Processing rate (digits 
presented per minute) 
• Fillmore et al. 
(2005) 
Sternberg • Load effect 
• If unavailable: accuracy  
• If accuracy was at ceiling, 
corresponding RTs were 
coded2 
• Sternberg (1966) 
 
Digit Span  • Accuracy  
• If unavailable: Longest length 
of correctly reported item 
• The 
Psychological 
Corporation 
(2002) 
CANTAB 
Spatial Working 
Memory 
• Within and between search 
errors 
• If unavailable: Within- or 
between-search errors 
• Owen et al. 
(1990) 
Spatial Delayed 
Response  
• Accuracy (percent correct) • Poste et al. 
(1997) 
Other WM 
measures  
• d’ or accuracy 
• If unavailable: omission 
errors 
• For spatial tasks: error to 
position and positional fit  
• Jaeggi et al. 
(2010), Kane et 
al. (2007) 
Immediate 
and delayed 
memory 
Recall (free and 
cued) and 
recognition 
tests 
• Sensitivity (d’ or a’), 
proportion of hits minus 
proportion of false alarms, 
accuracy or number of trials 
to criterion 
• If unavailable: hit rate  
• Henson et al. 
(2000) 
 
1 Only data from 2- and 3-Back tasks were coded, excluding data from 0-back conditions 
(which capitalize on sustained attention more than working memory) and 1-back 
conditions (which, while taxing some working memory components, such as on-line 
maintenance, minimally tax other facets of working memory, such as monitoring and 
manipulation). Thus, we only included the n-back conditions that maximized the 
possibility of detecting drug effect and minimized the possibility of ceiling effects. 
 
2 If there was no basis for inferring presence or absence of ceiling or floor effects, both 
accuracy and RT measures were coded. 
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Table 2.2. 
Stimulant Enhancement of Inhibitory Control: Effect Sizes and Study Characteristics 
 
 
 
Study Test Drug 
Dose 
(mg) 
N Design  Dose 
Caffeine 
Restriction 
%Mal
e 
Other 
reason to 
publish? 
Floor or 
Ceiling? 
Hedges's g 
Acheson & de Wit 
(2008) 
Stop Signal 
Task 
amp 20 28 
Within-
subjects 
High no 54.54 no 
not 
suspected 
0.23 
Agay et al. (2010) 
TOVA 
commissions 
mph 15 25 
Between-
subjects 
 
Low no 46.15 no possible 0 
Allman et al. (2010) 
Antisaccade 
Task 
amp 21 24 
Within-
subjects 
High no 70.83 no 
not 
suspected 
0.35 
Barch & Carter 
(2005) 
Stroop amp 17.5 22 
Within-
subjects 
Low no 55 no 
not 
suspected 
0.23 
Costa et al. (2012) 
Stop Signal 
Task, Go/No-
go 
mph 40 46 
Within-
subjects 
High yes 100 no 
not 
suspected 
0.07 
de Bruijn et al. 
(2004) 
Flanker amp 15 12 
Within-
subjects 
Low no 58.33 no 
not 
suspected 
0.22 
de Wit et al.  
(Unpublished) 
Stop Signal 
Task 
amp 
5, 10, 
20 
207 
Within-
subjects 
Both no 52.43 no 
not 
suspected 
0.21 
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de Wit et al. (2000) 
Stop Signal 
Task 
amp 10, 20 20 
Within-
subjects 
Both no 70 no 
not 
suspected 
0.28 
deWit et al. (2002) 
Stop Signal 
Task, Go/No-
go 
amp 10, 20 36 
Within-
subjects 
Both no 50 no 
not 
suspected 
0.35 
Engert et al. (2009) WCST mph 20 43 
Between-
subjects 
 
Low yes 100 no 
not 
suspected 
0.11 
Farah et al. 
(Unpublished) 
Flanker amp 10 15 
Within-
subjects 
Low no 25 no 
not 
suspected 
0.22 
Fillmore et al. 
(2005) 
Stop Signal 
Task 
amp 7.5, 15 22 
Within-
subjects 
Low yes 45.45 no 
not 
suspected 
0.1 
Hamidovic et al. 
(2009) 
Stop Signal 
Task 
amp 
5, 10, 
20 
93 
Within-
subjects 
Both no 53.76 yes 
not 
suspected 
0.2 
Hester et al. (2012) 
Go/No-go 
(modified) 
mph 30 27 
Within-
subjects 
Low yes 100 yes 
not 
suspected 
0.18 
Ilieva et al. (2013) 
Go/No-go, 
Flanker 
amp 20 43 
Within-
subjects 
High no 50 no 
not 
suspected 
0.05 
Kelly et al. (2006) 
Stop Signal 
Task 
amp 8, 15 20 
Within-
subjects 
Low no 50 no 
not 
suspected 
0.09 
Linssen et al. (2012) 
Stop Signal 
Task 
mph 
10, 20, 
40 
19 
Within-
subjects 
Both no 100 no 
not 
suspected 
0.35 
Mattay et al. (1996) WCST amp 17.5 8 
Within-
subjects 
Low yes 50 yes 
not 
suspected 
0.08 
Moeller et al. (2012) Stroop mph 20 15 
Within-
subjects 
Low no 93.33 yes 
not 
suspected 
0.37 
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Nandam et al. 
(2011) 
Stop Signal 
Task 
mph 30 24 
Within-
subjects 
Low no 100 yes 
not 
suspected 
0.58 
Pauls et al. (2012) 
Stop Signal 
Task  
mph 40 16 
Within-
subjects 
High yes 100 yes 
not 
suspected 
0.32 
Servan-Schreiber et 
al. (1998) 
Flanker amp 17.5 8 
Within-
subjects 
Low no 50 no 
not 
suspected 
0.72 
Sofuoglu et al. 
(2008) 
Go/No-go amp 20 10 
Within-
subjects 
High no 58.33 yes possible -0.36 
Theunissen et al. 
(2009) 
Stop Signal 
Task  
mph 20 16 
Within-
subjects 
Low yes 31.25 yes 
not 
suspected 
-0.01 
Overall Effect Size           0.20 
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Table 2.3. 
Stimulant Enhancement of Working Memory: Effect Sizes and Study Characteristics  
 
Study Test Drug 
Dose 
(mg) 
N Design  Dose 
Caffeine 
Restriction 
%Male 
Other 
reason to 
publish? 
Floor or 
Ceiling? 
Hedges's g 
Agay et al. (2010) Digit Span mph 15 26 
Between-
subjects 
Low no 56.25 yes 
not 
suspected 
0.22 
Agay et al. 
(Unpublished) 
CANTAB 
Spatial WM, 
Digit Span  
mph 20 19 
Within-
subjects 
Low no 
not 
reported 
yes 
not 
suspected 
0.23 
Barch & Carter 
(2005) 
Spatial 
Working 
Memory (8s 
delay) 
amp 17.5 22 
Within-
subjects 
Low no 55 yes 
not 
suspected 
0.10 
Dorflinger 
(Unpublished) 
2-Back, 3-
Back 
mph 14, 28 20 
Within-
subjects 
Low no 
not 
reported 
yes 
not 
suspected 
0.15 
Farah et al. 
(Unpublished) 
2-Back, 
Digit Span 
amp 10 16 
Within-
subjects 
Low no 25 no 
not 
suspected 
-0.10 
Fillmore et al. 
(2005) 
Rapid Info 
Processing, 
Spatial 
Delayed 
Resp. 
amp 7.5, 15 22 
Within-
subjects 
Low yes 45.45 no 
not 
suspected 
0.25 
Ilieva et al. (2013) 
2-Back, 
Digit Span 
amp 20 43 
Within-
subjects 
High no 50 no 
not 
suspected 
0.01 
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Kelly et al. (2006) 
Rapid Info 
Processing, 
Spatial 
Delay Resp. 
amp 7.5, 15 20 
Within-
subjects 
Low no 50 no 
not 
suspected 
0.38 
Linssen et al. 
(2012) 
Spatial 
Working 
Memory 
mph 
10, 20, 
40 
19 
Within-
subjects 
Low, 
High 
yes 100 no 
not 
suspected 
0.41 
Marquand et al. 
(2011) 
Spatial 
Working 
Memory 
(unrewarde
d) 
mph 30 15 
Within-
subjects 
Low yes 100 yes 
not 
suspected 
-0.11 
Mattay et al. 
(2000) 
2-Back  amp 17.5 10 
Within-
subjects 
Low yes 80 yes 
not 
suspected 
-0.04 
Mattay et al. 
(2003) 
2-Back, 3-
Back 
amp 17.5 26 
Within-
subjects 
Low no 40.74 yes 
not 
suspected 
-0.23 
Mehta et al. 
(2000) 
CANTAB 
Spatial WM 
mph 40 10 
Within-
subjects 
High no 100 yes 
not 
suspected 
0.27 
Mintzer et al. 
(2003) 
2-Back, 
Digit Recall 
amp 20 20 
Within-
subjects 
High no 70 yes 
possible on 
one 
measure 
0.25 
Mintzer et al. 
(2007) 
2-Back, 3-
Back 
amp 20, 30 18 
Within-
subjects 
High no 61.11 yes 
not 
suspected 
0.15 
Oken et al. 
(1995) 
Digit Span  mph 14 23 
Within-
subjects 
Low yes 47.83 yes 
not 
suspected 
-0.14 
Ramasubbu et al. 
(2012) 
2-Back mph 20 13 
Within-
subjects 
Low yes 38.46 yes 
not 
suspected 
0.62 
Schmedtje et al. 
Pattern 
Memory, 
amp 5 8 
Within-
Low no 
not 
yes 
not 
0.30 
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(1988) Digit Span  subjects reported suspected 
Silber et al. 
(2006) 
Digit Span  amp 5 20 
Within-
subjects 
Low yes 50 yes 
not 
suspected 
0.18 
Studer et al. 
(2010) 
Spatial 
Working 
Memory 
mph 20 11 
Within-
subjects 
Low no 45.45 yes 
possible on 
one 
measure 
0.10 
Overall Effect 
Size 
          0.13 
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Table 2.4. 
Stimulant Enhancement of Short-Term Episodic Memory: Effect Sizes and Study Characteristics 
 
 
Study Test Drug 
Dose 
(mg) 
N Design Dose 
Caffeine 
Restrictio
n 
Retention 
Interval 
%Mal
e 
Other 
reason to 
publish? 
Floor or 
Ceiling? 
g 
Farah et al. 
(Unpublished) 
Word Recall, 
Word 
Recognition, Face 
Recognition 
amp 10 16 
Within-
subjects 
Low no 30 min 25 no 
not 
suspected 
0.07 
Fleming et al. 
(1995) 
Paired 
Associates, Rey 
Verbal Learning 
Test 
amp 20 17 
Within-
subjects 
High no immediate 52.94 no 
possible 
on one 
measure 
0.16 
Linssen et al. 
(2012) 
Word Recall, 
Word Recognition 
mph 
10, 
20, 
40 
19 
Within-
subjects 
Low, 
High 
no 
30 min, 
immediate 
100 no 
possible 
on one 
measure 
0.20 
Soetens et al. 
(1995), Study 1 
Word Recall amp 10 18 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
0.23 
Soetens et al. 
(1995), Study 2 
Word Recall amp 10 14 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
0.39 
Soetens et al. 
(1995), Study 4 
Word Recognition amp 10 12 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
0.29 
Soetens et al. 
(1995), Study 5 
Word Recognition amp 10 12 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
0.31 
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Unrug et al. 
(1997) 
Word Recall mph 20 12 
Within-
subjects 
Low yes 20 min 50 yes 
possible 
on one 
measure 
0.32 
Willet (1962) 
Learning of Non-
word Lists 
amp 10 37 
Between-
subjects 
Low no immediate 0 no 
not 
suspected 
0.22 
Zeeuws et al. 
(2010b), Exp. 1 
Word Recognition amp 10 24 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
-0.17 
Zeeuws et al. 
(2010b), Exp. 2 
Word Recognition amp 10 16 
Within-
subjects 
Low no immediate 100 no 
not 
suspected 
-0.13 
Zeeuws & 
Soetens (2007) 
Word Recognition amp 10 36 
Within-
subjects 
Low no 
30 min, 
immediate 
100 no 
not 
suspected 
0.45 
Overall Effect 
Size 
           0.20 
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Table 2.5. 
Stimulant Enhancement of Long-Term Episodic Memory: Effect Sizes and Study Characteristics 
 
 
 
Study Test Drug 
Dose 
(mg) 
N Design Dose 
Caffeine 
Restrictio
n 
Retention 
Interval 
%Male 
Other 
reason 
to 
publish? 
Floor or 
Ceiling? 
g 
Brignell et 
al. (2007) 
Recognition 
Memory for 
Narratives 
mph 40 36 
Between-
subjects 
High no 
1 hour, 1 
day 
not 
reported 
yes 
not 
suspected 
0.52 
Ilieva et al. 
(2013) 
Word Recall, 
Word 
Recognition, 
Face 
Recognition 
amp 20 18 
Within-
subjects 
High no 2 hours 50 no 
not 
suspected 
0.01 
Mintzer et 
al. (2003) 
Word Recall 
and 
Recognition 
amp 20 16 
Within-
subjects 
High no 2 hours 70 yes 
not 
suspected 
0.24 
Mintzer et 
al. (2007) 
Word Recall 
and 
Recognition 
amp 20, 30 20 
Within-
subjects 
High no 2 hours 61.11 yes 
not 
suspected 
0.33 
Soetens et 
al. (1995), 
Exp.1 
Word Recall amp 10 44 
Within-
subjects 
Low no 1 day 100 no 
not 
suspected 
0.71 
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Soetens et 
al. (1995), 
Exp.2 
Word Recall amp 10 18 
Within-
subjects 
Low no 
1 hour, 1 
day 
100 no 
not 
suspected 
0.58 
Soetens et 
al. (1995), 
Exp.4 
Word Recall amp 10 14 
Within-
subjects 
Low no 
1 day, 2 
days, 3 
days 
100 no 
not 
suspected 
0.58 
Soetens et 
al. (1995), 
Exp.5 
Word 
Recognition 
amp 10 12 
Within-
subjects 
Low no 
1 day, 1 
week 
100 no 
not 
suspected 
0.74 
Zeeuws et 
al. (2010b), 
Exp.1 
Word 
Recognition 
amp 10 12 
Within-
subjects 
Low no 
1 hour, 1 
day, 1 
week 
100 no 
not 
suspected 
0.69 
Zeeuws et 
al. (2010), 
Exp.2 
Word 
Recognition 
amp 10 24 
Within-
subjects 
Low no 
1 hour, 1 
day, 1 
week 
100 no 
not 
suspected 
0.18 
Zeeuws & 
Soetens 
(2007) 
Word 
Recognition 
amp 10 16 
Within-
subjects 
Low no 
1 hour, 1 
day 
100 no 
not 
suspected 
0.80 
Overall 
Effect Size 
           0.45 
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FIGURE CAPTIONS 
 
Figure 1.1. Embedded Figures Task: An example stimulus. 
 
Figure 1.2. Experimental procedure. Each box corresponds to an individual 
testing session, with the time intervals between sessions indicated. Baseline testing 
(Sessions 2-3) always preceded drug/placebo testing (Sessions 4-7) to minimize the 
influence of practice effects on data from the placebo and Adderall conditions. Each 
individual participant’s four on-pill sessions were scheduled at the same time of the day.  
 
Figure 1.3. Mean performance of participants whose overall baseline 
performance was below and above the median on Word Recall, Embedded Figures and 
Raven’s Progressive Matrices. Conventional error bars are not shown because the 
comparisons are within subjects.  
 
Figure 1.4. Mean performance of participants homozygous for the val and met 
allele of the COMT gene on SAT Math and SAT Verbal. Conventional error bars are not 
shown because the comparisons are within subjects.  
 
Figure 2.1. Process of determining study eligibility 
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Figure 2.2. Funnel plot of research on stimulant effects on inhibitory control. Data 
points imputed by trim and fill appear in black. 
 
Figure 2.3. Funnel plot of research on stimulant effects on working memory. Data 
points imputed by trim and fill appear in black. 
 
Figure 2.4. Funnel plot of research on stimulant effects on short-term episodic 
memory. Data points imputed by trim and fill appear in black. 
 
Figure 2.5. Funnel plot of research on stimulant effects on long-term episodic 
memory. Data points imputed by trim and fill appear in black. 
 
Figure 3.1. Discrepancy between subjectively reported and objectively measured 
attention in users of unprescribed stimulants and controls, based on data on: a) overall 
attention tests; b) inattention subtests; c) impulsivity subtests.  
  
  
 
 
 
 
110
 
FIGURES 
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Figure 1.3. 
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Figure 1.4. 
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Figure 2.1.  
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Figure 2.2. 
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Figure 2.3.  
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Figure 2.4. 
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Figure 2.5. 
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Figure 3.1. (a) 
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Figure 3.1. (b) 
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Figure 3.1. (c) 
 
 
 
 
 
 
 
  
  
 
 
 
 
122
BIBLIOGRAPHY 
 
Acheson, A., & de Wit, H. (2008). Bupropion improves attention but does not 
affect impulsive behavior in healthy young adults. Experimental and Clinical 
Psychopharmacology, 16(2), 113–123.  
Advokat, C. (2010). What are the cognitive effects of stimulant medications? 
Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience & 
Biobehavioral Reviews, 34(8), 1256–1266.  
Agay, N. (2012). [Cognitive Effects of Stimulants.] Unpublished raw data. 
Agay, N., Yechiam, E., Carmel, Z., & Levkovitz, Y. (2010). Non-specific effects of 
methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy 
adults. Psychopharmacology, 210(4), 511–519.  
Allman, A.-A., Benkelfat, C., Durand, F., Sibon, I., Dagher, A., Leyton, M., … 
O’Driscoll, G. A. (2010). Effect of d-amphetamine on inhibition and motor planning as a 
function of baseline performance. Psychopharmacology, 211(4), 423–433.  
Angrist, B., Corwin, J., Bartlik, B., Cooper, T. (1987). Early pharmacokinetics and 
clinical effects of oral D-amphetamine in normal subjects. Biol psychiatry, 22(11), 1357-
68.  
Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. 
(2003). Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in 
humans. Nature Neuroscience, 6(2), 115–116.  
Aron, A. R., Robbins, T. W., & Poldrack, R. A. (2004). Inhibition and the right 
inferior frontal cortex. Trends in Cognitive Sciences, 8(4), 170–177.  
  
 
 
 
 
123
Arria, A. M., Garnier-dykstra, L. M., Caldeira, K. M., Vincent, K. B., Grady, K. E. 
O., & Wish, E. D. (2011). Non-medical use of Prescription Stimulants Among College 
Students : Possible Association With ADHD Symptoms. doi:10.1177/1087054710367621 
Bados, A., Gómez-Benito, J., & Balaguer, G. (2010). The state-trait anxiety 
inventory, trait version: does it really measure anxiety? Journal of personality 
assessment, 92(6), 560–7. doi:10.1080/00223891.2010.513295 
Ballard, M. E., Gallo, D. a, & de Wit, H. (2014). Amphetamine increases errors 
during episodic memory retrieval. Journal of clinical psychopharmacology, 34(1), 85–92. 
doi:10.1097/JCP.0000000000000039 
Balsamo, M., Romanelli, R., Innamorati, M., Ciccarese, G., Carlucci, L., & 
Saggino, A. (2013). The State-Trait Anxiety Inventory: Shadows and Lights on its 
Construct Validity. Journal of Psychopathology and Behavioral Assessment, 35(4), 475–
486. doi:10.1007/s10862-013-9354-5 
Baranski, J. V.,  Pigeau, R. A. (1997). Self-monitoring cognitive performance 
during sleep deprivation: effects of modafinil, d-amphetamine and placebo.  J Sleep Res, 
6, 84-91.  
Baranski, Joseph V, Pigeau, R., Dinich, P., Jacobs, I. (2004). Effects of modafinil 
on cognitive and meta-cognitive performance. Human Psychopharm, 19, 323-32. 
Barch, D. M., & Carter, C. S. (2005). Amphetamine improves cognitive function in 
medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia 
Research, 77(1), 43–58.  
  
 
 
 
 
124
Bavarian, N., Flay, B. R., Ketcham, P. L., and Smit, E. (2013). Illicit use of 
prescription stimulants in a college student sample: a theory-guided analysis. Drug 
Alcohol Depend. 132, 665–673. doi: 10.1016/j.drugalcdep.2013. 04.024 
Biggs, J. (1987). Study Process Questionnaire Manual: Student Approaches to 
Learning and Studying. Hawthorn, Australia: Australian Council for Education Research.  
Bjork, R. a, Dunlosky, J., & Kornell, N. (2013). Self-regulated learning: beliefs, 
techniques, and illusions. Annual review of psychology, 64, 417–44. 
doi:10.1146/annurev-psych-113011-143823 
Braver, T. S., Barch, D. M., Gray, J. R., Molfese, D. L., & Snyder, A. (2001). 
Anterior cingulate cortex and response conflict: effects of frequency, inhibition and 
errors. Cereb cortex, 11, 825-36.  
Brignell, C. M., Rosenthal, J., & Curran, H. V. (2007). Pharmacological 
manipulations of arousal and memory for emotional material: effects of a single dose of 
methylphenidate or lorazepam. Journal of Psychopharmacology, 21(7), 673–683.  
Bruijn, E. R. A. de, Hulstijn, W., Verkes, R. J., Ruigt, G. S. F., & Sabbe, B. G. C. 
(2004). Drug-induced stimulation and suppression of action monitoring in healthy 
volunteers. Psychopharmacology, 177(1-2), 151–160.  
Burns, J. T., House, R. F., Fensch, F. C., & Miller, J. G. (1967). Effects of 
Magnesium Pemoline and Dextroamphetamine on Human Learning. Science, 
155(3764), 849–851.  
Butcher, S. P., Fairbrother, I. S., Kelly, J. S., and Arbuthnott, G. W. (1988). 
  
 
 
 
 
125
Amphetamine- induced dopamine release in the rat striatum. J. Neurochem. 50, 346–
355. doi: 10.1111/j.1471-4159. 1988.tb02919.x 
Castaldi, S., Gelatti, U., Orizio, G., Hartung, U., Moreno-londono, A. M., Nobile, 
M., et al. (2012). Use of cognitive enhancement medication among Northern Italian 
university students. J Addict. Med. 6, 112–117. doi: 10.1097/ADM.0b013e3182479584 
Chamberlain, S. R., Robbins, T. W., Winder-Rhodes, S., Muller, U., Sahakian, B. 
J., Blackwell, A. D., Barnett, J. H.  (2010). Translational approaches to frontostriatal 
dysfunction in attention-deficit/hyperactivity disorder using a computerized 
neuropsychological battery. Biol Psychiatry, 69, 1192–1203.  
Chatterjee, A. (2009). Is it acceptable for people to take methylphenidate to 
enhance performance ? No Is it acceptable for people to take methylphenidate to 
enhance performance ?, (June), 6–8. doi:10.1136/bmj.b1956 
Christopoulos, J. P., Rohwer, W. D., & Thomas, J. W. (1987). Grade level 
differences in students’ study activities as a function of course characteristics. 
Contemporary Educational Psychology, 12(4), 303–323. doi:10.1016/S0361-
476X(87)80003-6 
Cooper, H. (2010). Research Synthesis and Meta-analysis. Thousand Oaks, CA: 
SAGE Publications, Inc.  
Costa, A., Riedel, M., Pogarell, O., Menzel-Zelnitschek, F., Schwarz, M., Reiser, 
M., … Ettinger, U. (2013). Methylphenidate Effects on Neural Activity During Response 
Inhibition in Healthy Humans. Cerebral Cortex, 23(5), 1179–1189.  
  
 
 
 
 
126
Credé, M., & Phillips, L. A. (2011). A meta-analytic review of the Motivated 
Strategies for Learning Questionnaire. Learning and Individual Differences, 21(4), 337–
346. doi:10.1016/j.lindif.2011.03.002 
Davis, D. R., (1947). Psychomotor effects of analeptics and their relation to 
fatigue phenomena in aircrew. Brit. Med. Bull., 5, 43-45. 
De Wit, H. (2012). [Stimulants’ Effects on Stop Signal Task Performance.] 
Unpublished raw data. 
De Wit, H., Crean, J., & Richards, J. B. (2000). Effects of d-Amphetamine and 
ethanol on a measure of behavioral inhibition in humans. Behavioral Neuroscience, 
114(4), 830–837.  
De Wit, H., Enggasser, J. L., & Richards, J. B. (2002). Acute Administration of d-
Amphetamine Decreases Impulsivity in Healthy Volunteers. Neuropsychopharmacology, 
27(5), 813–825.  
DeSantis, A. D., & Hane, A. C. (2010). “Adderall is definitely not a drug”: 
justifications for the illegal use of ADHD stimulants. Substance use & misuse, 45(1-2), 
31–46. doi:10.3109/10826080902858334 
DeSantis, A. D., Webb, E. M., and Noar, S. M. (2008). Illicit use of prescription 
ADHD medications on a college campus: a multi- methodological approach. J. Am. 
College Health 57, 315–324. doi: 10.3200/JACH.57.3.315-324 
Desantis, A., Noar, S. M., Webb, E. M. (2009). Nonmedical ADHD stimulant use 
in fraternities. J of studies on alcohol and drugs, 70(6), 952-4.  
  
 
 
 
 
127
Dorflinger, J. (2005). Methylphenidate and working memory: An investigation 
using fMRI (unpublished dissertation).  Rosalind Franklin University of Medicine and 
Science, Chicago, IL.  
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. 
A., et al. (2001). Amphetamine-induced dopamine release in human ventral stria- tum 
correlates with euphoria. Biol. Psychiatry 49, 81–96. doi: 10.1016/S0006-
3223(00)01038-6 
Dunlap, W. P., Cortina, J. M., Vaslow, J. B., & Burke, M. J. (1996). Meta-analysis 
of experiments with matched groups or repeated measures designs. Psychological 
Methods, 1(2), 170–177.  
Dunlosky, J., Rawson, K. a., Marsh, E. J., Nathan, M. J., & Willingham, D. T. 
(2013). Improving Students’ Learning With Effective Learning Techniques: Promising 
Directions From Cognitive and Educational Psychology. Psychological Science in the 
Public Interest, 14(1), 4–58. doi:10.1177/1529100612453266 
Dussault, C. L., & Weyandt, L. L. (2013). An examination of prescription stimulant 
misuse and psychological variables among sorority and fraternity college populations. 
Journal of attention disorders, 17(2), 87–97. doi:10.1177/1087054711428740 
Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J., Robbins, T. 
W., (1997). Effects of methylphenidate on spatial working memory and planning in 
healthy young adults. Psychopharmacology, 131, 196-206.  
Emanuel, R. M., Frellsen, S. L., Kashima, K. J., Sanguino, S. M., Sierles, F. S., & 
Lazarus, C. J. (n.d.). Cognitive Enhancement Drug Use Among Future Physicians : 
  
 
 
 
 
128
Findings from a Multi-Institutional Census of Medical Students, 9, 1028–1034. 
doi:10.1007/s11606-012-2249-4 
Engert, V., Joober, R., Meaney, M. J., Hellhammer, D. H., & Pruessner, J. C. 
(2009). Behavioral response to methylphenidate challenge: Influence of early life 
parental care. Developmental Psychobiology, 51(5), 408–416.  
Epstein, J. N., Goldberg, N. a., Conners, C. K., & March, J. S. (1997). The effects 
of anxiety on continuous performance test functioning in an ADHD clinic sample. Journal 
of Attention Disorders, 2(1), 45–52. doi:10.1177/108705479700200106 
Eriksen, B. A., & Eriksen, C. W. (1974). Effects of noise letters upon the 
identification of a target letter in a nonsearch task. Perception & Psychophysics, 16(1), 
143–149.  
Everling, S., & Fischer, B. (1998). The antisaccade: a review of basic research 
and clinical studies. Neuropsychologia, 36(9), 885–899.  
Farah, M. J. (2012). [Stimulants’ Cognitive Enhancement Effects in Healthy 
People.] Unpublished raw data. 
Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., 
Parens, E., et al. (2004). Neurocognitive enhancement: what can we do and what should 
we do? Nature reviews. Neuroscience, 5(5), 421–5. doi:10.1038/nrn1390 
Farah, M.J., Haimm, C., Sankoorikal, G., Smith, M.E., Chatterjee, A. (2008). 
When we enhance cognition with Adderall do we sacrifice creativity? A preliminary 
study.  Psychopharmacology, 202, 541-547. 
  
 
 
 
 
129
Fillmore, M. T., Kelly, T. H., & Martin, C. A. (2005). Effects of d-amphetamine in 
human models of information processing and inhibitory control. Drug and Alcohol 
Dependence, 77(2), 151–159.  
Fleming, K., Bigelow, L. B., Weinberger, D. R., & Goldberg, T. E. (1995). 
Neuropsychological effects of amphetamine may correlate with personality 
characteristics. Psychopharmacology Bulletin, 31(2), 357–362. 
Forbes, G. B. (1998). Clinical utility of the test of variables of attention (TOVA) in 
the diagnosis of attention- deficit/hyperactivity disorder. Journal of clinical psychology, 
54(4), 461-476. 
Franke, A. G. (2011). Non-medical use of prescription stimulants and illicit use of 
stimulants for cognitive enhancement in pupils and students in Germany. 
Pharmacopsychiatry 44, 60–66. doi: 10.1055/s-0030-1268417 
Franke, A. G., Bagusat, C., Dietz, P., Hoffmann, I., Simon, P., Ulrich, R., & Lieb, 
K. (2013). Use of illicit and prescription drugs for cognitive or mood enhancement among 
surgeons. BMC medicine, 11, 102. doi:10.1186/1741-7015-11-102 
Gredler, M.E. & Garavalia, L.S. (2000). Students’ perceptions of their self-
regulatory and other-directed study strategies: A factor analysis. Psychological Reports, 
86, 102–108. 
Greely, H. T. (2013). Some First Steps Toward Responsible Use of Cognitive-
Enhancing Drugs by the Healthy. The American Journal of Bioethics, 13(7), 39–41.  
Greenberg, L. M., & Waldman, I. D. (1993). Developmental normative data on 
the Test of Variables of Attention (T. O. V. A.). Journal of Child Psychology and 
  
 
 
 
 
130
Psychiatry, 34, 1019 –1030. doi:10.1111/j.1469- 7610.1993.tb01105.x 
Greenberg, L. M., Kindschi, C. L., Dupuy, T. R., & Hughes, S. J. (2007). TOVA 
clinical manual. Los Alamitos, CA: TOVA Company. 
Hall, W. D., & Lucke, J. C. (2010). The enhancement use of 
neuropharmaceuticals: more scepticism and caution needed. Addiction, 105(12), 2041–
2043.  
Hamidovic, A., Dlugos, A., Skol, A., Palmer, A. A., & de Wit, H. (2009). 
Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral 
inhibition and impulsivity/sensation seeking: An exploratory study with d-amphetamine in 
healthy participants. Experimental and Clinical Psychopharmacology, 17(6), 374–383.  
Heaton, R. K., Chelune, G. J., Talley, J. L., Kay, G. G., & Curtis, G. 
(1993). Wisconsin Card Sorting Test (WCST) Manual (Revised and Expanded). Odessa: 
Psychological Assessment Resources Inc. 
Helmers, K. F., Young, S. N., & Pihl, R. O. (1995). Assessment of measures of 
impulsivity in healthy male volunteers. Personality and Individual Differences, 19(6), 
927–935.  
Henson, R. N. A., Rugg, M. D., Shallice, T., & Dolan, R. J. (2000). Confidence in 
Recognition Memory for Words: Dissociating Right Prefrontal Roles in Episodic 
Retrieval. Journal of Cognitive Neuroscience, 12(6), 913–923.  
Hester, R., Nandam, L. S., O’Connell, R. G., Wagner, J., Strudwick, M., Nathan, 
P. J., … Bellgrove, M. A. (2012). Neurochemical Enhancement of Conscious Error 
Awareness. The Journal of Neuroscience, 32(8), 2619–2627.  
  
 
 
 
 
131
Hildt, E., Lieb, K., & Franke, A. G. (2014). Life context of pharmacological 
academic performance enhancement among university students--a qualitative approach. 
BMC medical ethics, 15, 23. doi:10.1186/1472-6939-15-23 
Huffcutt, A. I., & Arthur, W. (1995). Development of a new outlier statistic for 
meta-analytic data. Journal of Applied Psychology, 80(2), 327–334.  
Hunt, M. G., Momjian, A. J., & Wong, K. K. (2011). Effects of diurnal variation 
and caffeine consumption on Test of Variables of Attention (TOVA) performance in 
healthy young adults. Psychological assessment, 23(1), 226–33. doi:10.1037/a0021401 
Hurst, P.M., Weidner, M., Radlow, R., (1967). The effects of amphetamines upon 
judgments and decisions. Psychopharmacology. 11, 397-404. 
Ilieva, I. & Farah, M.J. (2013). Enhancement stimulants: Perceived motivational 
and cognitive advantages. Frontiers in Neuroscience – Neuropharmacology, 7 (1). 
 
Ilieva, I., Boland, J., & Farah, M. J. (2013). Objective and subjective cognitive 
enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology, 
64, 496–505.  
 Ioannidis J. P. (2005). Why most published research findings are false. PLoS 
Med 2 (8). 
Ioannidis J. P. (2011). Excess significance bias in the literature on brain volume 
abnormalities. Arch Gen Psychiatry. 68(8), 773-80.  
  
 
 
 
 
132
Jaeggi, S. M., Buschkuehl, M., Perrig, W. J., & Meier, B. (2010). The concurrent 
validity of the N-back task as a working memory measure. Memory, 18(4), 394–412.  
Johnson, L. G., Ph, D., & Benedict, K. B. (2006). Neurocognition in Depression : 
Patients on and, 217–225. 
Kane, M. J., A, R., Miura, T. K., & H, J. (2007). Working memory, attention 
control, and the n-back task: A question of construct validity. Journal of Experimental 
Psychology: Learning, Memory, and Cognition, 33(3), 615–622.  
Kelly, T. H., Robbins, G., Martin, C. A., Fillmore, M. T., Lane, S. D., Harrington, 
N. G., & Rush, C. R. (2006). Individual differences in drug abuse vulnerability: d-
Amphetamine and sensation-seeking status. Psychopharmacology, 189(1), 17–25.  
Lappin, J. S., & Eriksen, C. W. (1966). Use of a delayed signal to stop a visual 
reaction-time response. Journal of Experimental Psychology, 72(6), 805–811.  
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006). Evidence 
based medicine: The case of the misleading funnel plot. BMJ: British Medical Journal, 
333(7568), 597–600. 
Lehrer, J. (2010). The Truth Wears Off: Is there something wrong with the 
scientific method? The New Yorker, Retrieved from: 
http://www.newyorker.com/reporting/2010/12/13/101213fa_fact_lehrer#ixzz1zsJhcmej 
Linssen, A. M. W., Vuurman, E. F. P. M., Sambeth, A., & Riedel, W. J. (2012). 
Methylphenidate produces selective enhancement of episodic memory consolidation in 
healthy volunteers. Psychopharmacology, 221(4), 611–619.  
  
 
 
 
 
133
Lipsey, M. W., & Wilson, D. B. (2001). Practical Meta-Analysis. Thousand Oaks, 
CA: Sage.  
Logan, G. D., Schachar, R. J., & Tannock, R. (1997). Impulsivity and Inhibitory 
Control. Psychological Science, 8(1), 60–64.  
Low, K. G., & Gendaszek, A. E. (2002). Illicit use of psychostimulants among 
college students: A preliminary study. Psychology, Health & Medicine, 7, 283–287. 
doi:10.1080/13548500220139386 
Madrigal, A. (2008). 20 percent of scientists admit using brainenhancing drugs—
do you? Wired. Retrieved from http://www.wired.com/wiredscience/2008/04/20-of-
scientist/ 
Maher, B., (2008). Poll results: look who's doping. Nature 452, 674–675. 
Marquand, A. F., De Simoni, S., O’Daly, O. G., Williams, S. C., Mourão-Miranda, 
J., & Mehta, M. A. (2011). Pattern Classification of Working Memory Networks Reveals 
Differential Effects of Methylphenidate, Atomoxetine, and Placebo in Healthy Volunteers. 
Neuropsychopharmacology, 36(6), 1237–1247.  
Mattay, V. S., Berman, K. F., Ostrem, J. L., Esposito, G., Horn, J. D. V., Bigelow, 
L. B., & Weinberger, D. R. (1996). Dextroamphetamine Enhances “Neural Network-
Specific” Physiological Signals: A Positron-Emission Tomography rCBF Study. The 
Journal of Neuroscience, 16(15), 4816–4822. 
Mattay, V. S., Callicott, J. H., Bertolino, A., Heaton, I., Frank, J. A., Coppola, R., 
(2000). Effects of dextroamphetamine on cognitive performance and cortical activation. 
NeuroImage, 12, 268-275.  
  
 
 
 
 
134
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., 
Kolachana, B.,, Callicott, J.H., Weinberger, D.R., (2003). Catechol O-methyltransferase 
val158-met genotype and individual variation in the brain response to 
amphetamine. PNAS, 100, 6186-6191. 
McCabe, S. E., Knight, J. R., Teter, C. J., Wechsler, H. (2005). Non-medical use 
of prescription stimulants among US college students: Prevalence and correlates from a 
national survey. Addiction, 100, 96-106.  
McCabe, S. E., Teter, C. J., & Boyd, C. J. (2006). Medical use, illicit use, and 
diversion of prescription stimulant medication. Journal of Psychoactive Drugs, 38, 43–
56.  
McCabe, S. E. (2008). Misperceptions of non-medical prescription drug use: a 
web survey of college students. Addictive behaviors, 33(5), 713–24. 
doi:10.1016/j.addbeh.2007.12.008 
McCabe, S. E., & West, B. T. (2013). Medical and nonmedical use of prescription 
stimulants: results from a national multicohort study. Journal of the American Academy 
of Child and Adolescent Psychiatry, 52(12), 1272–80. doi:10.1016/j.jaac.2013.09.005 
Mednick, S., (1962). The associative basis of the creative process. Psychol Rev, 
69 (3).  
Mehta, M. A., Owen, a M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., 
Robbins, T. W., (2000). Methylphenidate enhances working memory by modulating 
discrete frontal and parietal lobe regions in the human brain. J Neurosci, 20(6). 
  
 
 
 
 
135
Meyer, J.S., Quenzer, L.F. (2005). Psychopharmacology: Drugs, the Brain, and 
Behavior. Sunderland,MA: Sinauer Associates, Inc. 
Mintzer, M. Z., & Griffiths, R. R. (2003). Triazolam-amphetamine interaction: 
dissociation of effects on memory versus arousal. Journal of Psychopharmacology, 
17(1), 17–29.  
Mintzer, M. Z., & Griffiths, R. R. (2007). A triazolam/amphetamine dose–effect 
interaction study: dissociation of effects on memory versus arousal. 
Psychopharmacology, 192(3), 425–440.  
Moeller, S. J., Honorio, J., Tomasi, D., Parvaz, M. A., Woicik, P. A., Volkow, N. 
D., & Goldstein, R. Z. (2012). Methylphenidate Enhances Executive Function and 
Optimizes Prefrontal Function in Both Health and Cocaine Addiction. Cerebral Cortex, 
34 (5).  
Murphy, K. R., & Adler, L. A. (2004). Assessing attention-deficit/ hyperactivity 
disorder in adults: Focus on rating scales. Journal of Clinical Psychiatry, 65(Suppl3), 8–
11. 
Nandam, L. S., Hester, R., Wagner, J., Cummins, T. D. R., Garner, K., Dean, A. 
J., … Bellgrove, M. A. (2011). Methylphenidate But Not Atomoxetine or Citalopram 
Modulates Inhibitory Control and Response Time Variability. Biological Psychiatry, 69(9), 
902–904.  
Noppe, L.D., Gallagher, J.M. (1977). A cognitive style approach to crative 
thought. J Pers Assessment, 41 (1). 
Novak, S. P., Kroutil, L. A., Williams, R. L., & Van Brunt, D. L. (2007). The 
  
 
 
 
 
136
nonmedical use of prescription ADHD medications: Results from a national Internet 
panel. Substance Abuse Treatment, Prevention, and Policy, 2:32. doi:10.1186/1747-
597X-2-32 
O’Donnell, J. P., McCann, K. K., & Pluth, S. (2001). Assessing adult ADHD using 
a self-report symptom checklist. Psychological Reports, 88, 871–881. 
doi:10.2466/PR0.88.3.871-881 
Oberauer, K. (2005). Binding and inhibition in working memory: individual and 
age differences in short-term recognition, J Exp Psychology. General, 134, 368–387. 
Oken, B. S., Kishiyama, S. S., & Salinsky, M. C. (1995). Pharmacologically 
induced changes in arousal: effects on behavioral and electrophysiologic measures of 
alertness and attention. Electroencephalography and Clinical Neurophysiology, 95(5), 
359–371.  
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. 
(1990). Planning and spatial working memory following frontal lobe lesions in man. 
Neuropsychologia, 28(10), 1021–1034.  
Partridge, B., Bell, S., Lucke, J., and Hall, W. (2013). Australian university 
students' attitudes towards the use of prescription stimulants as cognitive enhancers: 
perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 32, 295–302. doi: 
10.1111/dar.12005 
Pauls, A. M., O’Daly, O. G., Rubia, K., Riedel, W. J., Williams, S. C. R., & Mehta, 
M. A. (2012). Methylphenidate Effects on Prefrontal Functioning During Attentional-
Capture and Response Inhibition. Biological Psychiatry, 72(2), 142–149.  
  
 
 
 
 
137
Paulson, P.E., Robinson, T.E. (1995). Amphetamine-Induced Time-Dependent 
Sensitization of Dopamine Neurotransmission in the Dorsal and Ventral Striatum: A 
Microdialysis Study in Behaving Rats. Synapse, 19,  56–65. 
Peterkin, A. L., Crone, C. C., Sheridan, M. J., Wise, T. N., Peterkin, A. L., Crone, 
C. C., Sheridan, M. J., et al. (2011). Cognitive Performance Enhancement : Misuse or 
Self-Treatment ? doi:10.1177/1087054710365980 
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2007). 
Performance of the trim and fill method in the presence of publication bias and between-
study heterogeneity. Statistics in Medicine, 26, 4544-4562.  
Peters, J. L., Sutton, A. J., Jones, D. R., & Abrams, K. R., Rushton, L., & Moreno, 
S. G. (2010). Assessing publication bias in meta-analyses in the presence of between-
study heterogeneity. Journal of the Royal Statistical Society A, 173(3), 575-591.  
Pintrich, P., R., Smith, S.,  Garcia, T. & McKeachie, W. (1991). A Manual for the 
Use of the Motivated Strategies for Learning Questionnaire (MSLQ). Washington, DC – 
Office of Educational Research and Improvement.  
Postle, B. R., Desposito, M., Corkin, S., (2005). Effects of verbal and nonverbal 
interference on spatial and object visual working memory. Memory & cognition, 33, 203-
12.  
Postle, B. R., Jonides, J., Smith, E. E., Corkin, S., & Growdon, J. H. (1997). 
Spatial, but not object, delayed response is impaired in early Parkinson’s disease. 
Neuropsychology, 11(2), 171–179.  
  
 
 
 
 
138
Poulin, C. (2001). Medical and nonmedical stimulant use among adoles- cents: 
From sanctioned to unsanctioned use. CMAJ: Canadian Medical Association 
Journal/Journal de l’Association Medicale Canadienne, 165, 1039–1044. 
Poulin, C. (2007). From attention-deficit/hyperactivity disorder to medical 
stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: 
connecting the dots. Addiction, 102(5), 740–751.  
Rabiner, D. L., Anastopoulos, A. D., Costello, E. J., Hoyle, R. H., McCabe, S. E., 
& Swartzwelder, H. S. (2009). Motives and perceived consequences of nonmedical 
ADHD medication use by college students: are students treating themselves for attention 
problems? Journal of attention disorders, 13(3), 259–70. 
doi:10.1177/1087054708320399 
Rabiner, D. L., Anastopoulos, A. D., Costello, E. J., Hoyle, R. H., Swartzwelder, 
H. S., Costello, E. J., Hoyle, R. H., et al. (2010). Predictors of Nonmedical ADHD 
Medication Use by College Students. doi:10.1177/1087054709334505 
Ramasubbu, R., Singh, H., Zhu, H., & Dunn, J. F. (2012). Methylphenidate-
mediated reduction in prefrontal hemodynamic responses to working memory task: a 
functional near-infrared spectroscopy study. Human Psychopharmacology: Clinical and 
Experimental, 27(6), 615–621.  
Rasmussen, N. (2008). On Speed: The Many Lives of Amphetamine. New York, 
NY: New York University Press. 
Raven, J. C., (1976). Standard progressive matrices: Sets A, B, C, D & E. 
Oxford: Oxford Psychologists Press. 
  
 
 
 
 
139
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010). Modafinil and 
methylphenidate for neuroenhancement in healthy individuals: A systematic review. 
Pharmacological Research, 62(3), 187–206.  
Roache, R. (2009). Enhancement and Cheating. Expositions, 2(2), 153–156. 
doi:10.1558/expo.v2i2.153 
Robbins, T. W., Arnsten, A. F. (2009). The neuropsychopharmacology of fronto-
executive function: Monoaminergic modulation. Annu Rev Neurosci, 32, 267–287.  
Roediger, H. L., & Pyc, M. A. (2012). Journal of Applied Research in Memory and 
Cognition Inexpensive techniques to improve education : Applying cognitive psychology 
to enhance educational practice. Journal of Applied Research in Memory and Cognition, 
1(4), 242–248. doi:10.1016/j.jarmac.2012.09.002 
Rosenthal, R., & Rubin, D. B. (2003). R-equivalent: A Simple Effect Size 
Indicator. Psychological Methods, 8(4), 492–496.  
Rothstein, H. R., Sutton, A. J., & Borenstein, M. (2006). Publication Bias in Meta-
Analysis: Prevention, Assessment and Adjustments. John Wiley & Sons. 
Sahakian, B. J., & Morein-Zamir, S. (2011). Neuroethical issues in cognitive 
enhancement. Journal of Psychopharmacology, 25(2), 197–204.  
Sahakian, B., and Morein-Zamir, S. (2007). Professor's little helper. Nature 450, 
1157–1159. doi: 10.1038/4501157a 
Schatz, A. M. (2001). Sensitivity and specificity of a computerized test of 
attention in the diagnosis of Attention-Deficit/Hyperactivity Disorder. Assessment, 8(4), 
357 -365 
  
 
 
 
 
140
Schenk, S., Pattridge, B. (1997). Sensitization and tolerance in psychostimulant 
self-administration. Pharmacology, Biochemistry and Behavior. 57, 543-550. 
Schmeck, R. R. , Geisler-Brenstein, E. & Cercy, S.P. (1991). Self-concept and 
Learning: The revised Inventory of Learning Processes. Educational Psychology, 11 (3-
4), 343-362 
Schmedtje, J. F., Jr, Oman, C. M., Letz, R., & Baker, E. L. (1988). Effects of 
scopolamine and dextroamphetamine on human performance. Aviation, Space, and 
Environmental Medicine, 59(5), 407–410. 
Servan-Schreiber, D., Carter, C. S., Bruno, R. M., & Cohen, J. D. (1998). 
Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human 
subjects performing a selective attention task. Biological Psychiatry, 43(10), 723–729.  
Silber, B. Y., Croft, R. J., Papafotiou, K., & Stough, C. (2006). The acute effects 
of d-amphetamine and methamphetamine on attention and psychomotor performance. 
Psychopharmacology, 187(2), 154–169.  
Simmons, J.P., Nelson, L.D. & Simonsohn, U. (2011). False-positive psychology. 
Psychological Science, 22 (11).  
Sitzmann, T., Ely, K., & Group, F. M. (2011). A Meta-Analysis of Self-Regulated 
Learning in Work-Related Training and Educational Attainment : What We Know and 
Where We Need to Go, 137(3), 421–442. doi:10.1037/a0022777 
Smith, G. M.; Beecher, Henry K. (1964). Drugs and judgment: Effect of 
amphetamine and secobarbital on self-evaluation. J Psychology: Interdisciplinary and 
Applied, 58, 397-405. 
  
 
 
 
 
141
Smith, M. E., Farah, M. J. (2011). Are prescription stimulants “smart pills”? The 
epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy 
individuals. Psychological Bulletin, 137, 717–741.  
Sockol, L. E., Epperson, C. N., & Barber, J. P. (2011). A meta-analysis of 
treatments for perinatal depression. Clinical Psychology Review, 31(5), 839–849.  
Soetens, E., Hueting, J. E., Casaer, S., & D’Hooge, R. (1995). Effect of 
amphetamine on long-term retention of verbal material. Psychopharmacology, 119(2), 
155–162.  
Sofuoglu, M., Waters, A. J., Mooney, M., & Kosten, T. (2008). Riluzole and d-
amphetamine interactions in humans. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry, 32(1), 16–22.  
Son, L. K., & Kornell, N. (2009). Simultaneous decisions at study: time allocation, 
ordering, and spacing. Metacognition and Learning, 4(3), 237–248. doi:10.1007/s11409-
009-9049-1 
Steer, R. A, Ball, R., Ranieri, W. F., & Beck, A. T. (1999). Dimensions of the Beck 
Depression Inventory-II in clinically depressed outpatients. Journal of clinical 
psychology, 55(1), 117–28.  
Sternberg, S. (1966). High-speed scanning in human memory. Science, 
153(3736), 652–654.  
Storch, E. a, Roberti, J. W., & Roth, D. a. (2004). Factor structure, concurrent 
validity, and internal consistency of the Beck Depression Inventory-Second Edition in a 
  
 
 
 
 
142
sample of college students. Depression and anxiety, 19(3), 187–9. 
doi:10.1002/da.20002 
Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of 
Experimental Psychology, 18(6), 643–662.  
Studer, P., Wangler, S., Diruf, M. S., Kratz, O., Moll, G. H., & Heinrich, H. (2010). 
ERP effects of methylphenidate and working memory load in healthy adults during a 
serial visual working memory task. Neuroscience Letters, 482(2), 172–176.  
Tablot, M. (2009). Brain gain. The New Yorker. Retrieved from: 
http://www.iricss.org/fa/NewsRelease/News/Documents/Brain_Gain_The_New_Yorker.p
df 
Teter, C. J., Falone, A. E., Cranford, J.A., Boyd, C. J., and McCabe, S. E. (2010). 
Nonmedical use of prescription stimulants and depressed mood among college 
students: frequency and routes of administration. J. Subst. Abuse Treat. 38, 292–298. 
doi: 10.1016/j.jsat.2010.01.005 
Teter, C. J., McCabe, S. E., Cranford, J. A., Boyd, C. J., and Guthrie, S. K. 
(2005). Prevalence and motives for illicit use of prescription stimulants in an 
undergraduate student sample. J. Am. College Health 53, 253–262. doi: 
10.3200/JACH.53.6.253-262 
The Psychological Corporation., 2002. Updated WAISIII-WMS-III technical 
manual. San Antonio, TX.Tablot, M., 2009. Brain gain. The New Yorker.  
Theunissen, E. L., Elvira, J. de la A., van den Bergh, D., & Ramaekers, J. G. 
(2009). Comparing the stimulant effects of the H1-antagonist fexofenadine with 2 
  
 
 
 
 
143
psychostimulants, modafinil and methylphenidate. Journal of Clinical 
Psychopharmacology, 29(5), 439–443.  
Treadway, M. T., Buckholtz, J. W., Schwartzman, A. N., Lambert, W. E., & David, 
H. (2009). Worth the “ EEfRT ”? The Effort Expenditure for Rewards Task as an 
Objective Measure of Motivation and Anhedonia, 4(8), 1–9. 
doi:10.1371/journal.pone.0006598 
Unrug, A., Coenen, A., & van Luijtelaar, G. (1997). Effects of the Tranquillizer 
Diazepam and the Stimulant Methylphenidate on Alertness and Memory. 
Neuropsychobiology, 36(1), 42–48.  
Verdejo-García, A., Lawrence, A. J., & Clark, L. (2008). Impulsivity as a 
vulnerability marker for substance-use disorders: review of findings from high-risk 
research, problem gamblers and genetic association studies. Neuroscience and 
biobehavioral reviews, 32(4), 777–810. doi:10.1016/j.neubiorev.2007.11.003 
Volkow, N. D., Wang, G. J., Fowler, J. S., Telanfg F., Maynard, L., Logan, J., et 
al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task 
by increasing dopamine in the human brain. Am. J. Psychiatry 161, 1173–1180. doi: 
10.1176/appi.ajp.161.7.1173 
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., … 
Pappas, N. (1998). Dopamine transporter occupancies in the human brain induced by 
therapeutic doses of oral methylphenidate. American Journal of Psychiatry, 155(10), 
1325–1331. 
  
 
 
 
 
144
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, 
F., … Ma, Y. (2009). Evaluating dopamine reward pathway in ADHD: Clinical 
implications. JAMA, 302(10), 1084–1091. 
Vrecko, S. (2013). Just how cognitive is “cognitive enhancement”? On the 
significance of emotions in university students’ experiences with study drugs. AJOB 
Neuroscience, 4(1), 4–12.  
Vree, T. B., & Van Rossum, J. M. (1970). Kinetics of metabolism and excretion of 
amphetamines in man. Amphetamines and related compounds, 165-190. 
Wardle, M. C., and de Wit, H. (2012). Effects of amphetamine on reactivity to 
emotional stim- uli. Psychopharmacology 220, 143–153. doi: 10.1007/s00213-011-2498-
7  
Wardle, M. C., Hart, A. B., Palmer, A. A., & de Wit, H. (2013). Does COMT 
genotype influence the effects of d-amphetamine on executive functioning? Genes, 
Brain and Behavior, 12(1), 13–20.  
Wardle, M. C., Treadway, M. T., Mayo, L. M., Zald, D. H., and de Wit, H. (2011). 
Amping up effort: effects of d-Amphetamine on human effort-based decision-making. J. 
Neurosci. 31, 16597–16602. doi: 10.1523/JNEUROSCI.4387-11.2011 
Weyandt, L. L., Janusis, G., Wilson, K. G., Verdi, G., Paquin, G., Lopes, J., et al. 
(2009). Nonmedical prescription stimulant use among a sample of college students: 
relation- ship with psychological variables. J. Atten. Disord. 3, 284–296. doi: 
10.1177/1087054709342212 
  
 
 
 
 
145
Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., … 
Fusillo, S. (2008). Misuse and diversion of stimulants prescribed for ADHD: A systematic 
review of the literature. Journal of the American Academy of Child & Adolescent 
Psychiatry, 47(1), 21–31.  
Willett, R. A. (1962). The effect of a stimulant and a depressant drug on the serial 
rote learning of nonsense syllables. Psychopharmacologia, 3(1), 23–34.  
Zeeuws, I., & Soetens, E. (2007). Verbal memory performance improved via an 
acute administration of D-amphetamine. Human Psychopharmacology: Clinical and 
Experimental, 22(5), 279–287.  
Zeeuws, I., Deroost, N., & Soetens, E. (2010a). Effect of an acute d-
amphetamine administration on context information memory in healthy volunteers: 
evidence from a source memory task. Human Psychopharmacology: Clinical and 
Experimental, 25(4), 326–334.  
Zeeuws, I., Deroost, N., & Soetens, E. (2010b). Verbal memory improved by D-
amphetamine: influence of the testing effect. Human Psychopharmacology: Clinical and 
Experimental, 25(5), 377–387.  
 
 
 
 
 
